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 3 
Abstract 
 
 
It is estimated that one third of the world‘s population are infected with the bacterium M. 
tuberculosis and approximately 9.4 million new cases of tuberculosis were diagnosed 
globally in 2008. Molecular tools, developed over the previous two decades, have 
allowed further in-depth study of this historic disease. Genotyping M. tuberculosis allows 
the study of evolutionary relationships and well as the routes of transmission of the 
organism between hosts. The pairing of genotyping with demographic data allows the 
analysis of the current trends of disease within a given patient population. Two 
genotyping methodologies (IS6110 RFLP and Mycobacterial Interspersed Repetitive 
Units – Variable Number Tandem Repeats (MIRU-VNTR)), alongside patient 
demographic data have been utilised for the TB population at the Royal Free Hospital, 
London. The data shows a patient population that is largely concordant with that seen in 
London as a whole; with the majority of TB patients being born outside of the UK and 
drug resistance rates that are higher than the national average.  
 
The acquisition of drug resistance-conferring mutations by M. tuberculosis is often 
presumed to be associated with a fitness cost. Here we investigate the fitness of isolates 
from two outbreaks involving large numbers of drug resistant strains. The first group of 
strains was found to be part of the ongoing north London isoniazid resistant outbreak. 
The data suggests that this outbreak consists of successful, closely related, circulating 
strains with heterogeneous resistance profiles and mutations and little or no associated 
fitness cost.  
 
 4 
The relationship between the biology of the organisms isolated from a cohort of TB 
patients who underwent a novel diagnostic interferon gamma release assay was 
investigated. Genotyping, ESAT-6 gene sequencing and gene expression assays suggest 
that varying immune response between individuals is driven by host factors rather than a 
characteristic of the strain of M. tuberculosis.  
 
This study shows that this geographic location in London is home to a diverse population 
of M. tuberculosis with a low rate of transmission. The demographic characteristics of the 
TB patients are largely concordant with the UK as a whole. These findings show that M. 
tuberculosis genotyping is critically important in the identification of suspected outbreaks 
and contamination events as well as the investigation of successful related strains and 
characteristic disease phenotypes. Genotyping can augment classic epidemiology and 
clinical practice to provide a holistic approach in the investigation, treatment and control 
of the global health problem. Understanding the biology and genomics of M. tuberculosis 
is how the enormous disease burden will be tackled.  
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Chapter 1: Introduction 
 
1.1 Disease 
 
Tuberculosis (TB) is an ancient disease that currently presents an immense global health 
challenge. It is estimated that one third of the world‘s population (approximately 2 billion 
people) are infected with the tubercle bacilli. However, infection by the organism does 
not necessarily lead to disease and only 5-10% of these individuals will progress to active 
disease each year (WHO 2007). The remaining 90% of infected individuals will initially 
be asymptomatic and experience latent infection, from which reactivation may occur. The 
World Health Organisation (WHO) estimate that globally in 2008 there were 9.4 million 
cases of active TB leading to 1.3 million deaths (WHO 2009).  
 
The geographic incidence of infection and therefore disease burden varies greatly. Most 
of the estimated number of cases in 2008 occurred in Asia (55%) and Africa (30%).  The 
22 high-burden countries (in terms of absolute numbers of cases) account for 80% of all 
estimated cases worldwide. India and China alone account for an estimated 35% of TB 
cases worldwide (WHO 2009). Widely varying incidence rates are demonstrated in figure 
1.1.  
  
Living in or having visited a high incidence area are key risk factors, but host factors also 
play a role in the risk of patients progressing to active disease. The immunosuppressed, 
especially those individuals that are infected with HIV are particularly susceptible to TB 
disease. Individuals who have poor nutrition and general bad health, such as the homeless 
and those who misuse alcohol and drugs are also at increased risk. Other 
 20 
immunocompromised patients, such as patients with chronic renal disease, neoplastic 
disorders and those receiving immunosuppressive therapy are also susceptible. The 
vaccination status of the individual may also play a role.  
 
The HIV pandemic has greatly altered the global landscape of TB. WHO estimate that 
1.2–1.6 million (13–16%) of the 9.4 million cases in 2008 were HIV-positive. Of these 
HIV-positive cases, 78% were in the African Region and 13% were in the South-East 
Asia Region (WHO 2009). Individuals infected with HIV are more than 20 times more 
likely to reactivate TB than those who are HIV negative (Girardi E et al. 2000).  
 
 
 
 
Figure 1.1. Estimated TB incidence rates, 2008 (WHO 2009) 
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TB in humans is caused predominantly by Mycobacterium tuberculosis, but also by M. 
africanum and M. bovis. These species, together with M. microti, M. canettii and other 
animal-adapted M. bovis ecotypes make up the M. tuberculosis complex. TB primarily 
affects the lungs but can also infect the central nervous system, lymph nodes, bones, 
joints, urinary tract and other sites. The disease is infectious via the respiratory route by 
inhalation of aerosolised bacilli from patients with active respiratory disease.  
 
1.2 Organism 
 
M. tuberculosis belongs to the order Actinomycetales. The organism is a non-motile, non 
spore forming, slowly reproducing aerobe. Slow cell division, resistance to detergents 
and certain antimicrobial agents, persistence in the environment and an acid/alcohol fast 
nature are due to the characteristic hydrophobic cell wall (figure 1.2). Working from the 
bottom layer of the envelope towards the external surface of the bacterium there is a 
triple plasma membrane thought to be similar to those in other bacteria. Next follows a 
cell wall skeleton consisting of peptidoglycan, complexed with mycolic acids unique to 
mycobacteria and arabinogalactan, which forms a hydrophobic permeability barrier. 
Transport proteins in the plasma membrane and porins in the mycolic acid layer allow for 
the import of hydrophilic substances. Above this layer lies a capsule (or pseudocapsule as 
it is not covalently bound to the rest of the envelope) consisting of polysaccharides, 
proteins and lipid. (Draper and Daffe 2005).  
 
The lipid rich cell wall does not take up stain readily, but resists decolourisation when 
destained with an acid-alcohol wash. Mycobacteria are often stained with fluorescent 
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stains, such as auramine-O (a diamylmethane dye) or with more conventional stains for 
light microscopy, such Ziehl-Neelsen or Kinyoun using carbol fuchsin.  
 
1.3 Genome, Evolution and the Global Phylogeny of M. tuberculosis 
 
The complete genome of M. tuberculosis H37Rv was published in 1998 (Cole ST et al. 
1998). This revealed a circular genome in the region of 4.4 million base pairs containing 
approximately 4000 genes – see figure 1.3. The genome of M. tuberculosis is GC rich 
(65.6%), a feature that has been associated more often with aerobic prokaryotes (Naya et 
al. 2002). This was updated four years later and the function of 2058 genes (52%) was 
predicted (Camus et al. 2002).  
 
It was demonstrated that M. tuberculosis possesses all the genes necessary for 
synthesising essential amino acids, vitamins and enzyme co-factors. It was noted that 
there are a high proportion of genes encoding enzymes involved in lipogenesis and 
lipolysis. Additionally, M. tuberculosis possesses the genes to synthesise glycolytic 
enzymes and enzymes necessary for the anabolic pentose phosphate pathway, which 
generates NADPH and pentose sugars, the catabolic Kreb‘s cycle and the glyoxylate 
cycle, which synthesises carbohydrates from lipids. The tubercle bacillus also possesses 
enzymes used in aerobic, microaerophilic and anoxic electron transfer and is capable of 
surviving in a number of different environments including the oxygen rich lung, the 
macrophage and at the centre of caceous granuloma (Cole ST et al. 1998). 
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Figure 1.2 Mycobacterial cell wall (Park & Bendelac 2000) 
 24 
There are a number of repetitive DNA sequences in the M. tuberculosis genome 
including insertion sequences (IS), the direct repeat (DR) region, the major polymorphic 
tandem repeats (MPTR) and the polymorphic GC-rich repetitive sequence (PGRS) 
(Poulet & Cole ST 1995b).  
 
The genome contains two large protein families encoding acidic, asparagine- or glycine-
rich proteins referred to PE (proline-glutamate – n = 99) and PPE (proline- proline-
glutamate – n = 68) (Cole ST et al. 1998). Some of these genes are situated in the MPTR 
and the PGRS regions and are associated with antigenic variability and virulence 
(Karboul et al. 2006;Poulet & Cole ST 1995a;Poulet & Cole ST 1995b). 
 
Previous studies of clinical and laboratory strains have shown that the M. tuberculosis 
complex possesses a high degree of sequence homogeneity, demonstrated by a greater 
than 99.9% similarity in rDNA sequences (Frothingham, Hills, & Wilson 1994; 
Sreevatsan et al. 1997). Sequence homology extends even between different species of 
the M. tuberculosis complex. There is less than 0.05% sequence divergence between M. 
bovis and M. tuberculosis (Garnier et al. 2003). This genetic similarity may be viewed as 
significant when compared to other species, for example, two strains of Escherichia coli 
have shown sequence diversity of 1.6% (Perna et al. 2001).  
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Figure 1.3. A diagrammatic representation of the M. tuberculosis H37Rv genome. The outer circle shows 
the scale in Mb, with 0 representing the origin of replication. The first ring from the exterior denotes the 
positions of stable RNA genes (tRNAs are blue, others are pink) and the direct repeat region (pink cube); 
the second ring inwards shows the coding sequence by strand (clockwise, dark green; anticlockwise, light 
green); the third ring depicts repetitive DNA (insertion sequences, orange; 13E12 REP family, dark pink; 
prophage, blue); the fourth ring shows the positions of the PPE family members (green); the fifth ring 
shows the PE family members (purple, excluding PGRS); and the sixth ring shows the positions of the 
PGRSsequences (dark red). The histogram (centre) represents G + C content, with <65% G + C in yellow, 
and >65% G + C in red (Cole ST et al. 1998).  
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This lack of variation in M. tuberculosis may have resulted from limited selective 
pressure or the hypothesis that its distribution is very recent, in evolutionary terms. 
Indeed, some groups hypothesised that the lack of genetic variation meant that M. 
tuberculosis was younger than 20,000 years old (Fleischmann et al. 2002; Frothingham 
1999; Frothingham, Hills, & Wilson 1994; Kapur et al. 2000; Sreevatsan et al. 1997). In 
addition, there is little evidence of horizontal gene transfer in M. tuberculosis and so its 
evolution appears to have occurred in a clonal manner (Filliol et al. 2006; Hirsh et al. 
2004; Supply et al. 2003). With the exception of M. canetti (Gutierrez et al. 2005) there is 
limited evidence for genetic recombination in the M. tuberculosis complex (Hughes AL, 
Friedman R, & Murray M 2002; Liu et al. 2006). Indeed, M. tuberculosis exhibits 
relatively low levels of genetic recombination, similar to other clonal organisms such as 
Escherichia coli and Salmonella enterica (Smith et al. 2003) when compared to the 
heterogeneity in housekeeping genes other organisms, such as H. pylori (Go et al. 1996; 
Suerbaum et al. 1998; Feil & Spratt 2001; Linz & Schuster 2007) and Neisseria 
gonorrhoeae (O'Rourke & Stevens 1993; O'Rourke & Spratt 1994;). 
 
Although there is limited genetic diversity between strains, the differences that have been 
observed have been useful in the investigation of the global evolution of the M. 
tuberculosis complex. As M. tuberculosis rarely benefits from horizontal gene transfer, 
deletions and point mutations can be studied to track the global evolution of the 
organism. Due to the non-promiscuous nature of M. tuberculosis, the alterations within 
its genome are as a result of deletions or point mutations. Deletions in M. tuberculosis 
can be generated in three ways; 1) mobile genetic elements, such as insertion sequences, 
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2) homologous recombination of insertion sequences resulting in the deletion of 
intervening DNA and 3) deletions whose bordering genetic regions do not contain 
repetitive sequences (Brosch et al. 2002).  
 
Further investigation into significant genes directed the study of the organism‘s 
evolution. The katG gene encodes catalase peroxidae, and mutations in this gene can 
confer resistance to isoniazid in M. tuberculosis – see section 1.7. Mutations in the gyrA 
gene, which encodes DNA gyrase, may confer resistance to fluoroquinolones. Analysis of 
these genes implicated in drug resistance in over 800 geographically diverse isolates from 
the M. tuberculosis complex by Sreevatsan and colleagues identified three distinct groups 
of strains (Sreevatsan et al. 1997). It was surmised that the common precursor organism 
of the M. tuberculosis complex possessed codon katG
463
 CTG (Leu) and gyrA
95
 ACC 
(Thr). Members of the M. tuberculosis complex that possessed these codons were 
considered to be the oldest and members were termed to be in Principal Group 1 
(Sreevatsan et al. 1997). This group included some strains of M. tuberculosis as well as 
M. africanum and M. microti. The mutation to katG
463
 CGG (Arg) allocated the strain 
into Principal Group 2, whilst the presence of that mutation together with the mutation 
gyrA
95
 AGC (Ser) placed the strain in Principal Group 3 (figure 1.4). This group then 
analysed approximately 6000 strains from Houston and New York and found no strains 
belonging to Group 3. It was reasoned that this group was either the most recently 
evolved and/or was less virulent than the strains in Groups 1 and 2.  
 
 28 
The analysis of deletions further allowed the evolution of the M. tuberculosis complex to 
be mapped. Comparative genomic analysis showed 14 regions of difference (RD1-14), 
ranging in size from 2 to 12.7kb, that were present in M. tuberculosis, but absent in M. 
bovis BCG (Behr et al. 1999; Gordon et al. 1999). In addition, six deletions were 
identified in the reference strain M. tuberculosis H37Rv compared with other members of 
the M. tuberculosis complex (RvD1-5 and the M. tuberculosis specific deletion 1 (TbD1)) 
(Brosch et al. 1999; Gordon et al 1999).   Geographically distributed isolates from the M. 
tuberculosis complex were examined for the presence or absence of TbD1, a number of 
regions of difference (RD) as well as single nucleotide polymorphisms (SNPs) in the 
gene sequences of katG, gyrA, oxyR, pncA and mmpl6 (Brosch et al. 2002). Results 
showed that M. tuberculosis as well as other members of the M. tuberculosis complex 
had evolved from a common precursor (figure 1.4). Strains that possessed TbD1 were 
termed ‗ancient‘ whilst those lacking the region were labelled ‗modern‘. Additionally, the 
assumption that M. tuberculosis had evolved from M. bovis was discredited. This finding 
was also confirmed by Mostowy and colleagues (Mostowy et al. 2002).  
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Figure 1.4 Diagram of the evolution of M. tuberculosis complex. Principle Groups 1, 2 and 3 are shown 
towards the top of the figure and are indicated by blue, green and red arrows, respectively. (Donoghue et al. 
2004). 
 
Further analysis of well-characterised laboratory strains, as well as clinical isolates has 
contributed to the study of the evolution of the M. tuberculosis complex. In addition to 
the presence or absence of TbD1 and the SNPs at katG
463
 and gyrA
95
, other SNPs and 
long sequence polymorphisms (LSPs) have been investigated. Baker and colleagues 
(Baker et al. 2004) investigated SNPs in katG and gyrA, as well as a further five genes 
(rpoB, oxyR, ahpC, pncA, and rpsL). As sSNPs are neutral, they become fixed in a 
bacterial population and may be used to study its evolution.  
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The analysis of 37 neutral sSNPs allowed a phylogenetic tree to be constructed that 
divided the strains into four distinct groups (I – IV) (Baker et al. 2004). The analysis of 
katG
463
 and gyrA
95
 showed congruence between the groups found in this study and the 
work by Sreevatsan and colleagues (Sreevatsan et al. 1997); Groups I, III and IV aligned 
with Principal Group 1. Group IV (along with M. bovis, M. microti and M. africanum) 
possessed TbD1, confirming that the deletion of TbD1 preceded the SNPs at katG
463
 and 
gyrA
95
. Group II strains aligned with Principal Groups 2 and 3. The observation that 
common nsSNPs in rpoB, katG,  rpsL and inhA, causing antimicrobial resistance, were 
present in all groups indicates that these evolved independently due to selective pressure 
of drug treatment (Baker et al. 2004). 
 
Epidemiological data showed that there were strong associations between the groups and 
the country of birth of the patients. Groups I, II and III were associated with South East 
Asia, Europe and the Indian subcontinent, respectively. Group IV strains were globally 
disseminated, but were negatively associated with Europe. A large proportion of these 
Group IV strains possessed only one copy of IS6110 and were more likely to be drug 
susceptible. This, combined with the presence of TbD1 strongly suggested that this group 
was more closely related to the common ancestor than the other groups (Baker et al. 
2004).  
 
Filliol and Gutacker have used SNPs to further investigate the global phylogeny of M. 
tuberculosis (Filliol et al. 2006; Gutacker et al. 2006). Both studies allocated M. 
tuberculosis isolates into nine lineages that are largely congruent with others‘ findings in 
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the regards of the Principal Groups 1-3, based on SNPs at katG
463
 and gyrA
95
, other 
SNPs, LSPs and the country of origin of the patient.  
 
Gangeux and colleagues demonstrated similar findings based on LSPs and SNPs. They 
made strong associations between each of the six characterised groups and geographic 
region; Indo-Oceanic, East Asian, East African/Indian, Euro-American, West African-1 
and West African-2 (Gagneux et al. 2006). When investigating the diverse population of 
San Francisco, it was seen that >99% of strains were assigned to only three of the six 
groups: Indo-Oceanic, East Asian and European-American. Secondary cases in each of 
these groups were studied and it was shown that patients infected with a strain in the 
European-American group were three times more likely to give rise to a secondary case. 
Additionally, sympatric infections were far more common than allopatric infections. For 
example, US-born patients who defined themselves as Chinese were far more likely to be 
infected with a strain that was associated with patients born in China.  However, 
allopatric infections were disproportionately seen in more susceptible hosts. For example, 
US-born TB patients of non-Chinese and non-Philipino ethnicity who were infected with 
Indo-Oceanic or East Asian strains were more likely to be HIV positive or homeless 
(Gagneux et al 2006).  
 
Hirsh and colleagues studied unclustered isolates in San Francisco. Strains isolated from 
individuals from distinct geographical regions were genotypically linked regardless of 
whether the researchers believed that the individual had contracted the infection in the 
US or had reactivated disease from their home country (Hirsh et al. 2004). The strong 
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associations between phylogeographic lineage and a patient‘s country of origin have also 
been demonstrated by others (Dale et al. 2003b; Reed et al. 2009). These observations 
raise the hypothesis that some strains of M. tuberculosis may have adapted to infect 
individuals with a certain genetic background. For example, different human leucocyte 
antigens (HLA) of the major histocompatibility complex (MHC) have been associated 
with TB. A meta analysis of studies investigating HLA types and thoracic TB found a 
decreased risk of TB in carriers of B13, DR3 and DR7 antigens. Carriers of DR8 had an 
increased risk of thoracic TB (Kettaneh et al. 2006). Additionally, vitamin D deficiencies 
have been associated with TB. A meta analysis found that vitamin D levels were 
significantly lower in TB patients than in controls (Nnoaham & Clarke 2008). 
Associations between vitamin D receptor genotype and the response to TB treatment 
have also been made (Chocano-Bedoya & Ronnenberg 2009). A recent study showed, 
however, that the supplementation of anti-TB treatment with vitamin D did not improve 
outcome. The exception was individuals with the tt genotype of the TaqI vitamin D 
receptor polymorphism who became sputum culture negative more rapidly than controls 
(Martineau et al 2011). However, broader studies to separate the effect of social and 
epidemiological factors from the genetic background of the patient necessarily include 
large numbers of patients and few have been performed.  
 
The sum total of these five studies (Sreevatsan, Baker, Filliol, Gutacker and Gagneux), 
together with the analysis of an extremely large spoligotyping (section 1.9.4.3.) database 
of almost 40,000 strains (Brudey et al. 2006) gives rise to the current understanding of 
the global phylogeny of M. tuberculosis. The evolution of the organism appears to have 
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occurred in a clonal manner with no evidence of horizontal gene transfer. The six main 
groups of strains are characterised by SNPs and deletions (LSPs) and are strongly 
associated with geographic location (figure 1.5; Gagneux & Small 2007).    
 
Additionally, evolution of M. tuberculosis complex alongside that of humans has been 
suggested in some of these works. Gutierrez and colleagues suggest that an ancient 
ancestor of M. tuberculosis complex, ‗M. prototuberculosis‘ co-evolved with early 
hominids between 2.6 and 2.8 million years ago (Gutierrez et al. 2005). More recent 
evolution of M. tuberculosis complex can be mapped alongside the movement of humans 
from east Africa approximately 50,000 years ago (Hershberg et al. 2008). Wirth and 
colleagues suggest that the oldest common ancestor for the M. tuberculosis complex 
emerged from its progenitor in east Africa approximately 40,000 years ago (Wirth et al. 
2008). Hershberg and colleagues further aligned the evolution of the M. tuberculosis 
complex into the six phylogeograpic lineages alongside worldwide human migrations and 
trade routes over the past few hundred years (Hershberg et al. 2008). These findings, 
along with the predominance of sympatric infection suggest a co-evolution between 
pathogen and host. 
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Figure 1.5 – Global Phylogeny of M. tuberculosis. A: Groups I-IV adapted from Baker 2004. B six 
phylogeographic groups adapted from Gagneux 2007. C: Nine groups with corresponding Principal Genetic 
Groups 1-3 (Srrevatsan 1997) adapted from Gutacker 2006. D: nine groups and M. bovis adapted from 
Filliol 2003. Coloured areas indicate corresponding groups of strains (Gagneux & Small 2007).  
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One group of strains has been investigated more than any other. The predominance of a 
family of strains, based on spoligotyping, was seen in the Beijing area of China (van 
Soolingen et al. 1995). Representatives of the Beijing family are now seen worldwide and 
have been intensively investigated. They predominate over all of East Asia, Russia and 
the countries of the former Soviet Union (Bifani et al. 2002). A review of worldwide 
literature shows prevalence rates in China between 1956 and 1999 of 83-100%, and 
virtually no geographic location is without representatives of this lineage (Glynn et al. 
2002).  
 
The pathogenesis, host immune response and disease progression have also been studied. 
Increased virulence as well as early, but short lived TNF-α induction in mouse models 
has been demonstrated (Lopez et al. 2003). The organisms‘ ability to divide rapidly in 
human macrophages (Zhang et al. 1999) and the observation of a highly mutable 
phenotype have also been documented (Ebrahimi-Rad et al. 2003). The Beijing lineage, 
together with closely related MDR strain ‗W‘ first identified in New York, are 
characterised first by the deletion of TbD1. These strains are therefore described as 
‗modern‘. Additionally, they are placed in Principal Group 1 (Sreevatsan et al. 1997). 
Further differentiation is characterised by the spoligotype S000034 (these strains posses 
only the spacers 35-43). There is a diverse range of IS6110 patterns that fall within the 
Beijing/W lineage, but all possess large numbers of copies of the insertion sequence (15-
26) (van Soolingen et al. 1995) – figure 1.6.  
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Figure 1.6 Examples of spoligotype and IS6110 patterns of Beijing/W strains (Ebrahimi-Rad et al. 2003) 
 
Beijing/W strains have been implicated in outbreaks and have sometimes been associated 
with drug resistance and HIV patients (Glynn et al. 2002; Moss et al. 1997). Drug 
resistance and radiologically advanced disease has also been associated with Beijing 
strains by Drobniewski and colleagues (Drobniewski et al 2005). Further characterisation 
of Beijing strains has been demonstrated by the examination of LSPs. Tsolaki and 
colleagues demonstrated that all Beijing/W strains had RD105 deleted, and these strains 
were further subdivided into four groups by the subsequent deletion of RDs 181, 150 and 
142. It was noted that all strains retained an intact gene pks15/1, which is involved in 
phenolic glycolipd biosynthesis, and is a putative virulence factor (Reed et al. 2004b; 
Tsenova et al. 2005; Tsolaki et al. 2005). Additionally, Reed and colleagues found that 
Beijing/W strains accumulate large quantities of immunoregulatory triacylglycerides and 
have a dormancy advantage over other strains (Reed et al. 2007). Finally, the suspected 
route and time-scale of the co-migration and evolution of the Beijing/W lineage and 
humans from Africa has been described by comparing the bacterial genome to the non-
recombining portion of the human Y chromosome. The migration of humans and M. 
tuberculosis from Africa to Asia approximately 45,000 years ago was concluded from 
this analysis (Mokrousov et al. 2005).  
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As well as Beijing/W, associations have been made between other genotypes and 
progression to active disease (de Jong et al. 2008), pulmonary cavitation (Kato-Maeda et 
al. 2001), host immune response (Lopez et al. 2003; Theus, Cave, & Eisenach 2005), 
growth rates in ex-vivo monocytes (Theus, Cave, & Eisenach 2005) and macrophages 
(Zhang JID 1999), the ability to cause disseminated disease (Caws et al. 2008; Garcia de 
Viedma et al. 2005; Thwaites et al. 2008) and pulmonary smear negativity (Dale et al. 
2005a).  
 
Whatever the degree of recombination, and the reasons for this, in the M. tuberculosis 
complex, it is generally agreed that the rate of recombination in the sequenced strains is 
negligible (Smith et al. 2006), genetic variation between strains is scarce and the 
pathogen has evolved in a clonal manner from a common ancestor approximately 35,000 
years ago (Hughes AL, Friedman R, & Murray M 2002) and it is widely acknowledged 
that human TB is an ancient disease, in human terms at least (Donoghue et al. 2004; 
Donoghue 2009; Taylor, Young, & Mays 2005). Indeed, fossilised evidence of M. 
tuberculosis infection in Homo erectus, which evolved approximately 2 million years ago 
(Antón 2003), has been discovered in Turkey (Kappelman et al. 2008). 
 
1.4 Host-Pathogen Interaction 
  
The interaction of M. tuberculosis with the human host is central to the disease 
progression. TB is fundamentally an immune-related disease and infection occurs by 
entry into mononuclear phagocytes (macrophages or dendritic cells) by receptor-
mediated phagocytosis (Schlesinger 1993). For review, see (Ernst 1998). This mucosal 
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interaction largely occurs in the lung after inhalation of aerosolised bacilli, but may also 
occur in the gut following the ingestion of M. bovis in unpasteurised milk. Once 
phagocytosed, the organism causes progression in three directions: clearance, disease or 
latency (figure 1.7). If the phagocytosed bacilli are rapidly killed by the innate immune 
system then the individual shows no sign of infection or disease and no apparent immune 
response (Dietrich & Doherty 2009). Infected dendritic cells migrate to local lymph 
nodes where they induce specific B and T cell responses. If the infection is not contained, 
then haematogenous spread can occur at this stage (Ehlers 2009).   
 
 
 
Figure 1.7. The possible outcomes of an M. tuberculosis infected macrophage. Infection: The bacillus is 
taken up by the antigen presenting cell and contained in the phagosome. Active Disease: The growth of the 
bacillus is not restricted. Latency: Bacillus growth is restricted, but not eradicated. Immunity: Apoptosis of 
the host cell or formation of the lysosome eradicates the bacillus. (Dietrich & Doherty 2009) 
 
Infection Active Disease 
Immunity Latency 
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As already stated, latency occurs in the vast majority of infections. This occurs when the 
bacilli are taken up by antigen presenting cells (APC) and a rapid inflammatory immune 
response ensues. Activated T cells from the local lymph nodes migrate to the site of 
initial infection and create a cascade of cytokines that recruits a range of immune cells 
and a granuloma is formed. A granuloma consists of a small number of infected 
phagocytes in the centre, surrounded by activated monocytes and macrophages. Activated 
CD4, CD8 and small number of B cells then surround the mononuclear cells (Gonzalez-
Juarrero et al. 2001). At this stage, there begins a balance between the host and the 
organism. If the host‘s innate immune response is able to control the infection, then the 
granuloma shrinks and may even disappear, causing calcification and T cell memory to 
M. tuberculosis antigens (Dietrich & Doherty 2009). Alternatively, bacterial replication 
leads to the granuloma increasing in size. Eventually the centre of the granuloma 
becomes necrotic and tissue destruction begins. Characteristic granulation and AFB may 
be seen in histological specimens (figure 1.8a & 18b, respectively). If the granuloma is 
close to the surface of the lung then the tissue destruction can breach the mucosa and 
cause cavitation. Cavitation is associated with advanced disease as well as increased 
bacterial burden, infectivity and mortality (Golub et al. 2006; Helke, Mankowski, & 
Manabe 2006; Kourbatova et al. 2006; Perrin et al. in press).  
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Figure 1.8a H&E stained section of lung tissue x100. The centre of the granuloma is indicated with an 
arrow. Courtesy Steve Davis, Histopathology, Royal Free Hospital. 
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Figure 1.8b Ziehl-Neelsen stained section of lung tissue x400. AFB are indicated with an arrow. Courtesy 
Steve Davis, Histopathology, Royal Free Hospital. 
 
The organism is central to the stimulation and inhibition of all stages of the host immune 
response and this appears to benefit the survival of the host and pathogen. The cell 
surface of M. tuberculosis contains a number of molecules that bind to the host‘s 
pathogen-associated molecular pattern (PAMP) receptors (Dietrich & Doherty 2009), 
such as the Toll-like receptor family (Means et al. 1999b; Means et al. 1999a). These 
receptors allow rapid and efficient activation of the innate immune system to protect the 
host (Quesniaux et al. 2004; Stenger & Modlin 2002), but M. tuberculosis expresses a 
number of molecules (both membrane bound and secreted) that stimulate these pathways. 
Most of these molecules do not appear to be essential for the survival of M. tuberculosis 
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so it may be concluded that their conservation is due to the beneficial outcome from the 
resulting granuloma formation and cavitation (Brosch et al. 2002).  
 
M. tuberculosis is able to persist inside a host for extended periods due to its ability to 
survive inside macrophages and monocytes. These immune cells play a role in bacterial 
killing, but also stimulating an immune response by antigen presentation, which is 
summarised in figure 1.9. M. tuberculosis has co-evolved with humans to modulate these 
processes to its benefit. Stokes and colleagues showed that mannose derivatives on the 
surface of M. tuberculosis inhibit phagocytosis by activated macrophages and therefore 
may specifically target certain macrophage phenotypes (Stokes et al. 2004). The receptor 
DC-SIGN on the surface of dendritic cells is known to bind to lipoarabinomannan 
(LAM), which is a major cell wall component of M. tuberculosis. DC-SIGN is involved 
in dendritic cell maturation but LAM binding inhibits this as well as down-regulating IL-
12 production whilst stimulating IL-10 secretion (Appelmelk et al. 2003; van Kooyk Y. 
& Geijtenbeek 2003). These modifications by M. tuberculosis inhibit antigen presentation 
and MHC expression. Levels of IL-10 have been shown to be elevated patients with 
active TB, which may support this (Jang, Uzelac, & Salgame 2008; Olobo et al. 2001; 
Redpath, Ghazal, & Gascoigne 2001).  
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Figure 1.9. The interaction of the infected antigen-presenting cell and an antigen specific T cell after 
infection. The key pathways in the host‘s immune response are shown as solid arrows that can suppress 
(red) or enhance (blue) bacterial growth, together with the known bacterial products (white boxes, dotted 
arrows) that can interfere with the host‘s response (Dietrich & Doherty 2009).  
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Other cell wall components strongly stimulate the inflammatory response. Long chain 
fatty acids stimulate the host‘s immune response (Brennan 2003; Briken et al. 2004; Korf 
et al. 2005; Stenger & Modlin 2002), cause granuloma formation, up-regulation of 
antigen presentation  and subsequent NK and T-cell responses (Hunter et al. 2006; Ryll, 
Kumazawa, & Yano 2001). If the host‘s immune response is allowed to proceed without 
restriction, the infection is rapidly be cleared by the host (Dietrich & Doherty 2009). The 
19 kDa lipoprotein produced by M. tuberculosis has been shown to down-regulate the 
expression of IFN-γ by a third in murine macrophages (Pai et al. 2004), reduces antigen 
processing and MHC II expression (Fortune et al. 2004; Noss et al. 2001; Pai et al. 2004). 
Knocking out this lipoprotein attenuates M. tuberculosis in both immunocompetent mice 
and those deficient in the IFN- γ gene (Henao-Tamayo et al. 2007) and reduced immunity 
was seen in mice when expressed as a recombinant protein in M. smegmatis and M. 
vaccae (Yeremeev et al. 2000).  
 
The proteins early secretory antigen target-6 (ESAT-6) and culture filtrate protein-10 
(CFP-10) are co-transcribed, excreted by a novel secretory mechanism and are highly 
immunogenic (Berthet et al. 1998; Pallen 2002; Sorensen et al. 1995). ESAT-6 acts 
through TLR-2 and inhibits several pathways following TLR signalling (Pathak et al. 
2007). It is a virulence factor that is absent from the attenuated vaccine strain M. bovis 
BCG (Harboe et al. 1996; Lewis et al. 2003; Pym et al. 2002). Additionally, the absence 
of these proteins has been shown to reduce immungenicity and virulence of M. 
tuberculosis in vivo and vitro (Brodin et al. 2006; Guinn et al. 2004).  
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Once inside the macrophage, M. tuberculosis further attempts to avoid immune clearance 
by inhibiting the phagosome maturation process. However, the organism must control its 
own environment to allow the acquisition of essential nutrients (especially iron) by the 
fusion of other vesicles and membrane remodelling (Deretic et al. 2006; Russell 2001; 
Steinberg & Grinstein 2008). In order to perform effective killing, the phagosome must 
mature and reduce the pH to provide and acidic environment. ESAT-6/CFP-10 (Tan et al. 
2006), and SecA1/2 (Hinchey et al. 2007; Hou et al. 2008) interfere with this process by 
blocking the accumulation of ATPases and GTPases in the vacuole. M. tuberculosis 
further subverts host immune processes by molecular mimicry. The lipid manose-capped 
lipoarabinomannan (ManLAM) (Brennan 2003; Briken, Porcelli, Besra, & Kremer 2004; 
Steinberg & Grinstein 2008) appears to mimic host phosphatidylinositols, which are only 
usually present on the surface of a mature vacuole (Chua et al. 2004; Deretic et al. 2006). 
Also, M. tuberculosis produces a eukaryotic-like serine/threonine protein kinase G that 
can inhibit phagosome-lysosome fusion (Dietrich & Doherty 2009).  
 
M. tuberculosis produces ‗decoy‘ molecules that may be presented to stimulate a Th1 
response. Animal models have shown that the 27 kDa lipoprotein produces a strong IFN-
γ response that is antigen specific but non-protective and may even promote bacterial 
growth (Hovav et al. 2003; Hovav & Bercovier 2006). M. tuberculosis also utilises 
antigenic variation to evade host immune responses. The highly polymorphic PE-PGRS 
and PPE MPTR gene families are highly immunogenic, but although TB patients display 
significant IFN-γ responses to PGRS proteins, they are not protected (Singh et al. 2008; 
Zheng et al. 2008).  
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During the early stages of M. tuberculosis infection, the unconventional T-cell subsets 
(γδ, NK-T and CD-1 restricted cells) expand considerably (Ladel et al. 1995b; Ladel et al. 
1995a; Schaible & Kaufmann 2000). The receptors of these cells display far less variation 
than the MHC I and II molecules of conventional T cells. In this way, they can act as a 
bridge between the innate and adaptive immune responses by ‗kickstarting‘ cytokine 
production (Dietrich & Doherty 2009; Schaible & Kaufmann 2000). The secretion of 
IFN-γ by these cells activates APCs and stimulates the production of IL-12 and IL-18, 
which participate in a positive feedback loop for IFN- γ (Caccamo et al. 2006). The role 
of IL-12 in the susceptibility to TB is demonstrated by the protection of individuals with 
genotypes conferring high levels of the cytokine. Conversely, functional mutations in the 
IL-12 receptor have been associated with extreme susceptibility to mycobacterial disease 
(de Jong R. et al. 1998; Tso et al. 2004). The role of IL-12 in the proliferation of IFN-γ 
secreting CD4 T cells is important in immunity to TB. Increased susceptibility to disease 
has been shown in animal models when defects in CD4 T cell function (Saunders et al. 
2002; Scanga et al. 2000), or with IFN-γ expression or recognition (Cooper et al. 1993; 
Flynn et al. 1993). Increased susceptibility has also been seen in such patients (Havlir & 
Barnes 1999; Ottenhoff et al. 2005).  
 
The host‘s adaptive immune response plays a role in the control of M. tuberculosis 
infection, although the organism does manipulate this also. Some downstream effects of 
IFN-γ on cytotoxic CD8 T cells can be inhibited by either live M. tuberculosis or cell 
wall extracts. Even if IFN-γ is produced, its activity may be reduced (Kincaid & Ernst 
2003; Manca et al. 2005; Ting et al. 1999). Sodhi and colleagues have demonstrated that 
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IFN-γ responses are poor in patients with advanced TB (Sodhi et al. 1997), while IL-4 is 
elevated (Jimenez-Martinez et al. 2004; Roberts et al. 2007). Studies of disease severity 
in patients (Jalapathy, Prabha, & Das 2004; Jimenez-Martinez et al. 2004) and 
susceptibility to disease in individuals exposed to M. tuberculosis (Ordway et al. 2004; 
Wassie et al. 2008) have shown associations with raised IL-4 expression. The M. 
tuberculosis phosphoglycolipids and the 19 kDa antigen that stimulate of the production 
of IL-4 and IL-13 also inhibit IFN-γ (Briken et al. 2004; Manca et al. 2004; Reed et al. 
2004a). LAM binding to the DC-SIGN receptor stimulates IL-10 production, which also 
inhibits IFN-γ (Appelmelk et al. 2003; Redpath, Ghazal, & Gascoigne 2001; van Kooyk 
Y. & Geijtenbeek 2003). Progression to disease in patients exposed to M. tuberculosis is 
associated with a low IFN-γ/IL-4 ratio (Wassie et al. 2008) and a low IFN-γ/IL-10 ratio 
(Hussain et al. 2007; Sahiratmadja et al. 2007) and as such, phosphoglycolipids, the 19 
kDa antigen and LAM can be considered to be evolved virulence factors that help to 
modulate the host immune system.  
 
TNF-α plays a critical role in controlling M. tuberculosis infection (Jacobs et al. 2007). 
Patients with latent TB infection rapidly progress to active disease when treated with 
TNF-α antagonists, such as Infliximab (Anonymous 2004; Gomez-Reino et al. 2003). As 
such, patients should be thoroughly investigated for TB before commencing such therapy 
(British Thoracic Society 2005).  
 
Another part of the hosts‘ arsenal in controlling infection with M. tuberculosis is the 
ability to remove infected cells from the site of infection either by apoptosis or necrosis. 
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Necrosis is the more disruptive process and results in the destruction of surrounding 
tissue and the release of viable bacilli (Bocchino et al. 2005), whereas apoptosis can 
remove infected cells while minimising death to adjacent cells (Gutierrez et al. 2004). 
Stenger and colleagues have shown that in addition to stimulating the maturation of 
dendritic cells, activating antimicrobial activity in macrophages and the orchestration of 
leucocyte movement, TNF-α plays an important role in the induction of apoptosis 
(Stenger 2005). Furthermore, a reduced apoptotic capacity in the macrophages of HIV-
infected individuals is associated with an inability to control M. tuberculosis infection 
(Patel et al. 2007).  
 
It is highly likely that latent disease will follow infection with M. tuberculosis. Once 
infection occurs, the detection of this event may only be possible by immune-mediated 
investigations. The tuberculin skin test (TST) involves injecting M. tuberculosis antigens 
in the form of purified protein derivatives (PPD) subcutaneously to illicit a delayed-type 
hypersensitivity response indicating long-term T cell memory  (American Thoracic 
Society 2000). An interferon gamma release assay (IGRA) detects long-term T cell 
memory to specific M. tuberculosis antigens such as ESAT-6 and CFP-10 (Arend et al. 
2007b; Ferrara et al. 2006; Granger 2006; Lalvani 2007; Richeldi 2006). This assay is 
discussed in more detail in section 1.5. There is still a lot of uncertainty surrounding the 
process of latency and the dormant bacillus. It is true that those individuals with a 
positive IGRA response are more likely to have encountered the tubercle bacillus than 
those with a positive TST due to the cross reactivity of antigens with non-tuberculous 
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mycobacteria. However, it is uncertain how many of these individuals will proceed to 
active disease and indeed how many of them actually have viable bacilli within them.  
 
There are currently two major models for latency in tuberculosis, which are reviewed in 
(Ehlers 2009). The first describes slowly replicating organisms within granulomas that 
periodically interact with the immune system to recruit new cells to the lesion. This 
disruption of this intermittent interplay with the immune system causes reactivation. 
However, as this model describes free-living bacilli in the alveolar air-space, this 
contradicts the very definition of latency. The second argues that dormant, non-
replicating bacilli are found in alveolar epithelial cells and adipocytes. Here they are 
adapted to hypoxic conditions and are characterised by lipid inclusions (Garton et al. 
2008). Reactivation of disease is associated with the up-regulation by mycobacterial 
resuscitation promoting factors and the escape of bacilli into the alveoli and bronchi 
(Ehlers 2009). Surprisingly, the bacilli seen in the sputum of patients with active 
pulmonary TB contain lipid inclusions that characterise dormancy (Garton et al.  2008).    
 
Vaccination with the attenuated M. bovis BCG (Bacillus Calmette-Guérin) strain has 
been shown to give good protection in children (Colditz et al. 1995) and enhanced 
protection against death, disseminated disease and meningitis (Colditz et al. 1994) but 
this immunity wanes with age (Sterne, Rodrigues, & Guedes 1998) and does not provide 
equal immunity globally, particularly in the areas with the greatest burden (Eickhoff 
1977). It is thought that prior exposure to environmental mycobacteria, previous BCG 
vaccination or TB infection may account for the poor immunogenicity in some areas. 
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This theory is supported by the failure to boost immunity with repeat doses of BCG 
(Leung et al. 2001; Rodrigues et al. 2005). Indeed, previous infection with M. 
tuberculosis does not prevent subsequent re-infection. These findings highlight the scale 
of the challenge in developing novel TB vaccines.    
1.5 Disease Presentation and Diagnosis  
Although initial infection occurs in the lung, systemic effects are often seen in the clinical 
presentation of TB. Fever, weight loss and malaise are all common symptoms and are 
likely to be caused by cytokine release, especially tumour necrosis factor alpha (TNF-α) 
(Ernst 1998; Orme & Cooper 1999; Takashima et al. 1990; Valone et al. 1988). Indeed, 
such systemic symptoms are highlighted in UK guidance (NICE 2006). Biomarkers in 
peripheral blood are also seen. Anaemia and leukopenia may be present. Anaemia and 
pancytopaenia are more often seen when there is bone marrow involvement (Cameron 
1974). Inflammatory markers such as the acute phase protein C-reactive protein (CRP) 
are used in the diagnosis of TB. However, a prospective study has shown that 15% of TB 
patients had normal CRP levels. This study also found that fever, sweats and weight loss 
were absent in 37%, 39% and 39% of TB patients, respectively (Breen et al. 2008).  
1.5.1 Immunological Diagnosis 
 
The tuberculin skin test (TST) is an in vivo assay that is used to detect latent TB 
infection. The TST, also known as an intradermal Mantoux test since 1910, is one of the 
oldest diagnostic test still used in modern medical practice (Richeldi 2006). The validity 
of the TST suffers from low specificity. Purified protein derivative (PPD) is a culture 
filtrate of tubercle bacilli (Seibert & Dufour 1948) that contains over 200 antigens that 
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are shared with M. bovis BCG and most non-tuberculous mycobacteria (Huebner, Schein, 
& Bass, Jr. 1993). PPD is inoculated subdermally and the scale of the delayed-type 
hypersensitivity response, indicating long-term T cell memory, is measured in the size of 
the induration generated. Therefore, interpretation of this test is hampered due to 
exposure to environmental mycobacteria, previous BCG vaccination (Tissot et al. 2005; 
Wang et al. 2002) and in the immunocompromised.  
 
An improvement on the TST are two commercially available immunological assays that 
detect exposure to M. tuberculosis. The QuantiFERON-TB Gold (QFT-G; Cellestis, 
Carnegie, Australia) and the T-SPOT.TB (Oxford Immunotec, Oxford, UK) are ex vivo 
assays that measure the interferon gamma (IFN-γ) expressed by T cells in response to 
exposure to the antigens ESAT-6 and CFP-10, and as such, are collectively referred to as 
interferon gamma release assays (IGRA). The TB-SPOT.TB assay enumerates the IFN-γ 
secreting T cells in a venous blood sample, whilst the QFT-G assay quantifies the amount 
of IFN-γ secreted by patient derived, stimulated T cells (Lalvani 2007).  
 
The use of these assays is recommended in the diagnosis of latent TB infection by the 
National Institute of Health and Clinical Excellence (NICE). Alongside the tuberculin 
skin test, or Mantoux, and chest x-ray these assays are used when contract tracing 
individuals who have been exposed to a confirmed case (NICE 2006). The algorithm for 
the use of these assays in contact tracing is displayed in figure 1.10.  
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The antigens ESAT-6 and CFP-10 are much more specific to M. tuberculosis, than those 
used in the TST, and so the IGRAs are less likely to produce positive results in the case 
of BCG vaccination and exposure to environmental mycobacteria. Indeed, in one study of 
a contact tracing investigation, a positive IGRA result was associated with TB exposure 
whereas a positive TST result was not (Arend et al. 2007a). These assays will be 
discussed in more detail in chapter 5.  
 
1.5.2 Microscopy 
 
The early diagnosis of TB is central to its control. In the poorest parts of the world, where 
majority of the disease burden lies, the mainstay of diagnosis is microscopy. Microscopy 
of respiratory samples may be performed using either light microscopy with a Ziehl-
Neelsen or Kinyoun stain or fluorescent microscopy with a stain such as auramine-O. 
Light microscopy is easier and cheaper and is used in the diagnosis of TB in many 
resource poor settings. In addition, it may be performed in areas with no electricity by 
using reflected sunlight. Fluorescent microscopy is more sensitive but conventionally 
requires an expensive fluorescent microscope and a dark room. The introduction of low-
cost fluorescent LED technology has enabled this more sensitive diagnostic tool to be 
introduced into the areas where it is most needed (Mizuno et al. 2009).  
 
In addition to the type of microscopy used, the number of samples and sampling time are 
crucial to improving the sensitivity of this diagnostic assay. Early morning samples are 
considered to contain more organisms and Ulukanligil and colleagues (Ulukanligil, 
Aslan, & Tasci 2000) showed that the sensitivity of sputum smears increased with repeat 
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sampling. The sensitivity of Ziehl-Neelsen and fluorescence microscopy was found to be 
61% and 83% respectively when a single sample was submitted. When two were 
submitted the sensitivities were 66% and 83% and where three or more were submitted 
sensitivities were 80% and 92%, respectively.  
 
It has been shown that between 5,000 and 10,000 bacilli per milliliter of sputum are 
required to allow visualisation. This is a far higher number than is required for culture 
isolation but the detection of a symptomatic patient with a positive pulmonary smear 
provides the clinician with a presumptive diagnosis and allows the patient to be placed in 
respiratory isolation.  
 
1.5.3 Culture 
 
Culture, although not always positive in patients who are treated for TB, is considered the 
gold-standard for diagnosis. Recent UK data shows that only 56% of notified TB patients 
were confirmed with a positive culture (Health Protection Agency 2009). The sensitivity 
of culture is far higher than microscopy and as few as 10 bacilli per milliliter have been 
detected (Yeager, Jr. et al. 1967). In addition to the increased sensitivity, culture should 
be performed on all specimens to provide definitive species identification, drug 
susceptibility testing and genotyping. Following the removal of contaminating non-
mycobacterial organisms, the specimen is then cultured. It should be noted that, in the 
UK, members of the M. tuberculosis complex are designated to Hazard Group 3 
Pathogens and therefore, such specimens and cultures must be handled using appropriate 
biological safety cabinets inside a containment level 3 laboratory. Traditional culture 
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media are either egg-based (Löwenstein-Jensen), agar based (Middlebrook 7H10 or 
7H11) or liquid (Middlebrook 7H9, 7H12 or Kirshners).  
 
More recent advances into automation have allowed the sensitivity and time to detection 
to improve. The automated liquid culture systems such as MB/BacT system (bioMerieux, 
France) and the MGIT 960 (Becton Dickinson, New Jersey, USA) have both been shown 
to increase sensitivity and reduce detection time when compared to solid media 
(Muyoyeta et al. 2009; Palomino et al. 2008; Parrish et al. 2009; Somoskovi et al. 2000; 
Sorlozano et al. 2009). The MB/BacT system (bioMerieux, France) utilises a modified 
Middlebrook 7H9 broth and a pH-dependent indicator that alters when the pH falls in the 
presecence of increased CO2, which is produced by dividing organisms. The MGIT 960 
(Becton Dickinson, New Jersey, USA) uses a similar culture media, but the detection 
method varies from the MB/BacT. A fluorophore is bound to oxygen in the tube. When 
the organisms divide and utilise the oxyen, the fluorphore is released and detected by the 
analyser. This latter method has been shown to recover more organisms from 
extrapulmonary samples than solid culture (Hilleman et al 2006). Furthermore, an  
increase in time to detection of serial samples in MGIT 960 has been shown to correlate 
to disease resolation in TB patients (Epstein et al 1998).  
 
1.5.4 Nucleic Acid Amplification Tests 
 
Despite the reduction in time to detection by the advances in culture techniques, the 
bacteriological diagnosis of TB can still take several days. Clinicians often wish to start 
treating patients who are strongly suspected of having active TB disease before culture 
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results are available. Several molecular tools have become available over the past 15 
years to aid in the rapid diagnosis of TB. Various molecular targets have been used to 
amplify M. tuberculosis DNA to aid diagnosis. For example, the Qiagen Artus TB PCR 
(Crawley, UK) and the Roche COBAS TaqMan MTB assay (Indianapolis, USA) amplify 
an M. tuberculosis specific section of the 16S rDNA gene. The Cepheid Gene Xpert 
(Derby, UK) targets the rpoB gene whilst the insertion sequence IS6110 is the target in 
the strand displacement amplification (SDA) assay by Becton Dickinson (New Jersey, 
USA).  
 
Sensitivity and specificity for respiratory samples of 93% and 92%, respectively, have 
been reported for this latter assay (McHugh et al. 2004). It should be noted that most 
strains of M. tuberculosis possess multiple copies of IS6110, seemingly making it an 
excellent target for a diagnostic NAAT. However, a very small number of strains have no 
copies of IS6110, and therefore the use of this target should be considered carefully. 
Additionally, IS6110 homologs have been reported in other non-tuberculous 
mycobacteria, so cross-reactivity may reduce the specificity of this assay (McHugh, 
Newport, & Gillespie 1997).  
 
The observation that these assays perform best when used for respiratory samples was 
echoed in an evaluation of NAATs by Dinnes and colleagues (Dinnes et al 2007). 
However, due to a lack of direct comparisons it was not possible to recommend any one 
assay over another. A relatively recently introduced NAAT, the Cepheid GeneXpert, 
allows the detection of M. tuberculosis DNA and rifampicin resistance-causing mutations 
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simultaneously. Analysis of this assay found that the sensitivity was and similar to that of 
the Becton Dickinson assay but higher than that of the Roche Assay (Boehme et al 2010).  
 
1.5.5 Antimicrobial Susceptibility Testing 
 
Drug resistance is discussed further in section 1.7. The prompt detection of drug 
resistance is central to controlling the disease. A number of assays are in use for the 
phenotypic detection of drug resistance/susceptibility. The resistance ratio (RR) method 
is perhaps that the most accurate at measuring the drug susceptibilities of M. tuberculosis. 
(Heifets and Cangelosi 1999). The RR measures the Minimum Inhibitory Concentration 
(MIC – the lowest concentration of antimicrobial capable of inhibiting growth) of the 
strain, compared to reference strain H37Rv when measured in the same experiment. The 
MIC of tested strain is divided by the MIC of H37Rv. If the RR is 2 or less the strain is 
susceptible. An RR of 8 or higher indicates resistance. The modified proportion methed is 
less labour expensive and may utilise automated liquid culture systems (Pfyffer et al 
2002). The strain in question is incubated in the prescence of first line drugs. A growth 
control (1:100 dilution of the strain) is incubated in the absence of drugs. Should growth 
be detected in any of the drug-containing tubes prior to, or at the same time as the growth 
control, this indicates that at least 1% of the bacterial population is resistant to that agent. 
 
The European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the 
European Society of Clinical Microbiology and Infectious Diseases (ESCMID) has a 
Subcommittee on Antimicrobial Susceptibility Testing of Mycobacterium tuberculosis, 
which has reviewed these complex methods alongside molecular and novel assays. It 
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highlights that with regard to phenotypic antimicrobial susceptibility testing, accuracy is 
more important than speed and that stringent quality control measures are standardisation 
are required (Drobniewski et al 2007). Indeed, the WHO European Laboratory 
Strengthening Task Force has recommended standards for modern tuberculosis 
laboratory services in Europe to ensure quality (Drobniewski et al 2006).   
 
The phenotypic detection of antimicrobial susceptibilities is the gold-standard, but this 
takes several days following the isolation of the organism. Microscopic-observation drug-
susceptibility assays (MODS) allow the growth of resistant organisms in the presence of 
anti-tuberculosis drugs to be visualised. This assay may be performed directly on clinical 
samples and has shown some promise, particularly in resource poor settings (Moore et al. 
2006).  
 
The molecular detection of the most commonly occurring resistance genotypes provides a 
rapid diagnosis of drug-resistant TB. Nucleic acid amplification techniques (NAAT) and 
reverse hybridisation assays allow the detection of the most commonly occurring 
rifampicin resistance mutations direct from patient samples (Rossau et al. 1997). The 
detection of mutations conferring resistance to isoniazid and other anti-tuberculosis drugs 
are also available (Hillemann, Rusch-Gerdes, & Richter 2007).  
1.5.6 Imaging 
 
Imaging plays a significant role in the diagnosis TB. A multivariate analysis showed that 
upper lobe disease on a chest radiograph was positively associated with culture proven 
tuberculosis (odds ratio 14.6) (Wisnivesky et al. 2000). Chest radiographs (figure 1.11) 
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do not detect all cases of pulmonary TB however. Pepper and colleagues found that 9% 
of patients with culture-confirmed pulmonary TB had a normal chest x-ray (Pepper et al. 
2008). NICE guidance states that patients with suspected pulmonary TB should undergo 
a posterior–anterior chest X-ray. In addition, all patients with non-respiratory TB should 
have a chest X-ray to exclude or confirm coexisting respiratory TB (NICE 2006). CT 
scanning (figure 1.12) can aid in the diagnosis of both pulmonary and extra-pulmonary, 
especially lymph node and skeletal disease. In addition, CT allows guided biopsies to be 
obtained for laboratory analysis.  
 
1.6 TB Epidemiology in UK and London 
 
The incidence of TB in England and Wales has increased since 1988, following a decline 
over the previous two centuries. Recorded notifications have fallen over the last hundred 
years (figure 1.13). The number of cases of TB in the UK was 8655 in 2008 (14.1 per 
100,000). This was a slight increase from 2007 and numbers and rates had appeared to 
have stabilised since 2005 (Health Protection Agency 2009). The majority of disease is 
centred in major cities. London accounted for 45% of the total number of TB cases in 
England and Wales in 2008 compared with 28% in 1987 (Antoine D 2006;Health 
Protection Agency 2009). The rates and numbers of TB cases in England by region in 
2008 are depicted in figures 1.14 and 1.15. The remainder of cases are distributed 
unevenly across the country, with particular hotspots in the Midlands and North West. 
The burden of disease is also not spread evenly across the capital. Some Primary Care 
Trusts (PCTs) in between 2006-2008 experienced rates that were approximately ten times 
greater than others. For example, Newham and Brent Primary Care Trusts (PCTs) have 
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rates of greater than 80 per 100,000 individuals whilst Richmond and Twickenham PCT 
has rates of 5-9 per 100,000 individuals (figure 1.16). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 1.11 Chest x-ray demonstrating cavitation (indicated by arrow) in the upper right lobe and 
consolidation. Courtesy of Dr. Marc Lipman, Royal Free Hospital, London  
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Figure 1.12 CT scan of the same patient in figure 1.11. Note the large cavity in the upper right lobe 
(indicated by arrow). Courtesy of Dr. Marc Lipman, Royal Free Hospital, London 
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Figure 1.13 TB notifications from 1913 to 2008. A = introduction of streptomycin. B = Introduction of M. 
bovis BCG vaccination (Adapted from (Health Protection Agency 2008)) 
 
A B 
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Figure 1.14. Tuberculosis case reports and rates, UK, 2000-2008 (Health Protection Agency 2009).  
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Figure 1.15 Tuberculosis case reports and rates by region, England, 2008 (Health Protection Agency 2009) 
 
Rates of active transmission in London between 1995-1997 were low and the majority of 
cases were due to reactivation or importation of infection in recent immigrants (Maguire 
et al. 2002). In the UK in 2008 the majority of cases (72%) occurred in those born outside 
of the UK (Health Protection Agency 2009). A recent study has shown that of 21 
European countries, only the UK, Sweden and Norway experienced an increase in rates 
of TB between 1996 and 2005. Approximately three quarters of TB patients in these three 
countries were foreign-born. From the data available, the UK possessed only third highest 
number of foreign nationals (behind Germany and France), but received had the highest 
number of migrants from countries with a TB incidence of ≥ 250 per 100,000 (Gilbert et 
al. 2009).  
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Figure 1.16 Three-year average tuberculosis case rates by primary care organisation*, UK, 2006-2008 
(Health Protection Agency 2009) 
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Although the majority of cases in London are a result of immigration from high incidence 
areas, there are other groups of patients that present a challenge to control of the disease. 
A study by Story and colleagues (Story et al. 2007) of all TB patients who were or should 
have been on treatment in Greater London on July 1
st
 2003 showed strong associations 
with certain hard-to-reach groups. The overall prevalence of TB in this area was 27 per 
100,000. Rates per 100,000 in the homeless, problem drug users and prisoners were 788, 
354 and 208, respectively. Overall, these three groups accounted for 17% of TB cases in 
London and were more likely to be poorly compliant with treatment and lost to follow up. 
It has been further shown that pulmonary TB patients that used crack cocaine were 2.4 
times more likely to have smear-positive disease, and therefore be more infective, than 
those who were not known to use drugs (Story, Bothamley, & Hayward 2008).  
 
Of particular note is an outbreak of isoniazid resistant TB, centred on North London that 
was originally reported in 2004 (Ruddy et al. 2004). The demographics of the patients in 
this outbreak were unusual as the cases were more likely to be male and white or black 
Caribbean. Additionally, the outbreak was strongly associated with homelessness and 
prison detention. By the end of 2001 there were 70 confirmed cases and this was 
predicted to rise significantly. By 2006, the number of culture-confirmed cases had risen 
to 266, with 40 of these outside London. There were nine cases of MDR-TB. Four of 
these cases were a result of poor treatment adherence, while three cases were due to 
primary drug resistance by likely transmission in the community (Maguire H, Forrester, 
& Adam 2006).    
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1.7 Treatment, Drug Resistance and Fitness 
1.7.1 Treatment 
 
The treatment of TB was revolutionised in the 1940s with the discovery of streptomycin 
by Selman Waksman (Jones et al. 1944; Waksman, Reilly, & Schatz 1945), for which he 
received a Nobel Prize in 1952. However, resistance to streptomycin in M. tuberculosis 
was seen rapidly after the introduction of the drug (Crofton & Mitchison 1948). Indeed, 
the British Medical Research Council trial that investigated the efficacy of streptomycin 
showed that the majority of treated patients developed resistant strains (British Medical 
Research Council 1948). The discovery of para-aminosalicylic acid (PAS) by Jorgen 
Lehman in the same year that Waksman discovered streptomycin allowed combination 
therapy to be trialled (Lehman 1949). These trials showed that treatment with PAS and 
streptomycin combined was more effective than either agent when used alone (Turnbull 
et al. 1953).  
 
1.7.2 Modes of Antimicrobial Action and Resistance 
Streptomycin is an aminocyclitol glycoside and was the first anti-tuberculosis drug used. 
It has been shown in E. coli to bind to 16S rRNA, inhibit translational binding and 
therefore protein synthesis (Moazed & Noller 1987; Noller 1984). Resistance to 
streptomycin has been associated with mutations in the 16S rRNA gene (rrs) and rpsL 
encoding ribosomal protein S12 (Cooksey et al. 1996; Douglass & Steyn 1993; Finken et 
al. 1993; Honore & Cole 1994; Meier et al. 1994; Meier et al. 1996; Nair et al. 1993; 
Sreevatsan et al. 1996). Unlike other bacteria, members of the M. tuberculosis complex 
only have one copy of rrs (Bercovier, Kafri, & Sela 1986; Suzuki et al. 1987). Therefore, 
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a single polymorphism has the potential to result in phenotypic streptomycin resistance. 
Most mutations in rrs are focused in two locations (nucleotides 530 and 915), however 
clinical streptomycin resistance is predominantly caused by mutations in rpsL. The most 
common mutation occurs at codon 43 and results in a substitution of lysine with arginine 
(Cooksey et al. 1996; Finken et al. 1993; Honore & Cole 1994; Meier et al. 1994; Meier 
et al. 1996; Nair et al. 1993; Sreevatsan et al. 1996). Mutations are also seen at codon 88. 
A study of isolates from diverse geographic locations showed that 8% of resistant isolates 
were caused by mutations at nucleotides 530 and 915 in rrs. 54% were caused by 
missense mutations at codons 43 or 88 of rpsL whilst 25% showed no mutations in the 
530/915 regions of rrs or in rpsL (Sreevatsan et al. 1996).            
 
Isoniazid is a bactericidal drug that is thought to prevent mycolic acid synthesis and 
therefore cell wall production in M. tuberculosis. Isoniazid is a prodrug that is converted 
to isonicotinic acid by catalse-peroxidase and is used in first line therapy against M. 
tuberculosis. An association was made in the 1950s between isoniazid resistance and a 
reduction in catalase-peroxidase activity (Cohn et al. 1954; Hedgecock & Faucher 1957; 
Middlebrook 1954; Middlebrook, Cohn, & Schaefer 1954). Missense mutations, or small 
deletions or insertions have been found in the gene encoding catalase-peroxidase (katG) 
in ~50-60% of isoniazid resistant isolates (Musser 1995). The most common mutation is 
a serine to threonine at codon 315 (Musser et al. 1996), although this differs with 
geographic location (Marttila et al. 1996; Rouse et al. 1995). 
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Case finding and prompt, appropriate treatment to prevent further dissemination of the 
disease is key to controlling TB. This has been hampered, as with many other infectious 
diseases, by the continuing emergence of drug resistance. Drug resistance in bacteria may 
occur by several mechanisms. These include; the alteration of the drug target, 
modification of the antimicrobial agent, reduced permeability to the agent, its removal by 
efflux mechanisms or metabolic bypass by the utilisation of alternative pathways. 
 
Generally, the genetic mechanisms of resistance in bacteria arise by a number of routes, 
including the acquisition of genes by plasmids or other transposable elements (Guiney, Jr. 
1984; Lacey 1984; Maiden 1998; Ochman, Lawrence, & Groisman 2000), recombination 
of foreign DNA into the chromosome (Johnsborg, Eldholm, & Havarstein 2007) or 
spontaneous mutational events (Davies 1994).  
 
Modification of the intended target of the antimicrobial agent is seen in the case of 
glycopeptides, fluoroquinolone and rifampicin resistance. Modification of the cell wall 
leads to glycopeptide resistance in Enterococci (Werner et al. 2008). DNA gyrase and 
topisomerase IV, the targets of fluoroquinolones, are altered by mutations in gyrA/B or 
parC/E, respectively (Chen & Lo 2003).  
 
Some organisms, such as Staphylococci, produce enzymes known as β-lactamases. These 
enzymes cleave the β-lactam ring at the centre of penicillins and cephalosporins, making 
them inactive (Drawz & Bonomo 2010). The emergence of drug resistant organisms 
necessitates the development of additional antimicrobial agents. Several generations of 
 70 
cephalosporins are now in clinical use in the UK, but the emergence of extended 
spectrum β-lactamases in Enterobacteriaceae has continued (Pitout & Laupland 2008).  
 
An organism may reduce its exposure to an antimicrobial agent, and therefore have a 
reduced susceptibility, by either being less permeable to the agent, or by actively 
reducing the intracellular concentration via efflux pumps. Most antimicrobial agents gain 
intracellular access via porins. For example, imipenem resistant Pseudomonas 
aeruginosa have been shown to be deficient in the OprD porin (Wang & Mi 2006), which 
allows the uptake of imipenem. Additionally, high level chloramphenical resistance has 
been described in Burkholderia cepacia with reduced permeability of the outer 
membrane (Burns, Hedin, & Lien 1989). Efflux pumps actively remove toxic substances 
from both Gram positive and Gram negative organisms (Van Bambeke F., Balzi, & 
Tulkens 2000).  
 
An organism may utilise an alternative pathway, upon which an antimicrobial agent may 
not have an effect. Resistance to sulphonamide and trimethoprim occurs by altered 
production of dihydropteroate synthetase and dihydropholate reductase, respectively 
(Then 1982).  
 
Drug resistance in M. tuberculosis occurs spontaneously and at random (David 1970). 
Using the Luria and Delbrück fluctuation test (Luria & Delbruck 1943), Hugo David 
calculated the mutation rates for M. tuberculosis H37Rv to isoniazid, streptomycin, 
ethambutol and rifampicin. The mutation rate to isoniazid is approximately 100 times 
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higher per bacterium per generation than to rifampicin – 2.56 x 10-8 vs 2.25 x 10-10 
(David 1970). However, mutation rates of rpoB of between 1.3 x10
-7
 and 3.3 x10
-6
 have 
been reported (O'Sullivan, McHugh, & Gillespie 2008). If the selective pressure of 
antimicrobial treatment is present, then these resistant organisms will become fixed in the 
bacterial population due to this advantage. The development of drug resistance is often 
seen in non-compliant patients (Mahmoudi & Iseman 1993).   
 
Low level resistance to isoniazid, as well as to ethionamide (a structural analogue of 
isoniazid) is conferred by mutations in a two-gene operon mabA and inhA (Ramaswamy 
& Musser 1998). In addition, a study in the Netherlands found that 11 of 51 clinical 
isoniazid resistant strains showed a C→T substitution upstream of the presumed 
ribosome binding site of mabA. These strains lacked mutations at codon 315 in katG 
(Musser, Kapur, Williams, Kreiswirth, van, & van Embden 1996). It is hypothesised that 
these changes result in an increase in InhA protein production and therefore isoniazid 
resistance by target saturation (Ramaswamy & Musser 1998).  
 
Rifampicin is a bactericidal drug used in first line therapy against M. tuberculosis. 
Studies in E. coli have shown that rifampicin binds to the β-subunit of RNA polymerase, 
resulting in the inhibition of transcription initiation (McClure & Cech 1978). Rifampicin 
resistance has been well characterized to be the result of point mutations or small 
deletions in the RNA polymerase gene (rpoB) (Miller, Crawford, & Shinnick 1994; 
Musser 1995; Telenti et al. 1993). Importantly, >95% of resistance causing mutations are 
found in an 81bp region of rpoB (codons 507 – 533, encoding 27 amino acids) termed the 
 72 
RRDR (rifampicin resistance determining region) (Donnabella et al. 1994; Heym et al. 
1994; Kapur et al. 1995; Kapur et al. 1994; Morris et al. 1995; Musser 1995; Telenti et al. 
1993).  The most common mutation sites in the RRDR are at codon 531 (42%) and 526 
(23%) (Musser 1995). 
1.7.3 Fitness 
 
The often-used term ‗fitness‘ in relation to bacteria and drug resistance encompasses a 
number of overlapping factors. The term implies that there is a variation that is 
inheritable between different members of the same species. With regard to infectious 
pathogens, the term can be taken to be the representation of an organism‘s ability to 
survive, reproduce and be transmitted between hosts. The factors that influence the 
organism‘s ability in each of these areas are of course numerous. They include the growth 
characteristics, the ability to survive within (and outside) a host and the ability to be 
disseminated. 
 
Some of the characteristics that contribute to an organisms‘ fitness are measurable in the 
laboratory, such as the determination of growth rates in liquid culture (Bennett, Dao, & 
Lenski 1990; Kugelberg et al. 2005), infectivity in animal models (Bjorkman et al. 1999; 
Bjorkman, Hughes, & Andersson 1998) or the ability to survive a particular challenge. 
The ability to spread between hosts in a given population can be measured 
epidemiologically. The dissemination of a resistant strain in a population can be 
compared with sensitive strains to determine whether the acquisition of drug resistance 
has affected its transmissibility.  
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It had previously been assumed that the acquisition of antimicrobial resistance results in a 
fitness cost (Gillespie & McHugh 1997). This has been shown to be partially true, but the 
full picture is far from clear. A spontaneous mutation that confers drug resistance will 
therefore provide an advantage in an appropriately selective environment. If the mutation 
affects an essential function and therefore incurs a metabolic cost, then it would be 
sensible to hypothesise that the mutant will be ‗less fit‘ than its sensitive precursor. 
However, this is not always the case. A fitness cost is usually, but not always, seen 
initially. For example, Bjorkman and colleagues described streptomycin resistant 
Salmonella typhimurium strains with different mutations at the same locus in rpsL. Some 
strains demonstrated a reduced fitness, whilst some were comparable to wild type. In this 
case, fitness was measured by both growth rates in murine models and optical density in 
liquid culture (Bjorkman et al 1999).  
 
Another assumption was that when a selective pressure was removed, for example an 
antibiotic, then the less-fit resistant mutants would revert to sensitive wild type. Studies 
have shown that this does occur, but not often. For example, true reversion has been 
described in the fusA gene in fusidic acid resistant Salmonella typhimurium in murine 
models (Andersson & Levin 1999). More commonly, compensatory mutations occur 
which allow the organism to retain the resistance mutation whilst restoring fitness to a 
level that was previously present. These mutations may be within the same gene as the 
resistance-causing mutation (intragenic) or elsewhere (extragenic). Bjorkman and 
colleagues described intragenic compensatory mutations in the rpsL, gyrA and rpoB 
genes of S. typhimurium resistant to streptomycin, naladixic acid and rifampicin, 
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respectively. In each case, the drug resistance was maintained (Bjorkman et al 1999).  
Extragenic compensatory mutations in rpsD/E have been described in E. coli strains with 
streptomycin conferring mutations in rpsL (Schrag, Perrot, & Levin 1997).  
 
1.7.4 Epidemiology of Drug Resistance 
  
With hindsight, the rapid acquisition of drug resistance, especially to mono-therapy, was 
inevitable. Resistance arises due to genetic mutations brought about by selective pressure 
due to inappropriate or incomplete antimicrobial treatment (Aziz & Wright 2005). This 
may be a result of erroneous prescribing practices or erratic dosing on the part of the 
patient (Mahmoudi & Iseman 1993). Fitness and drug resistance in M. tuberculosis are 
explored in chapter 6. 
 
Standard first line therapy for sensitive respiratory disease in the UK consists of six 
months treatment with rifampicin and isoniazid, supplemented for the first two months 
with pyrazinamide and ethambutol or streptomycin. (NICE 2006). The most commonly 
seen drug resistance in clinical practice in the UK is isoniazid mono-resistance. The 
additional acquisition of resistance to rifampicin constitutes multi-drug resistance (MDR-
TB) (Kruijshaar et al. 2008; Zager & McNerney 2008). The emergence of MDR-TB 
necessitated the use of other antimicrobial agents and of course, in Darwinian fashion, the 
development of further resistance. 
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Figure 1.17. MDR-TB among new cases 1994-2007 (WHO 2008).  
 
In 2000 the WHO‘s Stop TB partnership noted a number of cases that were resistant to all 
second line agents (Anonymous 2006). On this basis, the WHO defined those strains that 
are resistant to isoniazid and rifampin and at least three of the six main classes of second 
line agents (aminoglycosides, polypeptides, fluoroquinolones, thioamides, cycloserine, 
and para-aminosalicyclic acid) as extensively drug resistant (XDR). Using this definition, 
surveillance between 2000 and 2004 by CDC and WHO of over 17,000 strains in an 
international network of TB laboratories domonstrtaed rates of MDR-TB at 20% and 
XDR-TB at 2% (Anonymous 2006).  
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Clinicians in a rural hospital in the KwaZulu Natal province of South Africa in early 
2005 noted high mortality rates in TB patients who were co-infected with HIV. 
Surveillance showed that of over 1500 TB patients, 221 had MDR strains and 53 of these 
had further resistances (Gandhi et al. 2006). These 53 strains were resistant to isoniazid, 
rifampicin and at least three of the six main classes of second-line drugs 
(aminoglycosides, polypeptides, fluoroquinolones, thiamides, cycloserine and PAS). The 
resistance profile was termed extensively drug resistant TB (XDR-TB). All 53 patients 
were HIV positive and over half claimed to have never been previously treated for TB, 
indicating primary acquisition of XDR-TB. All but one patient died with a mean survival 
of 16 days from the date sputum was first collected (Gandhi et al. 2006). XDR-TB was 
redefined by WHO in October 2006 to include the resistance to isoniazid, rifampicin, a 
fluoroquinolone and at least one of three injectable second-line drugs (amikacin, 
kapreomycin or kanamycin) (Anonymous 2007). This definition still stands today.   
 
The global spread of MDR and XDR-TB pose a huge challenge to the control of the 
disease. Surveillance by the Global Project on Anti-Tuberculosis Drug Resistance 
between 2002 and 2007 showed that resistance to any drug was seen 11.1% (Wright et al 
2009). Rates of MDR-TB increased in virtually all counties. Rates of 7% were seen in 
two provinces in China, between 6·8% and 22·3% in nine countries of the former Soviet 
Union, including 19·4% in Moldova and 22·3% in Baku, Azerbaijan. Five countries, all 
from the former Soviet Union, reported 25 cases or more of XDR-TB each.  
 
Control of TB depends on early detection and treatment of cases and it should also be 
noted that the prevalence of drug resistance is higher amongst individuals who have 
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previously been treated for TB (WHO 2008). Additionally, the prevalence of MDR and 
XDR-TB in an area or country is inversely proportional to the quality of the TB programs 
(Matteelli et al. 2007). The most recent estimates of global prevalence of MDR (figure 
1.17) and XDR-TB (figure 1.18) are shown.   
Figure 1.18. XDR-TB among MDR-TB cases 2002-2007 (WHO 2008) 
 
 Rates of drug resistance in the UK have been stable for the past ten years (figure 1.19) 
and in 2008, 6.8% of M. tuberculosis isolates in the UK were resistant to at least one first 
line drug. The majority (6%) were resistant to isoniazid, while 1.1% were resistant to 
both isoniazid and rifampicin, constituting MDR TB (Health Protection Agency 2009). 
The largest proportion of drug resistant cases in the UK (48.6% in 2008) is seen in 
London (Health Protection Agency 2009). However, it should be noted that although 
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resistance rates are stable, the overall rise in TB cases means that the absolute number of 
patients with drug resistant TB is increasing.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.19. Proportion of tuberculosis cases with first-line drug resistance, UK, 2000-2008 (Health 
Protection Agency 2009).  
 
It may occasionally be necessary to visually supervise the adherence to therapy for some 
patients to ensure treatment completion and minimise the risk of relapse. NICE guidance 
recommends that although the use of directly observed therapy (DOT) is not usually 
necessary in the management of most cases of active TB, all patients should have a risk 
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assessment for adherence to treatment. Some patients, such as street- or shelter-dwelling 
homeless people and those with likely poor adherence, in particular those who have a 
history of non-adherence are more likely to benefit from DOT (NICE 2006). Indeed, a 
study by Story and colleagues has shown that only 15% of homeless people, drug abusers 
and prisoners with TB start on DOT, but 46% end up on DOT due to poor compliance 
(Story et al. 2007).   
 
It should be noted that the treatment of drug-resistant TB is less effective than first line 
therapy and causes more drug related toxicity. A number of studies comparing clinical 
outcomes in MDR have been performed – see (Chan & Iseman 2008) for review. 
However, due to differences in data collection, end points and methods of drug-
susceptibility testing, it is not possible to directly compare these studies. Chan and 
colleagues did, however, identify risk factors that were associated with poor outcome in 
MDR and XDR-TB. These include: prior TB treatment, the number of anti-microbial 
agents that the strain was resistant to, resistance to (or prior use of) fluoroquinolones, 
HIV positivity, a history of imprisonment, a low BMI and the involvement of 
extrapulmonary sites (Chan & Iseman 2008). 
 
Two studies from the same institution have demonstrated that the care of patients with 
drug-resistant TB has improved in some settings, however. Goble and colleagues (Goble 
et al. 1993) studied 171 patients with pulmonary MDR-TB between 1973 and 1983. Only 
65% initially responded to treatment (as measured by three consecutive culture-negative 
sputum samples over three months). The long-term ‗cure‘ rate at 51 months was 56% and 
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the overall mortality rate was 37%. Between 1984 and 1998 Chan and colleagues (Chan 
et al. 2004) studied 205 MDR-TB patients. The initial success rate was 85%, long-term 
cure rose to 75% and mortality had declined to 12%.  
Furthermore, it is far more costly to treat a case of MDR TB compared to sensitive 
disease. In 2000 it was estimated that the cost of treating a single case of MDR TB was 
approximately £60,000 compared to £6,040 for susceptible disease (White & Moore-
Gillon 2000). Additionally, the patients who do not respond to treatment but survive may 
extend the period of infectiousness, which may cause increased transmission (Goble et al. 
1993).  
 
As clinicians in the UK have limited experience managing drug resistant cases an 
MDRTB Service was established at the
 
Cardiothoracic Centre in Liverpool and now the 
British Thoracic Society has been operational
 
since 1 January 2008. The service has the 
support of the relevant
 
professional bodies, including the British Thoracic Society,
 
the 
British Infection Society, and the Health Protection Agency (Davies & Cullen 2008). 
This expert group can give direct advice and support nationwide via an electronic 
network.  
 
1.8 TB and HIV  
 
The HIV pandemic plays a hugely significant role the global landscape of TB. The 
infection of CD4 T cells seen in HIV is central to this phenomenon. There is a range of 
CD4 cells from the early activated cells that produce only IL-2, cells making IFN-γ and 
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multifunctional cells expressing IL-2, IFN and TNF. These multifunctional cells are 
associated with protection (Cooper 2009). The loss of these cells increases the likelihood 
of succumbing to the disease (Havlir & Barnes 1999).   
Certain associations have been made regarding the phenotypes of TB disease in HIV 
patients. For example, Marshall and colleagues (Marshall et al 1999) noted a higher rate 
of pulmonary TB in HIV patients. This may be due to a higher rate of recently acquired 
disease. It has previously been shown that the diagnosis of TB in HIV infected 
individuals increases the risk of death (Perneger et al. 1995; Whalen et al. 1995), and 
there is even some evidence that suggests that M. tuberculosis may accelerate the 
progression of HIV disease (Wallis et al. 1993). An increased death rate from TB in HIV 
patients was also observed by Atun and colleagues (Atun et al 2005). However, there was 
no such association in a recent study in London (Rodger et al. 2010). This study also 
found no link between HIV and smear status in TB patients. Higher rates of drug-
resistant TB were observed in HIV patients in the UK between 1993 and 1997 by 
Djuretic and colleagues (Djuretic et al 2002). However, this was not observed in later 
studies (French et al. 2009; Rodger et al. 2010).   
 
TB was assigned as an AIDS-defining illness in 1998 and rates of HIV diagnosis 
increased partially due to this alongside the increase in immigration to the UK from areas 
with high rates of HIV (figure 1.20). Despite this, TB often occurs in HIV patients with 
more intact immune systems than other AIDS-defining illnesses (Antonucci et al. 1995). 
The proportion of TB patients who were co-infected with HIV increased in England and 
Wales from 3.1% in 1999 to 8.3% in 2003. HIV co-infected patients contributed to 
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almost a third of the increase in the number of cases of TB during this period (Ahmed et 
al. 2007). Indeed, universal testing for HIV in TB patients has been advocated for more 
than a decade. A recent study in London found a wide range in the percentage of TB 
patients being offered an HIV test. Overall, approximately 50% of patients were offered 
an HIV test. However, this varied widely between centres, with only one offering tests to 
over 80% of patients and more than half offering a test in fewer than 50% of cases 
(Bonora & Di 2008; Rodger et al. 2010).  
 
 
 
 
 
 
 
 
 
 
Figure 1.20 HIV notifications in the UK (Health Protection Agency HIV and AIDS reporting service) 
 
 
Finally, there are the complex interactions between antituberculosis drugs and highly 
active antiretroviral therapy (HAART) to consider in this important patient group 
(Bonora & Di 2008). The British HIV Association has issued guidelines for the treatment 
of TB/ HIV co-infection 2009 (British HIV Association 2009). It is necessary to 
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effectively treat TB whilst reducing the HIV viral load and maintaining CD4 counts. This 
has been shown to be achievable (Breen et al. 2006).  
  
One clinical presentation seen in these patients is the phenomenon of immune 
reconstitution inflammatory syndrome (IRIS). This syndrome contains a wide range of 
symptoms and is not restricted to infection to HIV/TB infection (French, Price, & Stone 
2004; Lipman & Breen 2006). IRIS may be seen in HIV patients co-infected with M. 
tuberculosis, M. avium or Cryptococcus neophormans (Shelburne et al. 2005) and other 
infectious and autoimmune conditions (French, Price, & Stone 2004). M. tuberculosis-
related IRIS in HIV usually presents within the first two months of commencing HAART 
but more commonly within the first 2–3 weeks. The most common presenting features 
are severe fever, intra-thoracic and cervical lymphadenopathy and pulmonary infiltrates. 
Extra-pulmonary disease is less commonly seen, but may include focal cerebritis, pleural 
effusions, hepatosplenomegaly and ascites (French, Price, & Stone 2004). It is also seen 
in non-HIV infected TB patients, although far less frequently (Breen et al. 2004), and 
may be compartmentalized, affecting only one area of the body (Wilkinson et al. 2005).    
 
1.9 Genotyping 
 
In addition to elucidating the evolutionary origins of M. tuberculosis, as already stated, 
genotyping of M. tuberculosis aids the investigation of known or suspected outbreaks, 
identifies laboratory cross contamination, facilitates the estimation of the extent of recent 
transmission and distinguishes between reactivation and re-infection. Identifying clusters 
and associated lineages can be useful in investigating virulence, transmissibility and drug 
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resistance. In essence, genotyping should measure genetic markers that are representative 
of the genome as a whole. The changes in these markers may then be used to hypothesise 
the degree of relatedness and evolutionary paths between strains.  
Molecular fingerprinting has been used in the UK to confirm or refute outbreaks, 
contributing to the management of an outbreak of sensitive tuberculosis centred around a 
high school in Leicester (Drobniewski et al. 2003) and an ongoing outbreak of isoniazid 
resistant tuberculosis in London (Ruddy et al. 2004). The former outbreak was largely 
identified by conventional epidemiology although strain typing was used to definitively 
include or exclude patients.  
 
1.9.1 Contamination 
 
Molecular strain typing M. tuberculosis isolates is useful in the monitoring of laboratory 
cross contamination. Cross contamination is an ongoing problem due to the ability of the 
organism to survive in the environment for long periods and the sensitive culture systems 
used. Contamination rates of between 0 and 60% have been reported (Ruddy et al. 2002). 
However, the highest reported rates were in studies where the laboratory suspected that 
contamination was occurring and contamination rates of below 3% are more common 
(Burman & Reves 2000; Ruddy et al. 2002). The identification of a false-positive culture 
from a clinical sample may have serious consequences as unnecessary drug treatment 
may be commenced, which can therefore cause toxicity. Additionally, unnecessary 
investigations, hospitalisation and contact tracing may be performed.  
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1.9.2 Re-infection vs. Relapse 
 
The presentation of a patient with symptoms consistent with TB following a previous 
episode usually falls into one of two categories. The patient may have been inadequately 
treated and a relapse with the original strain may have occurred. This may be complicated 
by the acquisition of drug resistance. Alternatively, the patient may have been 
successfully treated for their original infection, but has become re-infected with another 
strain.  
 
These two scenarios are impossible to distinguish on clinical presentation alone. 
Genotyping of any organism isolated allows comparison to previous isolates. An 
indistinguishable genotype indicates relapse (with or without acquired drug resistance) 
whilst a different genotype would suggest re-infection. Figure 1.21 shows the sequential 
IS6110 RFLP fingerprints from M. tuberculosis isolates cultured from a non-compliant 
TB patient. The patient re-presented over the course of over one year with recurrence of 
their disease. Genotyping was performed on each isolate to determine whether the patient 
has relapsed or been infected with a novel strain. The genotyping demonstrated that the 
patient was infected with the same strain and was relapsing. The asterisks indicate the 
time points at which drug-susceptibilities were performed. The organism was fully 
susceptible at week 31, was isoniazid mono-resistant at week 52 and additionally 
acquired rifampicin resistance at week 67. The acquisition of drug resistance did not 
affect the IS6110 RFLP fingerprint.  
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Figure 1.21. IS6110 RFLP of sequential isolates from an individual patient. Genotyping confirmed that the 
patient was undergoing multiple relapses and acquiring drug resistance (identified at weeks 31, 52 and 67) 
rather than being reinfected with different strains. Courtesy Dr. Nicky Hutchinson, St. George‘s University 
of London. 
Weeks      0   13  31  51  52  53  56  56        61 62  64   67 70  71 72
* * *
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1.9.3 Defining the Relatedness of Strains by Genotyping: Clusters, Lineages and 
Superfamilies 
 
It is important to understand the differences between genotyping and epidemiological 
data, as well as acknowledging the wealth of knowledge that they can cumulatively 
provide. Epidemiological links between patients and the collection of demographic data 
provide the backbone in outbreak investigation. The collection of complete 
epidemiological data is essential for any study or investigation. Alongside a thorough 
clinical history, including the date of onset of symptoms, a range of patient demographics 
must be noted. These may include the place of residence and work, country of birth, 
travel history and social habits to ascertain potential exposure. These may then be 
analysed alongside genotyping data. 
 
A number of different techniques have been used to genotype M. tuberculosis and these 
have been thoroughly reviewed (Barnes & Cave 2003a; Kanduma, McHugh, & Gillespie 
2003; Mathema et al. 2006) for reviews. Several factors are important when considering a 
genotyping method. Reliable reproducibility and transportability are crucial to allow the 
comparison of data between centres. The technical difficulty of the method plays a role in 
the reproducibility obtained. The level of discrimination is very important when 
interpreting data. This discriminatory power varies between methodologies and is directly 
related to the number of subdivisions in a group of strains that a genotyping method 
generates. That is, a highly discriminatory method will subdivide a cluster of strains into 
more groups than one with a lower discriminatory power. This will be explored later in 
chapters 3 and 4. 
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It is not always necessary to use the genotyping method that is most discriminatory, 
however. If, for example, a method with a low discriminatory power refutes a suspected 
outbreak, there is no need to use a more discriminatory method (Shorten et al. 2005). 
 
1.9.4 Genotyping Methodologies 
 
Regardless of the method used, the discriminatory power, and therefore the degree of 
clustering of genotyped strains will depend directly on the rate of change of the molecular 
element. The basic methodology and usefulness of the most widely used genotyping tools 
and their molecular stability are described here. 
 
1.9.4.1 IS6110 RFLP 
 
Repetitive elements were identified in the M. tuberculosis genome independently by 
Eisenach and colleagues (Eisenach, Crawford, & Bates 1988; Zainuddin & Dale 1989). 
The insertion sequence IS6110 was first sequenced and found to be a member of the IS3 
family by Thierry and colleagues (Thierry et al. 1990). This group described the insertion 
sequence as being specific to the M. tuberculosis complex, estimated that M. tuberculosis 
possessed between 10 – 20 copies scattered throughout the genome, and hypothesised on 
its usefulness in epidemiological studies. The insertion sequence was also amplified in 
clinical samples from patients with suspected and confirmed TB. Others independently 
identified the insertion sequences IS986 (McAdam et al. 1990) and IS987 (Hermans et al. 
1990). These two insertion sequences differed from each other, and also from IS6110, by 
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only a few base pairs so were considered to be essentially the same element, designated 
IS6110 (van Embden et al. 1993).   
 
The insertion of IS6110 has been shown to modify regulatory function in some strains. 
Safi and colleagues (Safi et al 2004) demonstrated that IS6110 can upregulate 
downstream genes through an outward-directed promoter in its 3‘ end. Promotor activity 
was orientation dependent but upregualtion was seen in during growth in monocytes and 
in in vitro cultures. This suggests that insertion and deletion of IS6110 may alter the 
phenotype of the organism as well as being a means by which its evolution may be 
studied.  
 
Insertion sequences have been used to genotype M. tuberculosis in numerous outbreak 
situations (Cave et al. 1991; Daley et al. 1992; Edlin et al. 1992; Fomukong et al. 1992; 
Hermans et al. 1990; Mazurek et al. 1991; Otal et al. 1991; van Soolingen et al. 1991) 
and a consensus was required to allow the standardisation of the methodology that would 
allow comparison of strain types between centres. Molecular fingerprinting using IS6110 
relies on the cultivation of the organism, genomic DNA extraction, enzymatic restriction, 
agarose gel electrophoresis, Southern hybridisation and detection of the IS elements with 
a labelled probe. The three elements that required standardisation were the restriction 
enzyme, nature of the labelled probe and the molecular size-markers used. In 
collaboration, researchers who had been instrumental in the discovery and 
characterisation of IS6110 concluded that PvuII should be used, since IS6110 possessed 
only one restriction site for this enzyme (figure 1.22). The probe was designed to bind 
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only to the right of the restriction site in order to allow the visualisation of only a single 
band per IS6110 copy (fig 1.22). Finally, it was agreed that a molecular size marker 
ranging between 0.9 and 10kb be used in addition to a reference strain Mt14323 (van 
Embden et al. 1993).  
 
 
Figure 1.22 Physical map of IS6110 (van Embden et al. 1993).  
 
 
It was soon noted that some strains posses few copies of IS6110 and therefore could not 
be adequately discriminated by this method (van Soolingen et al. 1993). This study also 
demonstrated one strain that lacked even a single copy of IS6110. This rare event may 
have a detrimental effect on the use of diagnostic NAATs that target this insertion 
sequence. Indeed, a respiratory sample from a symptomatic, smear-positive patient gave a 
false negative TB PCR result. The sample subsequently grew an organism that was 
identified as M. tuberculosis and was shown to lack IS6110 (Shorten, unpublished data). 
An example of an IS6110 RFLP image can be seen in figure 1.23, whilst an example of 
the distribution of strains with varying numbers of IS6110 copies can be seen in figure 
1.24.  
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Figure 1.23. Image of the IS6110 RFLP genotyping patterns of multiple clinical strains. Note the reference 
strain MT14323 in the first, twelfth and last lanes. Note also the low copy number strains (those possessing 
fewer than five copies of IS6110).  
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Figure 1.24. Frequency distribution of number of copies of IS6110 for 2490 clinical isolates of M. 
tuberculosis in London between 1995 and 1997 (Maguire et al. 2002) 
 
 
Knowledge of the rate of change of this insertion sequence is critical when interpreting 
any genotyping data. The insertion sequences may be duplicated and inserted into the 
genome, moved to another location in the genome or excised and lost from the genome. 
These events have occasionally been termed birth, shift and death, respectively 
(Rosenberg, Tsolaki, & Tanaka 2003). If the rate of change is rapid, then a strain 
transmitted from one individual to another may produce a different genotype, which 
would result in this chain of transmission being missed, and an underestimation of 
ongoing transmission in a community. However, if the rate of change is slow, then 
organisms that are not closely epidemiologically linked would produce false clusters and 
would over estimate the rate of transmission.  
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Several studies have been performed that investigate the rate of change in IS6110 
banding patterns in serial isolates from individuals infected with M. tuberculosis. It is 
difficult to standardise and control such studies as repeat samples from TB patients are 
usually only obtained should the patient be unwell and re-present to their clinician. 
 
Yeh and colleagues investigated 49 patients with two or more isolates of M. tuberculosis 
cultured from specimens taken at least 90 days apart (range 90 days – 3 years) (Yeh et al. 
1998). Changes in the IS6110 pattern were seen in 12 (25%) patients. IS6110 changes 
were not related to HIV status, drug resistance or adherence to treatment. This group 
concluded that as there was an unexpectedly high rate of change, patients with IS6110 
patterns that differ by a single band should maybe be considered related and be 
investigated as a possible transmission event.  
 
The investigation of serial isolates from 544 patients showed a much lower rate of change 
(de Boer et al. 1999). Only 25 (4.6%) of follow-up patient isolates differed from the 
original strain. This group calculated that in this cohort that there was a change in 
banding pattern (half-life) on average every 3.2 years (95% CI 2.1 – 5.0). There was an 
association with increased rate of change in strains cultured from patients with 
extrapulmonary as well as both pulmonary and extrapulmonary disease. The data 
collected by Yeh and colleagues (Yeh et al. 1998) was reanalysed by this group and the 
mean half-life was found to be 2 years (95% CI 1.2 – 3.5) (de Boer et al. 1999).  
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A longer half-life was described in the high-incidence setting of Cape Town, South 
Africa. Of 349 repeat patient samples, 14 (4%) demonstrated a variant IS6110 pattern 
compared to the initial IS6110 genotype (Warren et al. 2002). The percentage of altered 
strains was comparable with the findings of de Boer 4% vs. 4.6%, respectively, (de Boer 
et al. 1999), but the period between initial and subsequent samples being taken varied 
between 0 and 2000 days. Analysis showed a mean half-life of 8.74 years. Interestingly 
however, the 14 strains demonstrating variance in their IS6110 genotype fell into two 
distinct groups. Eight of the 14 (57%) were sampled within 20 days of the initial isolate, 
whilst the remaining six (43%) were sampled after at least 250 days. This gave two 
distinct groups of half lives – 0.57 years (the early group) and 10.69 years (the late group) 
(Warren et al. 2002).   
 
A slightly higher rate of change was seen in the study of 56 TB patients in Germany 
(Niemann, Richter, & Rusch-Gerdes 1999). This group observed that 5 out of 56 patients 
(9%) were infected with a strain that changed IS6110 pattern upon repeat isolation. The 
length of time between first and subsequent isolates varied between 1 and 772 days. 
There was a correlation between a change in IS6110 pattern and increased length of time 
between samples. However, there was no link between a change in IS6110 pattern and 
acquisition of drug resistance.  
 
The location of the insertion sequence has been shown to occur in a non-random manner. 
Certain ‗hotspots‘ have been identified where insertion sequences are more likely to be 
found. Indeed, strains possessing few copies of IS6110 were more likely to have 
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insertions in these locations (McHugh & Gillespie 1998). For this reason, isolates that 
possess fewer than five copies of IS6110 are termed ‗low copy number‘ strains and are 
not able to be differentiated by this method. Furthermore, low copy number strains that 
have been shown to possess the same insertion by sequence analysis have produced 
different IS6110 RFLP patterns (Dale et al. 2003a). This may be due to polymorphisms 
elsewhere that insert or delete a PvuII restriction site.  
 
One should therefore take into account the finer details of this method, including the lack 
of discrimination of strains with few IS6110 copies, the rate of change of the banding 
patterns obtained and the predisposition of the insertion sequence to insert into hotspots 
in a non-random fashion, when interpreting any data obtained. False clusters have been 
seen in epidemiologically unlinked isolates. A study in Northern Tanzania demonstrated 
that three strains of M. tuberculosis that were epidemiologically unlinked were 
indistinguishable by IS6110 RFLP (Gillespie, Dickens, & McHugh 2000). Further 
analysis showed that six of the nine copies of IS6110 that the strains possessed were in 
hotspots and polymorphic GC-rich repetitive sequence (PGRS) typing (see 1.10.4.4) 
revealed that they were distinct strains.  
 
IS6110 RFLP offers good discrimination but is slow, labour intensive, and requires large 
quantities of DNA (>200ng). Mature cultures are required to provide sufficient quantities 
of DNA, which makes the use of this method limited in real-time outbreak investigation. 
It is also unable to distinguish strains with few IS6110 copies (< 5).  
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1.9.4.2 Mycobacterial Interspersed Repetitive Units – Variable Number Tandem 
Repeats (MIRU-VNTR) 
 
Repetitive units of DNA in organisms are well described (Higgins, McLaren, & Newbury 
1988; Lupski & Weinstock 1992) and have been used to genotype a large array of 
bacteria such as Escherichia coli (Manges et al. 2009), Clostridium difficile (Marsh et al. 
2006; van den Berg et al. 2007), Bacillus anthracis (Keim et al. 1999; Le Fleche P. et al. 
2001), Yersinia pestis (Klevytska et al. 2001; Le Fleche et al. 2001), Listeria 
monocytogenes (Lindstedt et al. 2008), Shigella spp. (Gorge et al. 2008). Additionally, 
VNTRs are also used in mapping human genes (Nakamura et al. 1987).  
 
Supply and colleagues identified a novel group of such repetitive units that they named 
mycobacterial interspersed repetitive units (MIRU). They are mainly intergenic and are 
distributed throughout the genome. These units were unlike other repetitive units 
previously described as they contained no obvious palindromic sequences, were direct 
tandem repeats and were orientated in one direction relative to the transcription of the 
adjacent genes. Additionally, approximately half of the MIRUs described contained small 
ORFs and based on sequence homology of the M. tuberculosis sequences at the time, it 
was estimated that there may be 40-50 such MIRUs per genome (Supply et al. 1997). At 
approximately the same time, analysis of published sequences by Frothingham and 
Meeker-O‘Connell identified a number of repetitive regions in M. tuberculosis H37Rv. 
Some of these, termed exact tandem repeats A to F (ETR-A to F), were variable between 
strains (Frothingham & Meeker-O'Connell 1998). 
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Further work by Supply and colleagues identified a total of 41MIRU loci when analysing 
the complete H37Rv genome (figure 1.25) (Supply et al. 2000). These tandem repeats 
varied between loci and strains and may be amplified with the use of specific PCR 
primers to each MIRU-flanking region. If a strain lacked a single repeat at a MIRU locus 
a PCR product would still be generated. The sizing of these PCR products would enable 
the investigator to identify the number of repeats present at each locus and therefore 
generate a numerical genotype (figure 1.26).  
 
There was congruence between five of these MIRU loci and ETR A-E previously 
described (Frothingham & Meeker-O'Connell 1998). The variability between strains of 
these 41 loci differ and analysis of a set of internationally obtained strains (Kremer et al. 
1999) suggested that 12 of these loci exhibited a suitable degree of variability to be used 
in a genotyping methodology (Supply et al. 2000).  
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Figure 1.25 Location of MIRU loci in M. tuberculosis H37Rv genome (Supply 2000 Mol Micro)  
 
 
The discriminatory power of this method may be altered by varying the number of MIRU 
loci included in the analysis. For example, when only five loci were used, Kremer and 
colleagues found VNTR to be less discriminatory than IS6110 RFLP, spoligotyping  
(1.9.4.3) and PGRS (1.9.4.4) (Kremer et al. 1999). Kwara and colleagues analysed 64 M. 
tuberculosis strains clustered into ten groups by IS6110 RFLP (Kwara et al. 2003). 
Spoligotyping and 12 loci MIRU were used to attempt to further differentiate these 
clusters. MIRU analysis differentiated these strains to a higher degree than both IS6110 
RFLP and spoligotyping. In another study, however, 12 loci MIRU alongside 
spoligotyping was found to be less discriminatory than IS6110 RFLP (Supply et al. 
2006). Five loci VNTR was found to be more discriminatory than IS6110 RFLP in strains 
with few copies of IS6110 (Barlow et al. 2001). The further discrimination of apparent 
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clusters of high IS6110 copy number strains by 12-loci MIRU has also been described 
(van Deutekom et al. 2005). The relative levels of discrimination will of course vary 
depending on the number, and geographical representation of strains analysed.   
 
As some loci are more variable than others, the discriminatory power of MIRU does not 
increase in a linear manner with the analysis of additional loci. The more discriminatory a 
method, the fewer clusters will be generated when strain typing a group of strains. The 
allelic diversity (h) of each locus may be calculated as by Selander and colleagues as 
follows (equation 1.1):  
 
h = 1 - Σxi
2
 [n/(n – 1)],  
Equation 1.1 Calculation of allelic diversity ((Selander et al. 1986) 
 
where n is the number of isolates and xi is the frequency of the ith allele at the locus 
(Selander et al. 1986). 
 
Various combinations of MIRU loci have been suggested for genotyping of M. 
tuberculosis (Frothingham & Meeker-O'Connell 1998; Goyal et al. 1994; Kam et al. 
2006; Kremer et al. 2005; Le Fleche. et al. 2002; Magdalena et al. 1998; Magdalena, 
Supply, & Locht 1998; Mazars et al. 2001; Roring et al. 2002; Roring et al. 2004; Skuce 
et al. 2002; Smittipat et al. 2005; Supply et al. 2000; Surikova et al. 2005). Supply and 
colleagues showed by analysing 29 loci that five were unreliable for use in a genotyping 
methodology. A well characterised set of 90 strains (Kremer et al. 1999) were 
investigated with the remaining 24 loci (Supply et al. 2006). When using 24 loci, the 90 
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strains were separated into 89 distinct genotypes – H37Rv and H37Ra were 
indistinguishable by this method as well as by spoligotyping, and the addition of the five 
unreliable MIRU loci. Maximum resolution of these 89 genotypes could be achieved by 
the analysis of only nine loci (MIRU 04, 10, 16, 26 and 40 and VNTR 0577, 2163b, 2165 
and 4052), thus indicating that, in this group of strains at least, these nine loci were the 
most variable. Analysis of nearly 500 isolates identified the loci that demonstrated the 
most allelic diversity and were most likely to exhibit single, double and triple locus 
variants (SLVs, DLVs and TLVs). The removal of the loci with the least diversity 
generated a subset of 15 MIRU loci with 96% of the discriminatory power of the full set 
of 24 loci (Supply et al. 2006). It was reasoned that the 15 loci set may be used for 
epidemiological studies, whilst the 24 loci set would be of use in phylogenetic studies. 
The Health Protection Agency Mycobacterium Reference Unit (HPA MRU) in 
Whitechapel, London has adopted the set of 24 loci for prospective analysis from 1
st
 
January 2010.   
 
The stability of the original 12 MIRU loci (Supply et al. 2000) was assessed by 
comparing the MIRU genotypes obtained from serial isolates from patients over up to six 
years (isolates analysed in (Warren et al. 2002)). A total of 123 isolates, representing at 
least two isolates from 56 patients, were genotyped (Savine et al. 2002). The selected 
isolates belonged to a variety of distinct IS6110 RFLP families. All 12 MIRU loci were 
identical within 55 of the 56 serial patient groups. One isolate showed a reduction in one 
repeat in a single locus. Conversely, 11 of the 56 serial patient isolates showed a variation 
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in their IS6110 pattern. The MIRU genotype for these isolates remained unchanged, 
suggesting that 12 loci MIRU was more stable than IS6110 RFLP. 
 
 
 
 
 
 
 
 
 
 
 
 
MIRU locus 2 4 10 16 20 23 24 26 27 31 39 40 
Approx. size (bp) 510 320 850 770 590 410 450 320 640 700 700 550 
MIRU repeat 2 2 7 4 2 5 1 1 3 4 3 4 
 
 
Figure 1.26.12-loci MIRU amplicons on an agarose gel with ethidium bromide staining. The first six lanes 
are MIRU loci 2, 4, 10, 16, 20 & 23, followed by a 1000bp ladder and the remaining six MIRU loci 24, 26, 
27, 31, 39 & 40.    
 
 
MIRU analysis has several technical advantages over IS6110 RFLP. Only small amounts 
of genomic material are required as the method involves DNA amplification. The assay 
itself is extremely simple to perform when compared with the involved process of RFLP. 
1000bp 
900bp 
800bp 
700bp 
600bp 
500bp 
400bp 
300bp 
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Moreover, as a digital genotype is generated, the data may be readily transported and 
compared in other centres. The method can be simplified even further by the utilisation of 
multiplex PCR and automated DNA sequencing technologies (Supply et al. 2001). An 
example of sizing PCR amplicons by automated sequencing may be seen in figure 1.27. 
Additionally, the method may be used to genotype M. tuberculosis strains that posses 
both high and low numbers of IS6110.  
 
Furthermore, Brown and colleagues (Brown et al 2010) have shown that MIRU-VNTR 
types align with other phylogenetic markers and assign strains into the large phylogentic 
groups as previously reviewed (Gagneux & Small 2007). This group have also shown 
that there is >90% concordance between MIRU-VNTR types and phylogenetic groups by 
SNP analysis (Gibson et al 2005).    
 
 
Figure 1.27. GeneMapper Fragment analysis. The x-axis demonstrates the size of the fragment, or 
amplicon, detected. The y-axis demonstrates the number of fluorescent units detected. The red peaks are 
fragments in the 1000bb, ROX-labelled, marker whilst the black, blue and green peaks correspond to the 
PCR products for MIRU loci 960, 1644 and 3192, respectively. The sizes of these three peaks are 645bp, 
670bp and 710bp, which correspond to alleles 3, 2 and 4 at these loci.  
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1.9.4.3 Spoligotyping 
 
Spacer-oligonucleotide typing (Spoligotyping) is a PCR-based typing method that relies 
on identifying polymorphisms in the spacer units in the direct repeat (DR) region of the 
genome. The DR region comprises multiple, virtually identical, 36bp regions interspersed 
with non-repetitive spacer sequences of a similar size (Groenen et al. 1993). As a nucleic 
acid amplification method, small amounts of DNA are required, and as such, 
spoligotyping has been used to detect and genotype M. tuberculosis from paraffin wax-
embedded samples (van der Zanden et al. 1998). Examples of spoligotypes are displayed 
in figure 1.28.  
 
Variation in these regions was thought to be caused by homologous recombination 
between adjacent or distinct DRs or by transformation due to the insertion of IS6110, 
which is almost invariably present in the DR region (Groenen et al. 1993). These direct 
variant repeats (DVRs) differ between strains, but their order remains conserved (van 
Embden et al. 2000). The DR region contains over 60 such spacers, but 43 were selected 
as a basis of this typing methodology. The presence or absence of these spacers is 
detected by the amplification and subsequent reverse hybridisation (Kamerbeek et al. 
1997).  
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Figure 1.28. Hybridization patterns (spoligotypes) of amplified mycobacterial DNAs of 35 M. tuberculosis 
and 5 M. bovis strains. The order of the spacers on the filter corresponds to their order in the genome. Note 
that the spoligotype of strains 6, 12, and 37 corresponds to that of strains from the Beijing family, as 
described earlier (Kamerbeek et al. 1997). 
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This technique is widely used in both evolutionary and epidemiological studies. As such, 
an agreed nomenclature was proposed to allow comparison of genotypes (Dale et al. 
2001). Spoligotyping is superior to IS6110 RFLP when studying strains with few copies 
of IS6110. However, it is less discriminatory than IS6110 typing for all other strains 
(Kremer et al. 1999; Soini et al. 2001).  
 
The analysis of DVRs by Warren and colleagues revealed that the evolution of a 
spoligotype occurs by four processes; IS6110-mediated mutation, homologous 
recombination between repeat sequences leading to DVR deletion, strand slippage during 
replication leading to duplication of the DVR sequences and point mutation (Warren et 
al. 2002). Interestingly, it was demonstrated that the insertion of IS6110 into the DR 
region lead to the failed hybridisation with some DVRs, despite their presence. DR 
RFLP, together with cloning and sequencing showed that these DVRs were present 
although spoligotyping indicated their deletion. The authors concluded that as the 
evolution of spoligotypes was not an independent process, that this method should not be 
relied upon alone for evolutionary studies in M. tuberculosis. They advocate its use 
alongside other methodologies. A diagrammatic representation of the genomic sites 
utilised in IS6110 RFLP, MIRU-VNTR and Spoligotyping may be seen in figure 1.29.  
 
1.9.4.4 Polymorphic GC-rich Repetitive Sequence (PGRS) Genotyping 
 
The PGRS element is the most abundant repetitive sequence in the M. tuberculosis 
complex (Poulet & Cole ST 1995b). Like IS6110 RFLP, PGRS typing utilises Southern 
blotting and probe hybridisation to differentiate strains of M. tuberculosis. This 
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technique, first described by Ross and colleagues, uses a probe of 3.4kb that is specific to 
the PGRS sequence and was cloned into the plasmid pTBN12 (Ross et al. 1992). 
Genomic DNA, restricted with AluI, may be separated by agarose gel electrophoresis and 
hybridised with a labelled, PGRS-specific probe. This method has been shown to 
differentiate unrelated strains whilst clustering those that are epidemiologically linked 
(Ross et al. 1992; Yang et al. 1996). Some studies have shown that PGRS typing is more 
discriminatory than IS6110 RFLP, especially when examining strains with few copies of 
the insertion sequence (Chaves et al. 1996; Rhee et al. 2000; Yang et al. 1996). 
Computer-based analysis of the fingerprints is possible, however, the intensity of the 
obtained bands may vary and this means that additional visual verification is required 
(Kremer et al. 1999).  
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Figure 1.29 Representation of IS6110, MIRU and DR regions within the M. tuberculosis genome (Barnes 
& Cave 2003b) 
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1.9.4.5 Genome Sequencing and Genotyping 
 
The level of discrimination of genotyping technologies varies. Ultimately, the way to 
definitively distinguish individual strains is by whole genome analysis. The genotyping 
methodologies described so far are a ‗snap-shot‘ of the tubercle genome and act as a 
surrogate marker of their evolution.  
 
The advancement in sequencing technology means that entire genomes may be analysed 
rapidly and at a fraction of the previous cost (Ansorge 2009). Whole genome analysis has 
been used to establish chains of transmission of M. tuberculosis when the genotyping by 
established methods had been unable to (Schurch et al. 2010)  
  
1.9.5 The Utilisation of Genotype Data 
 
As stated earlier, it is often beneficial, or even essential, to use more than one genotyping 
methodology. The various levels of discrimination and rate of change of the genetic 
elements mean that a combination of methods is often required to definitively 
differentiate strains. For example, the prevalence of strains possessing few copies of 
IS6110 often prohibits its use, unaided. Likewise, the relatively low discriminatory power 
of spoligotyping means that it cannot be used alone to confirm related cases of TB.  
 
The discriminatory power of a typing method is its ability to distinguish between 
unrelated strains. It is defined by the number of genotypes detected by the methodology 
and the relative frequencies of these genotypes.  
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Hunter and Gaston suggested the use of a single numerical index of discrimination (D), 
based on the probability that two unrelated strains sampled from the test population will 
be placed into different typing groups (Hunter & Gaston 1988). They calculated this 
probability by using Simpson's index of diversity, which was developed for the 
description of species diversity within an ecological habitat (Simpson 1949). 
 
The aim is to assign a numerical value to a genotyping methodology using the following 
formula (equation 1.2):  
 
Equation 1.2 Calculation of the discriminatory power of a genotyping method using the Hunter Gaston 
index (Hunter & Gaston 1988) 
 
where N is the total number of strains in the sample population, s is the total number of 
types described, and nj is the number of strains belonging to the jth type. This equation is 
derived as follows. The probability that a single strain sampled at random will belong to 
the jth group is njN. The probability that two strains sampled consecutively will belong to 
that group is nj(nj - 1)IN(N - 1) (Hunter & Gaston 1988).  
 
The value calculated will be <1.0 - the higher the value, the more discriminatory the 
method. For example, take two hypothetical genotyping methods both differentiating 20 
types in a population of 100 strains. In the first, assume a distribution of strains of 40 in 
type 1, 30 in type 2, 7 in types 3 and 4, and 1 in the remaining 16 types. In the second, 
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assume an ideal distribution of five strains in each type. Working through the first 
example, we have N = 100, s = 20, n1 = 40, n2 = 30, n3 and n4 = 7, n5 to n20 = 1: D = 1-
[(40 x 39 + 30 x 29 + 7 x 6 + 7 x 6 + 1 x 0 . . . 1 x 0)/(100 x 99)] = 1 - (2514/9900) = 
0.746. Therefore, the first example has an index of 0.746. This index indicates that if two 
strains were sampled randomly from the population, then on 74.6% of occasions they 
would fall into different types. The second example is clearly more discriminating and 
has an index of 0.960 (Hunter & Gaston 1988). 
 
It is worthwhile reiterating that it is not always essential to opt for the most 
discriminatory method. The benefits and limitations of an assay must be taken into 
account when assessing the question that needs to be answered. For example, isolates 
displaying divergent spoligotypes in a suspected outbreak are sufficient to dispute chains 
of transmission. Indistinguishable strains would need secondary typing to confirm their 
common source.  
 
It has been shown that epidemiologically linked strains cluster together by IS6110 RFLP, 
MIRU-VNTR and spoligotyping (Maguire et al. 2002; van Soolingen et al. 1999). 
Isolates that are indistinguishable by the typing method(s) used, that is are 100% similar, 
may therefore be due to recent transmission between individuals. The discriminatory 
power of the method used (alongside the epidemiological data) must, of course, be 
considered.  
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The number of clustered strains in a population may used to calculate a percentage of 
cases due to active transmission, rather than progression to disease following infection in 
the past. The percentage may be calculated as follows (equation 1.3; Small et al. 1994):   
 
Rate of transmission =  No. of clustered strains – No. of clusters x100 
     Total number of strains 
 
Equation 1.3. Calculation for the rate of transmission of M. tuberculosis ((Small et al. 1994). 
 
Indeed, typing is an important means of ruling out sources of recent transmission. It has 
been shown that despite large increases in the incidence of TB London between 1995 and 
1997, only 14.4% of cases were due to active transmission. Reactivation of disease in an 
immigrant population was the main driving force behind the increase (Maguire et al. 
2002). Rates of transmission vary greatly between study populations. The geographic 
area and length of study will of course play a critical role in the calculated percentage if 
transmission. A higher percentage of related strains are likely to be seen in a larger 
geographic area. If a study covers only a small region, then some TB patients in an active 
chain of transmission may seek medical attention elsewhere and are therefore excluded 
from the sample. This will therefore falsely decrease the level of transmission. Likewise, 
as the incubation period of TB is significantly longer than for other infectious diseases, a 
short study may not identify all cases in a chain of transmission or outbreak. The rates of 
transmissions from a number of studies are listed in table 1.1.  
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Country/City Date/Duration Sample 
Size 
Typing 
Method 
Transmission 
% 
Reference 
Norway 1994-2001 551 IS6110 RFLP 11% (Dahle et al. 
2003) 
London 1995-1997 2042 IS6110 RFLP 14.4% (Maguire et al. 
2002) 
Paris 1995 181 IS6110 RFLP 14.9% (Gutierrez et al. 
1998) 
New York 1989-1992 104 IS6110 RFLP 26.0% (Alland et al. 
1994) 
Seville 1993-1995 176 IS6110 RFLP 27.3% (Safi et al. 1997) 
San Francisco 1991-1992 473  31.1% (Small et al. 
1994) 
Netherlands 1993-1997 4266 IS6110 RFLP 35% (van Soolingen et 
al. 1999) 
Amsterdam 1992-1994 459 IS6110 RFLP 35.1% (van Deutekom 
H. et al. 1997) 
Dublin 1998-2002 142 IS6110 RFLP 
& 
Spoligotyping 
50.0% (Fair et al. 2006) 
Harare 1997 224 Spoligotyping 
& 5 loci 
VNTR 
72.2% (Easterbrook et 
al. 2004) 
 
Table 1.1. Comparison of the percentage of TB cases as a result of active transmission.  
 
As already stated, genotyping may be used to study the evolutionary relationships 
between strains. If 100% similarity is an indicator of recent transmission then isolates that 
are related at lower levels of similarity must therefore suggest longer evolutionary 
relationships. For example, spoligotyping was instrumental in identifying the Beijing 
family. This family shares a common spoligotype, but is less closely related by other 
typing methods (van Soolingen et al. 1995). The analysis of 90 strains from 38 countries 
by Kremer and colleagues identified several families by multiple typing methods 
(Kremer et al. 1999). The presence of the Beijing/W family was shown alongside two 
other novel families. The first comprised 13 strains originating from eight countries in 
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Asia, Europe and the Americas. Organisms showed at least 54% similarity by IS6110 
RFLP, but were indistinguishable by 5-loci VNTR and spoligotyping. This group was 
designated as the Haarlem family. The second group of eight strains displayed shared 
polymorphisms and originated from central Africa. This group was termed the Africa 
family (Kremer et al. 1999).  
 
Taking into account the different levels of discrimination and the proposal to use more 
than one genotyping methodology, McHugh and colleagues (McHugh et al. 2005) 
defined a lineage as a group of strains that are > 70% similar by two typing methods. It is 
reasoned that if such a lineage is genuinely related evolutionarily, then it should remain 
robust when genotyped by an alternative methodology.  
 
The retrospective analysis of 2490 strains from the ethnically diverse population of 
London was performed to investigate their origins. Analysis of the IS6110 genotypes 
differentiated the strains into 12 groups, or ‗superfamilies‘ (sfams) related by at least 50% 
similarity (Dale et al. 2005b). Three sfams contained low copy number strains and were 
additionally investigated using spoligotyping and PGRS (Dale et al. 2003b). The 
superfamilies consisting of high copy number strains were designated sfam 1-9, whilst 
the three low copy number strains were named L1-3.  
 
There were associations between some sfams and the site of disease, but stronger 
associations were where some sfams correlated with the country of birth of the TB 
patients. There was concordance between the findings of this study and previous work. 
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For example, the Haarlem family described by Kremer and colleagues mapped to sfam 1, 
whilst the Africa and Beijing families mapped to sfam 5 (Kremer et al. 1999). 
Additionally, the low copy superfamilies L1-3 were broadly associated with the East 
African Indian family, Africa and Europe, respectively (Dale et al. 2003b). It may be 
suggested that strains that display a similarity of at least 50% share a common 
evolutionary path. 
1.10 Aims of Thesis     
 
The aim of this thesis was to study the molecular epidemiology of M. tuberculosis 
isolates in TB patients at the Royal Free Hospital between 2002 and 2007. The 
hypothesis presented here is that the characterisation of the genotype of M. tuberculosis 
could be used to give an insight into the biology of the organism that relates to its clinical 
phenotype. The hypothesis was addressed by performing M. tuberculosis genotyping 
alongside the collection of demographic data for all culture positive TB patients at the 
Royal Free Hospital Hampstead NHS Trust, London. These isolates are studied in chapter 
3 with the use of IS6110 RFLP and MIRU-VNTR. The isolates and patient demographic 
characteristics are compared with national data to assess if any associations can be made 
genotype and phenotype.  
 
An interesting cohort of patients who underwent a novel diagnostic interferon gamma 
release assay is investigated in chapter 4 to ascertain the relationship between immune 
response to M. tuberculosis and bacterial biology. The hypothesis is that the 
immunological response seen in the T cells of this group of TB patients is driven by the 
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infecting organism. The strains isolated from these patients will be investigated using 
genotyping, sequencing and gene expression studies to ascertain if this is the case. 
 
Isolates obtained from two separate outbreaks are investigated in chapter 5. Both 
outbreaks involve drug resistant strains so the effect of this on their relative fitness is 
analysed. The hypothesis is that these drug-resistant strains have suffered a negligible 
fitness cost as they have been able to transmit between individuals readily. This will be 
assessed by the measurement of generation times of the isolates in vitro, together with 
molecular analysis of the resistance genes, themselves. 
 
Finally, examples when genotyping has played an important clinical role are outlined in 
chapter 6. This chapter highlights the need for the integration of clinical, epidemiological 
and laboratory data to maximise the understanding of this complex global disease.  
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Chapter 2. Materials and Methods 
 
2.1 M. tuberculosis IS6110 RFLP database 
 
2.1.1 Organism Selection and Culture Methods 
Samples referred to the Department of Medical Microbiology, Royal Free Hampstead 
NHS Trust, London, for investigation of mycobacterial disease between 2002 and 2007 
were processed. Samples that may be potentially contaminated with commensal 
organisms were decontaminated with 4% sodium hydroxide for 20 minutes, followed by 
buffering to neutral pH. All samples were concentrated by centrifugation prior to smear 
preparation. Slides were heat-fixed, stained with auramine-O and examined using a 
fluorescent microscope. Positive smears were over-stained with carbol fuchsin using a 
hot Ziehl-Neelsen stain. 
 
Concentrated samples were inoculated into an automated liquid culture system; the MB 
BacT system (BioMerieux, France). Positive cultures were concentrated by centrifugation 
and confirmed by hot Ziehl-Neelsen stain. Confirmation of mycobacterial species was 
confirmed using Strand Displacement Amplification (SDA) on a ProbeTec (Becton 
Dickinson, USA) according to manufacturer‘s instructions. Positive cultures were 
additionally sub-cultured onto Lowenstein Jensen slopes.  
 
Positive cultures were referred to the Health Protection Agency (HPA) Mycobacterium 
Reference Unit (MRU) (Whitechapel, London) for species confirmation and phenotypic 
susceptibility testing by either the resistance ratio or modified liquid proportion methods. 
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2.1.2 Data collection 
Microbiological data was collated from the local information system (LIS), WinPath 
(Sysmed, UK). Patient demographic data was collated from WinPath and additionally 
from the London TB register (LTBR). The site of disease was surmised from the 
anatomical site(s) of the specimens collected. The number of isolates studied are outlined 
in figure 2.1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Flow diagram of isolates genotyped and included in subsequent analysis.  
 
2.1.3 Preparation of DNA probe by PCR 
The IS6110- specific INS probe is a PCR product of 245bp in length. The amplicon was 
generated with the following primer sequences, shown in table 2.1: 
294 (69.3%) 
 
Isolates genotyped 
424 (57.9%) 
 
Culture positive patients 
308 (42.1%) 
 
Culture negative patients 
732 
Royal Free TB patients notified to 
London TB Register between 2002-2007 
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Target Primer Sequence Reference 
IS6110 INS-1 (forward) 5‘CGT GAG GGC ATC GAG GTG GC 3‘ (van Embden et al. 
1993) 
INS-2 (reverse) 5‘GCG TAG GCG TCG GTG ACA AA 3‘ (van Embden et al. 
1993) 
 
Table 2.1 primers for the amplification of the INS probe for IS6110 RFLP hybridisation. 
 
The PCR master mix was prepared with final reagent concentrations as follows; 1x KCl 
buffer, which contains MgCl2  and gave a final MgCl2 concentration of 1.5mM, 0.15mM 
dNTPs, 0.5μM of each primer and 0.025 units of Taq/μL (Bioline, London, UK). 
Genomic DNA from the M. tuberculosis control strain H37Rv was added. Thermocycling 
conditions of 94°C for 2 minutes, followed by 35 cycles of 94°C for 1 minute, 65°C for 1 
minute and 72°C for 2 minutes. The final elongation step was 72°C for 5 minutes. The 
amplicon was detected using agarose gel electrophoresis with ethidium bromide staining. 
The PCR product was purified using the Qiagen QIAquick PCR Purification Kit Protocol 
following the manufacturer‘s instructions (Qiagen, Crawley, UK). The eluted solution 
containing the purified PCR product was stored at –20°C. 
2.1.4 Random labelling of DNA probe 
 
The purified PCR products were labelled using the Gene Images random prime labelling 
protocol (GE Healthcare, Chalfont St Giles, Bucks, UK) following the manufacturer‘s 
instructions.  The labelled probe was stored in the dark at -20˚C for up to 6 months. 
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2.1.5 Isolation of genomic DNA from M. tuberculosis 
 
A single isolate from each patient was selected unless relapse or re-infection was 
suspected. As M. tuberculosis is a hazard group 3 pathogen, all stages of the DNA 
extraction, up to and including the addition of chloroform, were performed in a class 1 
biological safety cabinet in a containment level 3 laboratory.  
 
A loopful of colonies from an LJ slope was added to 400 L 1x TE buffer and incubated 
at 80°C for 20 minutes. The tubes were cooled to room temperature and 50 L 10mg/mL 
lysozyme (Sigma, UK) was added. The tubes were incubated at 37°C overnight. The 
following morning, 70 L 10% SDS and 5 L 10mg/ml proteinase K (Sigma, UK) were 
added before incubation at 65°C for 10 minutes. Then, 100 L of 5M NaCl 100 L and 
CTAB/NaCl (pre-warmed to 65°C) were added and incubated at 65°C for 10 minutes. 
750 L chloroform/isoamylalcohol (24:1) was added and the tubes were mixed by 
inversion. The tubes were centrifuged at 10,000g for 5 minutes and the upper aqueous 
phase containing the DNA was removed and added to 450 L of ice-cold isopropanol. 
These tubes were mixed gently before chilling at –20°C for at least 30 minutes. The tubes 
were centrifuged at 10,000g for 15 minutes at room temperature, the supernatant was 
removed and the DNA pellet was washed with 1mL ice-cold 70% ethanol. The tubes 
were centrifuged at 10,000g for 5 minutes at room temperature, the supernatant was 
removed and the pellet was allowed to air-dry. The pellet was rehydrated using TE buffer 
overnight at 4°C. The concentration of DNA obtained was estimated by comparing with 
serial dilutions of lambda DNA using agarose gel electrophoresis. DNA was also 
extracted from the M. tuberculosis reference strain MT14323, which was kindly provided 
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by Prof. Peter Hawkey and Jason Evans, West Midlands Public Health Laboratory, 
Health Protection Agency, Birmingham Heartlands Hospital. 
 
2.1.6 Restriction enzyme digestion of chromosomal DNA 
 
200ng of DNA was restricted at 37°C for 1 hour with 2.5 L 10x reaction buffer, 1.25 L 
PvuII and 0.25 L BSA in a final volume of 25 L.  To achieve a final image with  
standardised intensity, all samples were electrophoresed on an agarose gel and restricted 
DNA concentrations were compared visually to ensure that similar quantities are of DNA 
were loaded to the large agarose gel (step 2.1.7). 
  
2.1.7 Separation of DNA fragments by electrophoresis and Southern blotting 
 
The restricted DNA was applied to a 25 x 20cm 0.8% agarose gel using λ HindIII as a DNA 
marker. The restricted DNA of MT14323 was loaded into three wells of the gel (lane 
two, one off-centre lane in the middle and the final well) to allow the final image to be 
orientated and compared with others. An electric current was applied until the 2.2kb 
fragment of λ HindIII had migrated 11cm. The DNA in the gel was then depurinated in 
200mL 0.2M HCl for 10 minutes with gentle agitation and the gel was briefly rinsed three 
times in distilled water. The DNA in the gel was denatured in 1.5M NaCl, 0.5M NaOH 
(200mL) for 40 minutes with gentle agitation and neutralised in 1M Tris (pH7.4), 1.5M 
NaCl (200mL) for 40 minutes with gentle agitation. The gel was rinsed briefly in 10x SSC 
before transferring the DNA from the gel to a nylon membrane – Hybond N+ (GE 
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Healthcare, Bucks, UK) by Southern blotting for 2 hours. The membrane was air-dried and 
the DNA cross-linked to the membrane by exposure to UV light for 3 minutes. 
 
2.1.8 Hybridisation and detection. 
 
The membrane was pre-wetted with 5x SSC before adding 80mL of hybridisation 
solution (5x SSC, 0.1%SDS, 5% liquid block and 5% dextran sulphate). Prehybridisation 
took place for 30 minutes at 50 C shaking at approximately 80 rpm on an orbital shaker. 
The INS probe was denatured at 95°C for 5 minutes and quenched on ice. 15μL of the 
denatured probe was added to 1mL of hybridisation solution, which was removed from 
the membrane, before returning this mixture to the bioassay tray (containing the 
hybridization solution and membrane), taking care to distribute the mixture evenly. The 
bioassay tray was sealed with Parafilm (Alpha Labs, Eastleigh, Hampshire, UK) to 
prevent the membrane drying out and hybridisation took place overnight at 50 C shaking 
at approximately 80rpm. Stringency washes were performed the following morning with 
pre-warmed solutions as follows: 300ml 1x SSC, 0.1% SDS for 7.5 minutes twice, 
followed by 300ml 0.5x SSC, 0.1% SDS for 7.5 minutes twice at 50 C with gentle 
agitation. The membrane was placed in a fresh bioassay tray and was washed briefly with 
Buffer A (100mM Tris base and 300mM NaCl), which was autoclaved prior to use. The 
membrane was blocked with 300mL of 1:10 Liquid Block in Buffer A for 90 minutes at 
room temperature with gentle agitation. 
 
The membrane was incubated with 130mL of Buffer B (1:5000 anti-fluorescein alkaline 
phosphate-conjugate in 0.5% BSA in Buffer A) for 1 hour at room temperature with gentle 
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agitation. The membrane was washed with 300mL Buffer C (Buffer A, 0.3% Tween 20) for 
10 minutes at room temperature with gentle agitation three times to remove any non-bound 
conjugate. The membrane was drained and 16mL of detection solution (GE Healthcare, 
Bucks, UK) was applied to the membrane 5 minutes. A piece of Hyperfilm (GE Healthcare, 
Bucks, UK) was aligned with the membrane in dark room conditions, developed and fixed 
to produce a molecular fingerprint.  
   
2.1.9 Entry of images into BioNumerics 
 
Images were scanned as greyscale TIFF files and uploaded into BioNumerics version 3.5 
(Applied Maths, Sint-Martens-Latem, Belgium). The reference strain MT14323 lanes were 
assigned as reference markers by the software in order to normalise against other images. 
Each lane was carefully examined visually by the researcher to assign bands indicating an 
insertion sequence in the genome.  
 
Once each isolate had been inserted into the database, patient demographics were added. 
These included patient identifiers, such as the isolate number and associated laboratory 
number, hospital number, date of birth, site of disease and drug susceptibility. If duplicate 
isolates from the same patients were identified and inspected to confirm similarity and 
removed from the final analysis. If multiple isolates from a given patient generated different 
genotypes, then the possibility of re-infection with a different strain, mutation of the 
incumbent strain or laboratory error were investigated.  
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The relatedness of the isolates in the database was assessed using the Dice coefficient and a 
band tolerance of 1.2% to generate a dendrogram. Isolates related at 100% similarity were 
termed clusters and were assigned an arbitrary number from the top of the dendrogram. 
Likewise, isolates related at >70% similarity were termed lineages and were assigned an 
arbitrary number from the top of the dendrogram.  
 
2.2 – Mycobacterial Interspersed Repetitive Units – Variable Number Tandem 
Repeats (MIRU-VNTR) 
 
2.2.1 Isolate selection 
 
Isolates from the IS6110 database were additionally typed using 24-MIRU if they were a 
member of a 100% cluster or a 70% lineage. Furthermore, all strains that possessed fewer 
than five copies of IS6110 were MIRU typed.   
 
2.2.2 Isolation of genomic DNA from M. tuberculosis 
 
Genomic DNA was extracted as in 2.1.5. Occasionally there were insufficient volumes of 
DNA remaining following the processing of the IS6110 RFLP. In this case, 20µL of PCR 
grade water was added to the empty tube and mixed gently.  
2.2.3 MIRU Polymerase Chain Reaction 
 
The 24 MIRU targets were amplified in eight triplex polymerase chain reactions using 
fluorescently labeled primers as described by Supply (Supply et al.). Reactions were set 
up in 96-well microtitre plates (Applied Biosystems, Warrington, UK) using a 
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QiaSymphony liquid handler (Qiagen, Crawley, Surrey, UK). The PCR primer sets and 
master mixes are listed below in tables 2.2 – 2.4.  
 
Table 2.2 MIRU primer sets (Supply 2005) 
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Table 2.3 MIRU PCR master mixes (1-5). 
a
 Six in total, i.e. one forward and one reverse primer for each of 
the 3 pairs. Initial concentration for all unlabeled primers: 20pmol/µL. Initial concentration for the labeled 
oligonucleotides: 2pmol/µL for locus 0577, 3690 and 1955, 8pmol/µL for locus 4052, 20pmol/µL for locus 
4156 and 4pmol/µL for the other loci (Supply 2005).  
 
 
Table 2.4 MIRU PCR master mixes (6-8). 
a
 Six in total, i.e. one forward and one reverse primer for each of 
the 3 pairs. Initial concentration for all unlabeled primers: 20pmol/µL. Initial concentration for all labeled 
oligonucleotides: 4pmol/µL (Supply 2005).  
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2.2.4 Fragment analysis of the MIRU PCR products 
 
0.2µL of ROX labeled 1000bp DNA marker (MapMarker 1000, 8fmol/band/μL, 
Bioventures, Tennessee, USA) was added to each well in the 96-well microtitre plate.  
 
Fragment Analysis software (Applied Biosystems, Warrington, UK) was used to assign 
amplicon sizes and therefore MIRU copy number for each well. The fluorescent signals 
generated in each well were examined by eye to verify that the software had called the 
fragments correctly and to identify any stutter-peaks generated by strand slippage during 
primer annealing or large fluorescent flares due to high amplicon concentrations. PCR 
products that generated large flares could be diluted and re-analysed.  
 
2.2.5 Entry of MIRU Data into BioNumerics.  
The 24-digit MIRU type was added for each isolate in the BioNumerics database. 
Relatedness was assessed using MIRU data alone to assess whether the IS6110 clusters and 
lineages were corroborated. The relatedness of the IS6110 low copy number strains was 
then assessed using MIRU to differentiate any clusters and lineages.  
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2.3 ESAT-6 and the Host Response 
 
2.3.1 Patient selection 
 
Isolates cultured from a cohort of TB patients described elsewhere (Breen et al 2008a) 
were selected for analysis. The relatedness of the isolates by IS6110 and MIRU-VNTR 
was assessed as in sections 2.1 and 2.2, respectively.  
2.3.2 esxA PCR and Sequencing 
 
An initial PCR was designed, optimised and performed by the author. It amplified a 
228bp product was designed to identify the presence or absence of the gene. The 
conditions were as follows (table 2.5):  
Target Primer Sequence Reference 
esxA Forward 3‘ CCAGGGAAATGTCACGTCCATTCA 5‘ This experiment 
Reverse 3‘ AACATCCCAGTGACGTTGCCTT 5‘ This experiment 
 
Table 2.5. Primers for the amplification of the esxA gene 
 
The PCR master mix was optimised to final reagent concentrations as follows; 1x PCR 
buffer, 2mM MgCl2, 0.2mM dNTPs, 0.4μM of each primer and 0.5 units of Taq/μL 
(Invitrogen, Paisley, UK). 1μL of DNA of at least 0.5ng/mL was added. Thermocycling 
conditions of 95°C for 5 minutes, followed by 30 cycles of 95°C for 30 seconds, 50°C for 
30 seconds and 72°C for 30 seconds. The final elongation step was 72°C for 5 minutes. 
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DNA amplification was detected by agarose gel electrophoresis with ethidium bromide 
staining. 
 
The esxA gene was sequenced from PCR positive isolates, using a second PCR protocol 
(626bp product) to search for polymorphisms. The conditions were as follows:  
Target Primer Sequence Reference 
esxA plus flanking 
region 
Forward 3‘ CCAAGAAGCAGCCAATAAGC 5‘ This experiment 
Reverse 3‘ GGAGCTTCCATACCTTCGTG 5‘ This experiment 
 
Table 2.6. Primers for the amplification of the esxA gene plus flanking region. 
 
The PCR master mix was optimised to final reagent concentrations as follows; 1x PCR 
buffer, 2mM MgCl2, 0.2mM dNTPs, 0.4μM of each primer and 0.5 units of Taq/μL 
(Invitrogen, Paisley, UK). 1μL of DNA of at least 0.5ng/mL was added. Thermocycling 
conditions of 95°C for 5 minutes, followed by 30 cycles of 95°C for 30 seconds, 50°C for 
30 seconds and 72°C for 30 seconds. The final elongation step was 72°C for 5 minutes. 
The amplification of the gene was detected by agarose gel electrophoresis with ethidium 
bromide staining. Where a PCR product was detected, it was purified using the QIAGEN 
QIAquick PCR Purification Kit Protocol (Qiagen, Crawley, UK) following 
manufacturer‘s instructions.  
 
A cycle sequencing reaction was set up using the purified PCR product. Four tubes were 
set up for each PCR product, consisting of two forward and two reverse reactions. A final 
concentration of 1.05μM of one primer (2μL), 2μL Big Dye RRM V3.1 (Applied 
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Biosystems, Warrington, UK), 10μL water and 5μL purified PCR product. 
Thermocycling conditions of 96°C for 1 minute, followed by 40 cycles of 96°C for 10 
seconds, 50°C for 5 seconds and 72°C for 4 minutes.  
 
Each 19µL cycle sequencing product was precipitated with the addition of 3µL 3mM 
NaCl pH4.6, 62.5µL 95% ethanol and 14.5µL water. The mixture was vortexed before 
being centrifuged at >15,000g for 15 minutes at 4°C. The supernatant was removed 
without disturbing the pellet. 200μL of 70% ethanol was added to each tube followed by 
inversion to wash the pellet. The tubes were centrifuged at >15,000g for 5 minutes at 
4°C. The supernatant was removed and the pellet was allowed to dry completely. 15μL 
formamide was added to each tube before being loaded onto the automated plate 
sequencer (Applied Biosystems, Warrington, UK).  
 
2.3.3 Sequence Analysis 
 
The sequences obtained were analysed by the author using BioNumerics, version 3.5 
(Applied Maths, Sint-Martens-Latem, Belgium). Consensus sequences were visually 
checked for correct base-calling by the researcher. These were then aligned with the esxA 
sequence of M. tuberculosis H37Rv using Clustal W 
(http://www.ebi.ac.uk/Tools/clustalw2/index.html).  
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2.3.4 esxA mRNA Reverse Transcriptase PCR 
 
2.3.4.1 Evaluation of optimal esxA expression 
 
Triplicate cultures of M. tuberculosis H37Rv (0.5 Macfarland initial turbidity) were 
incubated in Kirshner‘s medium (E&O Laboratories, Scotland) at 37°C for 7, 14 and 28 
days, to represent lag, log and stationary phase of growth. RNA was extracted at these 
time-points by the method stated below. Reverse transcription, quantitative polymerase 
chain reaction (RT-qPCR) was performed on each RNA extract as stated below.  
2.3.4.2   RNA Extraction 
 
Cultures of the selected isolates were sub-cultured into Kirshner‘s broth (E&O 
Laboratories, Scotland) and incubated at 37ºC for 10 days. After this time, the growth 
was assessed by observing the turbidity of the broth culture. A turbidity of Macfarland 
0.5 was necessary. Any broths that were more turbid than this were diluted with fresh 
Kirshner‘s broth (E&O Laboratories, Scotland) until Macfarland 1 was achieved. These 
broths were then incubated at 37 ºC for the required number of days to reach an optimal 
level of esxA transcription (see 2.3.3.1).  
 
The RNA in each 10mL broth was stabilised by the addition of 35mL 5M guanine 
thiocyanate (GTC) and 245μL β-mercaptoethanol (0.7% final volume). This solution was 
centrifuged at 2000g for 30 minutes at room temperature. The supernatant was discarded 
and 1mL of RNApro (MP Biomedicals, Illkirch, France), was added to the deposit and 
was completely resuspended with gentle pipetting.   
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1mL of this suspension was added to a RNA extraction tube (MP Biomedicals, Illkirch, 
France) containing lysing matrix beads. These tubes were placed in a ribolyser (FastPrep 
24, MP Biomedicals, Illkirch, France) on setting 6.0 for 40 seconds. The tubes were then 
centrifuged at >12,000g for 5 minutes at room temperature. 
 
The supernatant (approximately 750μL) was transferred to a fresh microcentrifuge tube 
without disturbing the matrix interface. The transferred samples were allowed to stand at 
room temperature for 5 minutes to increase the RNA yield.  
300μL of chloroform was added to each sample, vortexed for 10 seconds and allowed to 
stand at room temperature for 5 minutes to permit nucleoprotein disassociation and 
increase RNA purity. Tubes were then centrifuged at 12,000g for 5 minutes at room 
temperature and the upper phase was transferred to a fresh microcentrifuge tube without 
disturbing the interface. 500μL ice-cold absolute ethanol was added to the fresh tube and 
inverted 5 times. The samples were then placed at -80ºC for 15 minutes.   
 
The samples were centrifuged at 12,000g for 20 minutes at 4ºC and the supernatant 
discarded. The nucleic acid pellet was washed by the addition of 500μL ice-cold 70% 
ethanol (prepared with diethylpyrocarbonate (DEPC) treated water to remove RNAase) 
and inversion. The sample was centrifuged at 12,000g for 15 minutes at 4ºC. The 
supernatant was removed completely and the pellet was allowed to air dry at 50ºC. The 
pellet was rehydrated with 100μL RNAase-free water and was used immediately or 
stored at -80ºC.  
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2.3.4.3 RNA clean-up 
 
43μL of the extracted RNA was mixed with 1μL (1 unit) of Turbo DNase and 5μL 10x 
Turbo DNase buffer (Ambion, Turbo DNA-free kit, Applied Biosystems, Warrington, 
UK). This mixture was incubated at 37ºC for 30 minutes. A further 1μL of Turbo DNase 
was added and the mixture was incubated for an additional 30 minutes. 10μL of DNase 
Inactivation Reagent (Ambion, Turbo DNA-free kit, Applied Biosystems, Warrington, 
UK) was added and the mixture was incubated at room temperature for 5 minutes with 
occasional mixing. Finally, the mixture was centrifuged at 12,000g for 90 seconds and 
the supernatant removed to a fresh tube. This DNase-treated RNA could be used 
immediately or stored at -80ºC.   
 
 
2.3.4.4 Reverse transcriptase qPCR 
 
RT-qPCR was performed for the target gene esxA as well as the housekeeping, or 
reference genes 16S rDNA and sigA. Each reaction was performed in triplicate. The 
conditions were as shown in table 2.7.  
 
The PCR master mix was optimised to final reagent concentrations as follows; 12.5μL 
Quantitect RT PCR mastermix (Qiagen, Crawley, UK), 0.4μM of each primer and 
0.15μM of probe. 0.25μL reverse transcriptase (RT) mix was added to each tube. Water 
was added to make a final volume of 20μL. 5μL of RNA (diluted 1:10 from 2.3.3.3) was 
then added. Thermocycling conditions on a RotorGene 3000 (Qiagen, Crawly, UK) of 
50°C for 30 minutes (RT step), 95°C  for 15 minutes, followed by 40 cycles of 94°C for 
15 seconds and 60°C for 60 seconds.  
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Target Primer Sequence Reference 
esxA Forward 3‘ CCAAGAAGCAGCCAATAAGC 5‘ This experiment 
Reverse 3‘ GGAGCTTCCATACCTTCGTG 5‘ This experiment 
Probe 3‘ CGCGGCAAGCGCAATCCAGGGAAATGT 5‘ 
(FAM) 
This experiment 
16S Forward 3‘ GTGATCTGCCCTGCACTTC 5‘ Amani Alnmir, 
personal 
communication 
Reverse 3‘ ATCCCACACCGCTAAAGCG 5‘ Amani Alnmir, 
personal 
communication 
Probe 3‘ AGGACCACGGGATGCATGTCTTGT 5‘ (ROX)  Amani Alnmir, 
personal 
communication 
sigA Forward 3‘ AAACCATCTGCTGGAAGCCA 5‘ (Hampshire et al. 
2004) 
Reverse 3‘ TTCTCGACCTGATCCAGGAAG 5‘ O‘Sullivan 2007 
Probe 3‘ CCTGCGCCTGGTGGTTTCGC 5‘ (JOE) (Hampshire et al. 
2004) 
 
Table 2.7 Primers and probes for RT-qPCR 
 
Each RT-qPCR was analysed as follows; slope correct was selected and the thresholds 
for esxA, 16S and sigA were optimised to 0.01, 0.05 and 0.1, respectively. The Ct of the 
reactions with and without RT were compared for gross DNA contamination. Once this 
was ruled out, the relative gene expression change was quantified using the ∆∆CT 
method (Livak and Schmittgen 2001). The formulae are as follows:  
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Relative fold gene expression = 2
-∆∆Ct
 
Where: ∆∆Ct = ∆Ct selected strain - ∆Ct H37Rv  
and ∆Ct = (Ct target gene – Ct reference gene) for each selected strain 
 
Equation 2.1. Calculation of relative gene expression change using ∆∆Ct (Livak and Schmittgen 2001). 
  
 
2.4 The Fitness of Over-Represented strains and Acquired Isoniazid Resistance  
2.4.1 Isoniazid Resistance Gene Sequencing  
 
Genomic DNA was extracted as follows; organisms were inoculated into Kirshner‘s 
medium (E&O Laboratories, Scotland) and incubated until growth was visible. Cells 
were pelleted in a 2mL screw-cap tube by centrifugation and were washed in 1x TBE. 
The organisms were heat killed at >95˚C for 30 minutes. Glass beads (Becton Dickinson, 
Oxford, UK) were added and the tubes were placed in a Ribolyser (FastPrep 24, MP 
Biomedicals, Illkirch, France) on setting 6.0 for 45 seconds. The tube was then 
centrifuged at 12,000g for 5 minutes and the supernatant removed. DNA extraction was 
performed by Dr. Alastair McGregor as part of his MSc degree project under the 
supervision of the author.  
 
Selected regions of the inhA and katG genes of all strains were amplified using the 
following PCR conditions (table 2.8). PCR amplification was performed by Dr. Alastair 
McGregor as part of his MSc degree project under the supervision of the author.  
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The PCR master mix was previously optimised in this laboratory as follows; 1x KCl 
buffer (Bioline, London, UK), 0.04μM of each primer, 0.15mM dNTP and 2 units Taq 
polymerase (Bioline, London, UK). Water was added to make a final volume of 90μL. 
10μL of extracted DNA was then added. Thermocycling conditions of 95°C for 5 
minutes, followed by 30 cycles of 94°C for 1 minute, either 56°C (katG) or 65°C (inhA) 
for 2 minutes and 72°C for 3 minutes. A final elongation step of 72°C for 7 minutes was 
used. 
 
Target Primer Sequence Reference 
katG (185bp 
fragment targeting 
codon 315) 
Forward 5‘ GTC ACA CTT TCG GTA AGA CC 3‘ (O‘Sullivan 2007) 
Reverse 5‘ TTG TCC CAT TTC GTC GGG 3‘ (O‘Sullivan 2007) 
katG (296bp 
fragment targeting 
codon 463) 
 
Forward 5‘ GCG AAG CCG AGA TTG CCA GC 3‘ (O‘Sullivan 2007) 
Reverse 5‘ ACA GCC ACC GAG CAC GAC GA 3‘ (O‘Sullivan 2007) 
inhA (248bp 
fragment of the 
promoter region) 
Forward 5' CCTCGCTGCCCAGAAAGGGA 3'   (Telenti et al. 
1997) 
Reverse 5‘ ATCCCCCGGTTTCCTCCGGT 3‘ (Telenti et al. 
1997) 
 
Table 2.8 Primers for amplifying isoniazid-conferring mutations.  
 
 
Where a PCR product was detected by agarose gel electrophoresis with ethidium bromide 
staining, it was purified using the QIAGEN QIAquick PCR Purification Kit Protocol 
(Qiagen, Crawley, UK) following manufacturer‘s instructions.  
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Cycle sequencing reactions were set up using the purified PCR product. Four tubes were 
set up for each PCR product, consisting of two forward and two reverse reactions for 
each gene. A final concentration of 1.05μM of one primer (2μL), 2μL Big Dye RRM 
V3.1 (Applied Biosystems, Warrington, UK), 10μL water and 5μL purified PCR product. 
Thermocycling conditions of 96°C for 1 minute, followed by 40 cycles of 96°C for 10 
seconds, 50°C for 5 seconds and 72°C for 4 minutes.  
 
Each 19µL cycle sequencing product was precipitated with the addition of 3µL 3mM 
NaCl pH4.6, 62.5µL 95% ethanol and 14.5µL water. The mixture was vortexed before 
being centrifuged at >15,000g for 15 minutes at 4°C. The supernatant was removed 
without disturbing the pellet. 200μL of 70% ethanol was added to each tube followed by 
inversion to wash the pellet. The tubes were centrifuged at >15,000g for 5 minutes at 
4°C. The supernatant was removed and the pellet was allowed to dry completely. 15μL 
formamide was added to each tube before being loaded onto the automated plate 
sequencer (Applied Biosystems, Warrington, UK). Sequencing was performed by Dr. 
Alastair McGregor as part of his MSc degree project under the supervision of the author.  
 
 
2.4.2 Sequence Analysis 
 
The sequences obtained were imported into BioNumerics, version 3.5 (Applied Maths, 
Sint-Martens-Latem, Belgium) and were analysed by the author. Consensus sequences 
were visually checked for correct base-calling by the researcher. These were then aligned 
with the corresponding gene sequences of M. tuberculosis H37Rv using Clustal W 
(http://www.ebi.ac.uk/Tools/clustalw2/index.html ). 
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2.4.3 Fitness Assays 
 
Isolates were incubated in Kirshner‘s medium (E&O Laboratories, Scotland) and 
incubated until 0.5 Macfarland of growth was visible. 0.5mL of each broth was 
inoculated into a MGIT (mycobacterial growth indicator tube) tube (Becton Dickinson, 
Oxford, UK) containing growth supplement, which contains bovine albumin, catalase, 
oleic acid, dextrose and polyoxyethylene stearate The MGIT tubes were incubated in the 
MGIT 960 system. Within 24 hours of these cultures signaling positive, 1:10 (termed 
dilution A) and 1:10,000 (termed dilution B) dilutions were prepared. A 0.5mL aliquot of 
each dilution was inoculated in triplicate into fresh MGIT tubes containing growth 
supplement. These tubes were incubated in the MGIT 960. This was performed in 
triplicate for all isolates.  
 
A modified Youmans and Youmans method (Youmans and Youmans 1949) was used to 
calculate the growth rate constant, k; k=(logA – logB / t, where A is the largest inoculum 
(dilution A), B is the smallest inoculum (dilution B) and t is equal to the difference of the 
three replicates of the time to positivity (TTP) between dilution A and B. To determine 
the generation time G, the equation G = log 2/k was used. This process was repeated 
three times for each strain. 
 
 
2.5 Statistical analysis 
 
2.5.1 Chi squared and Fisher’s Exact Test 
 
These two methods calculate a P value from a population with an assumed normal 
distribution and assesses whether there is an association between the variables analysed, 
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particularly in a 2 x 2 table. When calculating the P value, one starts with the assumption 
about the population (the null hypothesis) and determines the probability of randomly 
selecting the samples with as large a difference as is observed. The P value is a figure 
between 0 and 1. For example, a P value of 0.034 means that if this null hypothesis is 
true, 3.4% of all possible experiments of this size would results in a difference between 
mean values as large (or larger) than was observed (Motulsky 1995). A P value of ≤0.05 
is generally considered to be statistically significant. The Fisher‘s test will always give a 
theoretically correct P value, while the Chi squared test gives an approximation. The 
factor that decides whether a Chi Squared or a Fisher‘s exact test is used is largely sample 
size. Small samples (if total number of samples less than 40 or if the value in any cell is 
less than 5) must be analysed using a Fisher‘s exact test. This method is used in Chapter 3 
to assess the statistical significance of the difference in gender RFH and UCLH patients, 
smear positivity and HIV status, smear status and country of birth.  
 
Samples larger than this are analysed using a Chi squared test. This method is used to 
assess the significance of smear positivity and ethnicity, ethnicity and HIV status, age 
and site of disease in RFH and UCLH patients and drug resistance with HIV status, 
ethnicity and country of birth.  
 
 
2.5.2 One-way Anova with Kruskal-Wallis post test 
The one-way analysis of variance using the Kruskal–Wallis post-test compares the 
medians among groups. The Kruskal–Wallis test does not assume a normal population 
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distribution. It does, however, assume an identically-shaped and scaled distribution for 
each group, except for any difference in medians (Motulsky 1995). 
This method is used to compare the median generation times of the isolates studied for 
variation of fitness in chapter 5. 
 
2.5.3 Two-way Anova  
This method compares the whether the means or medians of several groups (more than 
two) are all equal. It is comparable to performing multiple t-tests. This has the advantage 
over performing a statistical analysis on the groups separately as this would result in an 
increased chance accumulated error (Motulsky 1995). 
 
This method is used to compare the ethnicities of patients from this data set, national data 
(Health Protection Agency 2009) and patients in London between 1995 and 1997 
(Maguire et al. 2002).  
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Chapter 3: Development and Characterisation of an M. tuberculosis 
database for North London 
 
3.1 Introduction 
 
 
Typing databases are powerful tools for epidemiological and evolutionary studies. 
Collation of all strains from a given geographical area allows the investigator to 
understand the prevalence of strains within that population and gives an indication of 
levels of transmission as well as genotypes that are over-represented, suggesting a 
biological or clinical advantage. It is possible to identify and study outbreaks and this 
may contribute to early interventions that prevent further transmission (Kik et al. 2008).  
 
This study will attempt to identify any clusters or lineages of strains that are particularly 
associated with a disease or bacterial phenotype. This will be achieved by genotyping 
isolates from the TB service at the Royal Free Hospital between 2002 and 2007 and 
investigating these alongside demographic data. 
 
The highly discriminatory IS6110 RFLP was used as the primary typing method for the 
isolates outlined in chapter 2. The addition of a secondary typing technique may augment 
the discriminatory power of an initial method. The discriminatory power of a genotyping 
method is displayed by the number of indistinguishable clusters generated from a group 
of strains (Kremer et al. 1999). Alternatively, clustered isolates may require secondary 
genotyping to confidently determine their relatedness. For example, strains that clustered 
by IS6110 RFLP genotyping were shown to be unrelated using the polymorphic GC-rich 
repetitive-sequence (PGRS) method (Gillespie, Dickens, & McHugh 2000) and the 
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poorly discriminatory spoligotyping cannot be used in isolation in an outbreak setting; 
Beijing/W strains share a common spoligotype despite possessing varying IS6110 RFLP 
fingerprints (Ebrahimi-Rad et al. 2003)    
 
In addition to the limitations regarding the discriminatory power of genotyping 
methodologies, IS6110 RFLP genotyping is unable to differentiate isolates that possess 
fewer than five copies of IS6110. A study in London between 1995 and 1997 showed that 
although the overall discriminatory power of RFLP typing was high, almost 20% of 
strains in the UK capital fell into this group (Maguire et al. 2002). Secondary typing of 
these strains using PGRS and spoligotyping was required to fully investigate the rate of 
active  transmission these strains  (Dale et al. 2003).  
 
The robust characterisation of evolutionarily related strains clearly requires an integrated 
approach and the use of two genotyping methodologies has been proposed as a minimum 
standard for defining related lineages (McHugh et al. 2005). McHugh and colleagues 
suggest that isolates of M. tuberculosis are genuinely related in a lineage only if they are 
related at greater than 70% similarity by two typing methods. Therefore, any isolates 
related at ≥70% similarity by IS6110 were secondarily typed using MIRU-VNTR.  
 
MIRU-VNTR was selected as secondary typing method in this data set for a number of 
reasons. In contrast to other methods, MIRU-VNTR generates an objectively 
interpretable numerical genotype, it is possible to automate the method thus facilitating 
high sample throughput, and finally, the use of differing numbers of loci allows varying 
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discriminatory power. When only five loci were used, Kremer and colleagues found 
MIRU-VNTR to be less discriminatory than IS6110 RFLP, PGRS and spoligotyping 
(Kremer et al. 1999). Twelve-loci MIRU-VNTR has been shown to be both more (Kwara 
et al. 2003), and less (Supply et al. 2006), discriminatory than IS6110 RFLP.  
 
A set of 24 loci is now widely used, but a subset of the 15 most discriminatory MIRU 
loci generates 96% of the discriminatory power of the full set of 24 loci (Supply et al. 
2006). It was reasoned that the 15 loci set may be used for epidemiological studies, whilst 
the 24 loci set would be of use in phylogenetic studies. The Health Protection Agency has 
adopted the set of 24 loci for prospective analysis in January 2010. 
 
3.1.1 Investigating Outbreaks  
 
An outbreak may be defined as incidence of disease clearly in excess of normal 
experience or expectancy (Bannister et al 2006). With regards to TB, due to the often 
prolonged incubation period the increase in case numbers may not be sudden as seen in 
outbreaks of other infectious diseases, such as measles (Heathcock and Watts 2008) or 
Legionnaire‘s disease (Coetzee et al. 2009). Nevertheless, an unexpected increase in 
cases may warrant investigation.  
 
If there is no obvious common link between cases, such as attendance at the same school 
(Caley et al. 2010) or public house (Gaber et al. 2005), or there is no marked increase in 
cases, then genotyping can be useful in detected unknown outbreaks (Bifani et al. 1999; 
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Lopez-Calleja et al. 2009.; van Soolingen D. et al. 1999). Indeed, epidemiological links 
may only be investigated following the availability of genotyping data (de Vries.et al. 
2009).  
3.1.2 Transmission rates  
 
The number of clustered strains in a population can be used to calculate a percentage of 
cases due to active transmission, rather than progression to disease following infection in 
the past. The percentage is calculated as follows (equation 3.1; Small et al. 1994):   
 
Percentage of transmission =  No. of clustered strains – No. of clusters x100 
      Total number of strains 
 
 Equation 3.1.Calculation for the rate of transmission of M. tuberculosis (Small et al. 1994). 
 
Subtracting the number of clusters from the number of clustered strains is important so as 
not to double-count a transmission event. For example, a cluster of five patients with 
indistinguishable strains represents four transmission events. 
 
The calculation of transmission events can be useful in tackling outbreaks and directing 
public health interventions, assessing the effectiveness of TB control measures (de Vries 
et al. 2009) or allocation of resources for contact tracing. Establishing the rate of 
transmission can also have wider social implications. For example, the knowledge that a 
large proportion of individuals diagnosed in London with TB were born outside the UK 
may lead to unfounded and inflammatory headlines. In comparison, the data showing that 
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the rate of transmission in London between 1995 and 1997 was low (14.4%) (Maguire et 
al. 2002) can allay fear of the uncontrolled propagation of the disease.   
3.1.3 Laboratory contamination 
  
The lipid–rich nature of the cell wall of M. tuberculosis makes the organism hardy and 
enables it to persist in a number of environments. For example, viable bacilli have been 
recovered from heat fixed sputum smears and from 0.9% sodium chloride 
decontamination solutions up to 3 weeks after inoculation (Aber et al. 1980). False 
positive cultures can occur due to contamination at any stage from specimen collection, 
such as from contaminated bronchoscopes, clerical and laboratory based errors. Faulty 
bronchoscopes may be incompletely decontaminated between patients and result in the 
inoculation of organisms into other samples. Samples may be labelled with the incorrect 
patient details and may lead to the wrong diagnosis. (Burman and Reves 2000). 
Additionally, the automated liquid culture systems used today enhance the possibility of 
laboratory cross contamination due to their increased sensitivity. 
 
Currently at the Royal Free Hospital, laboratory contamination is suspected if a patient 
sample becomes culture positive for M. tuberculosis but does not fit with the clinical 
diagnosis of TB. On suspicion of a contamination event, the date that the sample was 
processed is identified; samples processed during the preceding seven days that 
subsequently grew M. tuberculosis are identified and genotyped. In addition, any M. 
tuberculosis strains isolated in the preceding seven days are genotyped. If any of these 
isolates are indistinguishable from the suspected isolate, then laboratory contamination is 
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presumed (de Boer et al 2002; Ruddy et al. 2002). In good practice  contamination rates of below 3% 
are more common (Burman and Reves 2000; Ruddy et al. 2002). 
 
It is important to ensure that false-positive cultures are identified as quickly as possible, 
as the prolonged combination therapy has several potential side effects, including 
gastrointestinal symptoms, rashes and most significantly, hepatotoxicity (Walker et al. 
2008; Saukkonen et al. 2006). Overall incidence rates of side effects of 1.48 per 100 
person-months have been reported (Yee et al. 2003 ;Walker et al. 2008; Saukkonen et al. 
2006). Additionally, unnecessary investigations, hospitalisation and contract tracing may 
be performed. Three patients wrongly diagnosed with TB as a result of laboratory 
contamination in Massachusetts, USA in the late 1990s found that the cost was on 
average $10,873 (range $1,033 – $21,306) (Northrup et al. 2002). 
 
3.1.4 Investigating Over-represented Strains  
 
Genotyping may be used to identify evolutionarily-linked or over-represented groups of 
strains, such as the Beijing/W family (van Soolingen et al. 1995), the Kilimanjaro and 
Meru lineages in northern Tanzania (McHugh et al. 2005) and the Haarlem family 
(Kremer et al. 2005). The over-representation of a group of strains may indicate their 
success or fitness. The strains may have a selective advantage over other strains within 
the same geographic locus. The Beijing/W family is an example of this (Parwati et al. 
2010).   
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A database was established in 2002 to correlate genotype and demographic data of all 
isolates of M. tuberculosis cultured in the Department of Medical Microbiology at the 
Royal Free Hampstead NHS Trust, London. IS6110 RFLP was used as the primary 
typing tool (Chapter 2: van Embden et al. 1993). The TB service at the Royal Free 
Hospital has a catchment area of approximately 350,000 people and includes the London 
boroughs of South Barnet, Islington, North Camden and a small portion of Westminster 
(figure 3.1).  
 
 
 
Figure 3.1. Greater London boroughs (londoncouncils.gov.uk).  
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3.2 Results 
 
Samples referred to the Department of Medical Microbiology, Royal Free Hospital NHS 
Hampstead Trust, for mycobacterial investigations between 2002 and 2007 were 
processed. Positive cultures from the MB BacT system (bioMerieux, France) were sub-
cultured onto Lowenstein Jensen slopes. The database was rationalised by including only 
a single isolate from each culture confirmed case of tuberculosis diagnosed at the 
laboratory. All stages of the RFLP analysis were performed by the author.  
 
Microbiological data was collated from the local information system (LIS), WinPath 
(Sysmed, UK). Patient demographic data was collated from WinPath and additionally 
from the London TB register (LTBR). These data were collected for routine diagnostic 
use, but utilised by the author retrospectively for the purposes of this study.  
 
The site of disease was surmised from the anatomical site(s) of the specimens collected. 
If M. tuberculosis was cultured only from respiratory samples (for example, sputum or 
broncho-alveolar lavage) then the patient was classified as having pulmonary disease, 
whilst if only samples from other sites were positive then the patient was characterised as 
having an extrapulmonary infection. A patient could be placed into a third category by 
having culture positive samples from respiratory and non-respiratory sites.  
 
IS6110 RFLP typing was already established in the laboratory to provide genotyping data 
for the diagnostic TB service. The images generated (figure 3.2) were analysed using 
BioNumerics version 3.5 (Applied Maths, Sint-Martens-Latem, Belgium).  
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The relatedness of the isolates in the database was assessed using the Dice coefficient as a 
measure of similarity of assigned bands and a band tolerance of 1.2% to generate a 
dendrogram, a small example of which is shown in figure 3.3. These settings are as 
described in the internationally agreed methodology (Van Embden et al 1993). Isolates 
related at 100% similarity were termed clusters and were assigned an arbitrary number from 
the top of the dendrogram. Likewise, isolates related at >70% similarity were termed 
lineages and were assigned an arbitrary number from the top of the dendrogram.  
 
Mycobacterial interspersed repetitive units – variable number tandem repeats (MIRU-
VNTR) was used as a secondary typing method in this study. This data was also analysed 
using BioNumerics and will be discussed in chapter 4. 
 
3.2.1 Database coverage 
 
At the Royal Free Hospital a total of 732 patients were notified to the local Health 
Protection Unit (HPU) over the six year period. Of these, 424 patients (57.9%) were 
culture positive for M. tuberculosis. An RFLP strain type (figure 3.2) was obtained on 
294 isolates (69.3%). In turn, these fingerprints were used to establish the relationships 
between the isolates (figure 3.3). The number of notified cases that were culture positive 
for M. tuberculosis varied from 66% in 2005 to 50% in 2002. The proportion of isolates 
genotyped between 2002 and 2007 varied from 96% in 2003 to 30% in 2007. These 
differences are demonstrated in figure 3.4.  
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Figure 3.2 Example of an RFLP image. The reference strain MT14323 is present in lanes 1, 12 and 29. Note the 
variation in band intensity between strains, which is caused by slight differences in DNA concentration. Also 
note the low copy number strains, for example. 02:327 in lane 26.   
 
1    2    3    4    5     6   7   8    9  10  11  12  13  14 15  16  17  18  19  20  21 22  23 24  25  26  27   28  29 
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Figure 3.3 Example of IS6110 RFLP dendrogram. The scale of relatedness is displayed on the left hand side – 
the vertical lines indicate how related the strains are. For example, 02:292, 03:303 and 04:493 are 100% similar 
(indistinguishable), whilst 07:118 and 02:302 are approximately 93% similar.  
 
 
 
 
Figure 3.4 Notifications of TB from 2002 – 2007, including the breakdown of culture positive and number 
(%) of strains typed (Royal Free patients only).  
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A total of 478 strains were investigated during the years 2002 to 2007. The majority (387, 
81.0%) were patients from Royal Free Hospital (RFH). The majority of the remainder 
were patient samples referred from University College London Hospital (UCLH) (82, 
17.2%). The remaining nine isolates were referred from private practice. The notification 
of these patients was performed by the TB team at UCLH. Full patient demographic 
details were not available for all of the ULCH patients although if UCLH strains were 
implicated in significant clusters or lineages, every effort was made to obtain this 
information.  
 
There was no significant difference in the age, gender or site of disease of the UCLH 
patients when compared to the RFH. This is shown in table 3.1.  
 RFH patients 
n = 394 
Number (%) 
UCLH patients 
n = 84 
Number (%) 
 
Patient age 
0-19 20 (5.2%) 6 (7.3%) p = 0.8157 
(Chi-square) 
 
20-34 167 (43.0%) 35 (42.7%) 
35-59 146 (37.6%) 27 (32.9%) 
60+ 55 (14.2%) 11 (13.4%) 
 
Gender 
Female 174 (44.8%) 31 (37.8%) p = 0.2691 
(Fisher's exact test)
  
Male 210 (54.1%) 50 (61.0%) 
 
Site of disease 
Extra Pulmonary 122 (31.4%) 26 (32.1%) p = 0.6651 
(Chi-square) Pulmonary 230 (59.3%) 50 (61.7%) 
Pulmonary & 
Disseminated 36 (9.3%) 5 (6.2%) 
 
Table 3.1 The age, gender and site of disease of the Royal Free and University College London Hospital 
patients. These data show no difference between these patient groups in regard of age, gender or disease 
site. 
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3.2.2 Database demographics 
 
The data set demonstrated a male (54%) to female (43%) ratio of 1.3:1 and an age range 
of <1 year to 97 years. The mean age was 38.7 years, the median 35 years and the mode 
25 years (figure 3.5).  
 
 
 
 
Figure 3.5 Distribution of patients by age. Almost 80% of patients are between 20 and 59.  
 
 
The place of birth was available for 162 of the 478 patients, the majority of which (118, 
72.8%) were born outside of the UK or Ireland. This data was analysed retrospectively 
and omissions from patient notes and the London TB Register could not always be 
rectified after the event. The majority of those patients who were born outside the UK 
were from the African continent (n = 49, 30.2%), with 42 (25.9%) from south Asia and 
the Middle East. The country of origin for these 162 patients is displayed in table 3.2.  
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Ethnicity was available for 242 patients. The majority were black African (n = 118, 
48.8%), 47 (19.4%) were of European descent whilst 53 (21.9%) were from south Asia, 
which comprises India, Pakistan, Bangladesh, Sri Lanka, Afghanistan and Nepal.  These 
data are demonstrated in figure 3.6.  
 
 
Country Number % Country Number % 
Afghanistan 5 3.1 Mozambique 1 0.6 
Bangladesh 2 1.2 Nigeria 2 1.2 
Burma 1 0.6 Pakistan 3 1.9 
Cameroon 1 0.6 Philippines 2 1.2 
China 2 1.2 Poland 2 1.2 
Columbia 1 0.6 Portugal 3 1.9 
Dubai 1 0.6 Sierra Leone 2 1.2 
Egypt 1 0.6 Slovakia 1 0.6 
Ecuador 1 0.6 Somalia 23 14.2 
Ethiopia 1 0.6 South Africa 2 1.2 
Gambia 1 0.6 Spain 3 1.9 
India 26 16.0 Sri Lanka 2 1.2 
Iran 1 0.6 Tanzania 1 0.6 
Ireland 5 3.1 Thailand 1 0.6 
Italy 2 1.2 Tibet 1 0.6 
Jamaica 3 1.9 Turkey 3 1.9 
Japan 1 0.6 Uganda 1 0.6 
Kenya 3 1.9 UK 39 24.1 
Kuwait 1 0.6 Vietnam 1 0.6 
Malawi 1 0.6 Zambia 2 1.2 
Mauritius 1 0.6 Zimbabwe 4 2.5 
Morocco 2 1.2    
 
Table 3.2 Country of birth of 162 TB patients. Sub-Saharan Africa accounts for the majority of patients, 
followed by the UK and South Asia. 
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Figure 3.6 Distribution of patients by ethnicity. Black African patients comprise almost 50% of the 
patients. South Asian and European patients account for approximately 20% each.  
 
 
The HIV status of 202 patients was known, 59 (29.2%) were HIV positive while 143 
(70.8%) were HIV negative. Five patients refused an HIV test. The HIV status of the 
patients was analysed alongside other demographic details and parameters.   
 
Of the 323 patients with respiratory involvement (figure 3.7), 165 (51.1%) had a 
respiratory sample that was smear positive. There was no correlation between HIV status 
and smear positivity (table 3.3).   
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 Smear positive Smear negative  
p = 0.5171 
(Fisher's exact test) 
 
HIV negative 62 (74.7%) 75 (69.4%) 
HIV positive 21 (25.3%) 33 (30.6%) 
Total 83 108  
 
Table 3.3 Comparison of pulmonary smear and HIV status. These data show no association between smear 
and HIV status (Fisher‘s exact test).   
 
Figure 3.7 Site of disease. Nearly 60% of patients had pulmonary involvement and over 40% had 
extrapulmonary involvement.  
 
The analysis of HIV status and ethnicity was performed. There were insufficient numbers 
to statistically examine all ethnicities represented, but there was no significant link 
between HIV status and black African, European or South Asian ethnicity. These data is 
shown in table 3.4.  
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 HIV negative HIV positive  
p = 0.3385 
(Chi-square) 
Black African 61 (50.8%) 36 (66.7%) 
European 24 (20.0%) 11 (20.4%) 
South Asian 35 (29.2%) 7 (13.0%) 
Total 120 54  
 
Table 3.4 Comparison of HIV status and ethnicity. These data show no association between HIV status and 
ethnicity (Chi squared test). 
 
The potential link between smear positivity and ethnicity was investigated. As with HIV 
status, there were insufficient numbers from all ethnic groups for valid statistical analysis, 
so the largest represented groups were studied (table 3.5). The data showed that European 
patients were more likely, whilst south Asian patients were less likely to have smear 
positive disease.  
 Smear negative Smear positive  
P = 0.0004**  
(Chi-square) 
Black African 68 (57.1%) 44 (51.2%) 
European 15 (12.6%) 29 (33.7%) 
South Asian 36 (30.3%) 13 (15.1%) 
Total 119 86  
 
Table 3.5 Comparison of pulmonary smear status and ethnicity. There is a positive association between 
smear positivity and European ethnicity. 
 
 
Additionally, the smear status and country of birth was analysed. Due to small patient 
numbers, this was broken down to UK or non-UK born (table 3.6). This shows that UK-
borne patients are more likely to have smear positive disease. 
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 Smear negative Smear positive  
p = 0.0322* 
(Fisher's exact test) 
UK born 15 (16.9%) 20 (32.3%) 
Non-UK born 74 (83.1%) 42 (67.7%) 
Total 89 62  
 
Table 3.6 Comparison of pulmonary smear status and country of birth. There is a positive association 
between smear positivity and being born in the UK. 
 
3.2.3 Drug susceptibilities  
 
Susceptibility data was available for 93.1% of the database (445/478 isolates). The 
database contained 370 (83.1%) sensitive isolates of M. tuberculosis. Resistance to any 
drug was present in 75 isolates (16.9%). Of these, isoniazid and streptomycin mono-
resistance were the most prevalent, 29 (6.5%) and 18 (4.0%), respectively. Resistance to 
any of the commonly used first line drugs (rifampicin, isoniazid, ethambutol and 
pyrazinamide) was seen in 57 isolates (12.8%).  
 
There were 13 (2.9%) isolates that were resistant to at least isoniazid and rifampicin, 
constituting multidrug resistant TB (MDR TB). The majority of these (10/13), were also 
resistant to other antimicrobial drugs. No extensively drug resistant (XDR-TB) isolates 
were identified and the full array of antimicrobial resistances is listed in table 3.7.  
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Resistance Profile Number % 
Total number of strains 478  
Sensitivities available 445 93.1 
Sensitive 370 83.1 
H mono-resistant 29 6.5 
S mono-resistant 18 4.0 
R mono-resistant 1 0.2 
Z mono-resistant 4 0.9 
HS resistant 7 1.6 
HZ resistant 1 0.2 
HSE resistant 1 0.2 
H Ethi resistant 1 0.2 
HR resistant (MDR) 3 0.7 
HRS resistant (MDR) 1 0.2 
RHES resistant (MDR) 2 0.4 
RHES Ethi resistant (MDR) 1 0.2 
HR Cip resistant (MDR) 1 0.2 
HSR Clari resistant (MDR)            1 0.2 
HR Clari ethi resistant (MDR)            2 0.4 
HRE Cip Cap Ethi resistant (MDR) 1 0.2 
HRZ Ethi resistant (MDR) 1 0.2 
 
Any resistance 75 16.9 
Any first line resistance (not S) 57 12.8 
MDR total 13 2.9 
MDR plus additional resistance 10 2.2 
 
Table 3.7 Break down of antimicrobial resistance. Key: H = isoniazid, S = streptomycin, R = rifampicin, Z 
= pyrazinamide, E = ethambutol, Ethi = ethionamide, Cip = ciprofloxacin, Clari = clarithromycin, Cap = 
capreomycin,   
 
 
The relationship between drug resistance and other demographic data was analysed. Due 
to the small numbers of MDR isolates, these were excluded from statistical analyses. 
There was no link between HIV status and drug resistance (table 3.8). Additionally, there 
was no correlation between drug resistance and either ethnicity or country of birth (tables 
3.9 and 3.10, respectively). 
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 HIV negative HIV positive  
p = 0.7642  
(Chi-square) 
Isoniazid resistant 9 (6.8%) 5 (9.3%) 
Resistant to any 8 (6.1%) 3 (5.6%) 
Sensitive  115 (87.1%) 46 (85.2%) 
Total 132 54  
 
Table 3.8 Comparison of drug susceptibility and HIV status. These data show no association between HIV 
status and drug resistance.  
 
 
 Isoniazid resistant Resistant to any Sensitive  
p = 0.3190 
(Chi-square) 
Black African 6 (37.5%) 11 (68.8%) 91 (53.5%) 
European 3 (18.8%) 2 (12.5%) 38 (22.4%) 
South Asian 7 (43.8%) 3 (18.8%) 41 (24.1%) 
Total 16 16 170 
 
Table 3.9 Comparison of drug susceptibility and ethnicity. These data show no association between 
ethnicity and drug resistance.  
 
 
 Isoniazid resistant Resistant to any Sensitive  
p = 0.5633 
(Chi-square) 
UK born 2 (14.3%) 3 (33.3%) 30 (23.4%) 
Non-UK born 12 (85.7%) 6 (66.7%) 98 (76.6%) 
Total 14 9 128 
 
Table 3.10 Comparison of drug susceptibility and country of birth. These data show no association between 
country of birth and drug resistance.  
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3.2.4 Site of infection 
 
The site of disease was categorised as either pulmonary only, extrapulmonary only or as 
pulmonary and extrapulmonary.  Most patients (323, 67.7%) had pulmonary disease. Of 
these, 282 (59.1%) patients had pulmonary disease only while 41 (8.6%) had disease in 
another site also. 154 (32.3%) patients had extrapulmonary disease only. This is 
summarised in figure 3.7. There was no association between the site of disease and HIV 
status (table 3.11). 
 
 HIV negative HIV positive  
p = 0.3385 
(Chi-square) 
Extra Pulmonary 36 (25.2%) 19 (32.2%) 
Pulmonary 91 (63.6%) 31 (52.5%) 
Pulmonary & 
Disseminated 
16 (11.2%) 9 (15.3%) 
Total 
143 59  
 
Table 3.11 Comparison of site of disease and HIV status. These data show no association between HIV 
status and site of disaese.  
 
3.2.5 Molecular characteristics 
 
When examining the 478 strains in the database, it was found that the mean number of 
IS6110 copies was 9.2 and the mode was 12. There were 90 (18.8%) strains which 
possessed fewer than five copies of IS6110 and were deemed to be low copy number 
strains. The largest number of IS6110 copies possessed by a strain was 21. This is 
demonstrated in figure 3.8.  
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Figure 3.8 Distribution of strains with varying numbers of IS6110. These data show a bimodal distribution, 
comprising approximately 20% of strains with fewer than 5 IS6110 copies. The mode number of copies 
was 12 and the maximum 21.  
 
There were 28 clusters of 100% similarity involving 101 strains.  However only 20 of 
these clusters contained strains which possessed five or more copies of IS6110. The 
majority of these clusters contained only two isolates (13 clusters) or three isolates (five 
clusters). One cluster contained four isolates and one contained eight isolates. A summary 
of these clusters and IS6110 fingerprints is shown in table 3.12.   
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100% 
Cluster 
Number 
of 
IS6110 
copies 
No. of 
isolates 
per 
cluster 
IS6110 
fingerprint 
 
 
 
MT14323 
 
1 4 2 07:182  
2 2 11 07:147  
3 1 3 03:495  
4 3 3 02:204  
5 2 2 03:442  
6 1 7 07:132  
7 8 2 02:230  
8 8 2 04:511  
9 11 2 02:109  
10 12 3 03:303  
11 13 3 02:292  
12 17 3 04:053  
13 9 2 03:188  
14 8 2 03:220  
15 5 3 04:612  
16 7 2 02:011  
17 12 8 03:014  
18 9 2 04:599  
19 8 2 04:468 
 
20 13 2 04:419  
21 14 3 02:093  
22 15 2 03:138  
23 11 6 04:473  
24 12 3 02:023  
25 13 2 02:129  
26 8 2 03:468  
27 1 3 03:251  
28 1 16 02:017  
Total No. of 
clustered isolates 
101  
No. clustered 
isolates with >5 
copies IS6110 
56 
 
Table 3.12 Summary of 28 100% clusters. The given cluster number is listed in the first column. The 
number of IS6110 copies is listed in column two. The number of isolates in each cluster is shown in 
column three whilst the fingerprint of a named member of each cluster is shown in columns for and five.  
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There were 70 lineages of 70% similarity containing 318 isolates. However, three of 
these lineages (containing a combined 39 isolates) possessed fewer than five copies of 
IS6110. Of the remaining 67 lineages (containing 279 strains), the majority (33) 
contained only two isolates. The distribution of the remaining lineages is outlined in table 
3.13. The six most populated lineages are further displayed, including a representative 
IS6110 fingerprint in table 3.14.  
 
 
Number of 
isolates in a 70% 
lineage 
Number of 
lineages 
2 33 
3 9 
4 7 
5 5 
6 6 
8 1 
10 1 
13 2 
15 1 
16 1 
21 1 
 
Table 3.13 Number and size of lineages. Most lineages (33) contained only two isolates. Six lineages 
contained 10 or more isolates.  
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70% 
Lineage 
Range of 
number 
of IS6110 
copies 
No. of 
isolates 
per 
lineage 
% 
Similarity 
Example of 
IS6110 
fingerprint 
 
MT14323 
 
15 11 - 14 16 80.0% 03:303  
19 14 - 18 15 71.8% 04:053  
41 6 – 11 21 70.5% 02:011  
43 12 - 13 10 77.5% 03:014  
54 11 – 14 13 71.1% 02:093  
61 11 – 14 13 73.9% 02:023  
 
Table 3.14. Summary of the six most populated 70% lineages. The given cluster number is listed in the first 
column. The range of IS6110 copies is listed in column two. The number of isolates in each cluster is 
shown in column three. The level of relatedness is shown in column four whilst the fingerprint of a named 
member of each cluster is shown in columns for and five. 
 
 
Analysis of the 100% clusters was performed to establish two important pieces of 
information; the level of laboratory contamination and the rate of transmission in the 
community.  
 
3.2.6 Laboratory Contamination Rate and Transmission Events 
 
Following investigation with the multidisciplinary TB team at the Royal Free Hospital, it 
was agreed that six clustered isolates were due to laboratory contamination events. Using 
the total number of strains typed over the period of this study (n = 478), this gives a 
laboratory contamination rate of 1.3%.  
 
The clustered strains involved in the probable laboratory contamination events (6) were 
removed from the total number of clustered strains (56) to give a total number of 
genuinely clustered strains as 50. Using the formula from Small and colleagues (equation 
3.1; Small 1994) a rate of transmission rate of 6.3% was calculated. 
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3.2.7 Secondary Typing: MIRU-VNTR Data 
 
The isolates from the first twelve months of this study were analysed using 12-loci 
MIRU-VNTR by conventional PCR and agarose gel electrophoresis. The subsequent 
isolates were genotyped using 24-loci MIRU-VNTR using an automated capillary DNA 
sequencer (Chapter 2, section 2.2).  Isolates were selected for 24 loci MIRU-VNTR 
typing following the analysis of the IS6110 genotypes. Isolates that were characterised in 
one of the six largest 70% lineages and those possessing fewer than five copies of IS6110 
were analysed. 
 
All 12-loci MIRU-VNTR genotyping was optimised, implemented and performed by the 
author. The optimisation and implementation of the automated 24-loci genotyping 
method was also performed by the author. Analysis of the majority of the isolates in this 
chapter by the later method was performed by research assistants Laura Wright and 
Selina Bannoo. 
 
3.2.7.1 Secondary MIRU-VNTR typing of >70% IS6110 lineages 
 
A MIRU-VNTR genotype was determined for 10 of the 16 isolates in lineage of North 
London isoniazid resistant strains (lineage 15, table 3.14). All ten were present in a 
MIRU-VNTR lineage at >70% similarity, demonstrating a genuine evolutionary lineage 
(figure 3.9). The analysis of the low copy number strains using MIRU-VNTR revealed 
two further isolates that appear to be members of this outbreak (05:373 and 05:344). The 
IS6110 genotypes indicated that these isolates were not related to the North London 
outbreak strains, however the MIRU-VNTR types were indistinguishable from each other 
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and the outbreak strains. Additionally, 05:373 was an MDR strain, whilst 05:344 was 
isoniazid mono-resistant. This lineage is displayed in figure 3.9 and is discussed in more 
detail in Chapter 5.  
 
 
 
Figure 3.9. MIRU-VNTR dendrogram of IS6110 RFLP lineage 15. The level of relatedness (%) is on the 
left hand side. The MIRU-VNTR loci names are listed at the top and isolate numbers are listed on the right. 
The IS6110 lineage is split into two groups by MIRU-VNTR that are approximately 94% similar. This 
confirms that these isolates are closely related. 
 
 
 
MIRU-VNTR analysis of 15 isolates in the IS6110 lineage 19 revealed that two lineages 
are present. Two smaller lineages, 19a & 19b, consisting of five and six members, 
respectively, were seen. Isolate 05:085 did not converge with any others in this lineage, 
but only one of the 24 loci was amplified. Another isolate (06:060) aligned at a similarity 
of ≥70% with lineage 19b, but as only two loci were amplified, further work is required 
to confirm this. These results are displayed in figure 3.10.  
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Figure 3.10 MIRU-VNTR dendrogram of IS6110 RFLP lineage 19. The level of relatedness (%) is on the 
left hand side. The MIRU-VNTR loci names are listed at the top and isolate numbers are listed on the right. 
These data show IS6110 lineage 19 being split into two lineages (19a & 19b) by MIRU-VNTR typing. 
 
 
 
 
The remaining IS6110 RFLP lineages (41, 43, 54 and 61) were largely confirmed as 
being evolutionarily related by secondary MIRU-VNTR typing. A MIRU-VNTR 
genotype was available on 18 of the 21 isolates in IS6110 lineage 41. Fifteen of these 
isolates were confirmed at a similarity of ≥70% by MIRU-VNTR.  IS6110 lineage 43 
contained ten members. A MIRU-VNTR genotype was available on eight of these and 
seven were confirmed at a similarity of ≥70% by this secondary typing method. IS6110 
lineages 54 and 61 both contained 13 isolates. A MIRU-VNTR genotype was available 
on eight and three of the isolates in these lineages and a ≥70% lineage was confirmed for 
six and three members of these lineages, respectively. The data is displayed in figures 
3.11 – 3.14.  
 
Linage 
19a 
Linage 
19b 
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Figure 3.11 MIRU-VNTR dendrogram of IS6110 RFLP lineage 41. The level of relatedness (%) is on the 
left hand side. The MIRU-VNTR loci names are listed at the top and isolate numbers are listed on the right. 
 
 
 
 
Figure 3.12 MIRU-VNTR dendrogram of IS6110 RFLP lineage 43. The level of relatedness (%) is on the 
left hand side. The MIRU-VNTR loci names are listed at the top and isolate numbers are listed on the right. 
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Figure 3.13 MIRU-VNTR dendrogram of IS6110 RFLP lineage 54. The level of relatedness (%) is on the 
left hand side. The MIRU-VNTR loci names are listed at the top and isolate numbers are listed on the right. 
 
 
 
 
 
 
 
Figure 3.14 MIRU-VNTR dendrogram of IS6110 RFLP lineage 61. The level of relatedness (%) is on the 
left hand side. The MIRU-VNTR loci names are listed at the top and isolate numbers are listed on the right. 
 
 
 
The MIRU-VNTR genotypes were additionally analysed by Dr. Steve Platt at the 
Department of Bio Informatics, Health Protection Agency Centre for Infections using 
BioNumerics version 6.1 to generate a minimum spanning tree (MST). This data is 
displayed in figure 3.15. The MST demonstrates that the isolates grouped together into 
lineages by IS6110 RFLP group closely together when typed with MIRU-VNTR.  
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3.2.7.2 Secondary MIRU-VNTR typing of IS6110 low copy number strains 
 
The use of MIRU-VNTR typing revealed one possible transmission event of a strain with 
few copies of IS6110. The isolates 03:109 and 03:268 shared 18 common MIRU-VNTR 
loci (table 4.1). The patients were not shown to be epidemiologically linked when their 
notes were reviewed, however. The MIRU-VNTR dendrogram of all low IS6110 copy 
number strains is displayed in figure 4.8.    
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03;109 2 1 4   1 2 3 2 2   2 3 4 2 4 2 4 3 3 2 2 2   2 
03;268 2 1 4 2 1 2 3   2   2 3 4 2 4 2 4 3 3 2 2 2   2 
 
Table 3.15 MIRU-VNTR genotypes of two low-copy IS6110 isolates. The MIRU-VNTR loci are listed 
across the top of the table. The copy number of each of the two isolates are listed below. The isolates are 
indistinguishable.  
 
 
Isolates 02:099 and 03:427 were also matched at 100% similarity (figure 4.8). 
Investigation of the patients‘ notes showed that they were not epidemiologically linked. 
However, these isolates only shared 9 MIRU-VNTR loci. Isolates 05:344 and 05:373 
were also indistinguishable by MIRU-VNTR genotyping and were identified as being 
members of the North London isoniazid outbreak and lineage 15 (figure 4.1).  
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Figure 3.16 MIRU-VNTR dendrogram of all low IS6110 copy number strains. The level of relatedness (%) 
is on the left hand side. The MIRU-VNTR loci names are listed at the top and isolate numbers are listed on 
the right. 
 
3.3 Discussion 
 
Investigations showed that of the patients who were notified to the Health Protection Unit 
(HPU) during this study, 57.9% were culture positive. This figure is comparable to the 
national rates in 2007 and 2008 of 57% and 56%, respectively (HPA 2008; HPA 2009). 
This will vary between centres due to a number of reasons; a proportion of patients 
remain culture negative despite having symptoms and a clinical history compatible TB. 
These patients often respond to anti-tuberculosis therapy and are given a clinical 
diagnosis of TB. Additionally, diagnostic specimens are not submitted from some 
patients and a proportion of samples become overgrown with contaminating commensal 
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organisms. Of these culture positive TB patients, 69.3% were genotyped using IS6110 
RFLP. The coverage varied between a low of 30% 2007 and a high of 96% in 2003. The 
number of patients who are culture positive (58%) is comparable with national data 
(Health Protection Agency 2009). It is of note that the patients whose isolates were 
genotyped (69%) were representative of our patient population as a whole with regard to 
age, gender ethnicity and site of disease. Additionally, this is comparable with the 
proportion captured in a study in London between 1995 and 1997 (Maguire et al 2002). 
We know that the patient population in London as a whole is very mobile and transient 
(Greater London Authority 2006) and these data provide a representative snapshot of the 
TB in our catchment area between 2002 and 2007. 
 
There were 90 strains (18.8%) which possessed fewer than five copies of IS6110, which 
is comparable to the proportion seen in London between 1995 and 1997 (17.9%). Further 
work is needed to ascertain whether the strains possessing only one copy if IS6110 
belong to Principal Group IV (Sreevatsan et al. 1997; Baker et al. 2004).  
 
There was no difference in age, gender and site of disease between the patients at the 
Royal Free and University College London Hospitals and therefore the two patient 
groups were treated as equal in these regards. The proportion of male patients in the 
dataset was 54.2% (female 43.1%). This is comparable to the proportions seen in a study 
in London between 1995 and 1997 (male = 58.6%, female = 41.4%) (Maguire et al. 
2002) and the cases seen in the UK as a whole in 2008 (male = 54.2%, female = 45.2%) 
(HPA 2009). 
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The age of our patients was comparable to that of a study in London between 1995 and 
1997 (Maguire et al. 2002). There was no difference between the ages of the patients in 
this study and those seen in the data of Maguire (table 3.16).  
 
Age RFH 2002 – 2007 Maguire 1995 – 1997  
0 – 19 5.6% 7.6%  
 
p value = 0.9187 
(two-way Anova) 
20 – 34 43.1% 42.3% 
35 – 59 36.8% 33.0% 
60+ 13.8% 17.1% 
  Table 3.16 Comparison of patient ages between this data set and (Maguire et al.)   
 
There are differences between the ethnicity of our set of patients compared with the UK 
as a whole. In the UK in 2008 52.2% of TB patients were born in South Asia (India, 
Pakistan, Bangladesh, Sri Lanka, Afghanistan and Nepal) (HPA 2009). Our data shows 
that the majority of our TB patients were black African (47.3%), while only 21.9% were 
from the South Asia. Demographic data, including the country of birth was not available 
for all patients. This data is collected as part of the routine TB service. Omissions in this 
data collection may be due to patients being unwilling to divulge potentially sensitive 
information or due to oversight because of pressures on the clinical service. These gaps 
are regrettable and cannot always be corrected if this data is collected retrospectively. 
 
The three most commonly represented groups of patients by country of birth were the UK 
(24.1%), India (16.0%) and Somalia (14.2%). This proportion of TB patients of Black 
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African ethnicity was higher than those from South Asia (58.8% vs. 21.9%). This is 
divergent from national data where patients of South Asia ethnicity outnumber those 
black African (40.6% vs. 21.4%) (HPA 2009). This may be partly explained by the high 
number of Somalis in the catchment area of the Royal Free. The boroughs of Barnet, 
Camden, Islington and Westminster contain 13.7% of the nearly 34,000 Somalis in 
London, whilst only 9.5% of the approximately 172,000 Indians  in London (Greater 
London Authority 2006). The full breakdown of ethnicity between this dataset, recent 
HPA figures and those seen in London between 1995 and 1997 are demonstrated in table 
3.17.   
Ethnicity RFH  
2002 – 2007 
London 1995 – 1997 
(Maguire 2002) 
UK 2008 (HPA 
2009) 
 
Black African 47.3% 25.2% 21.4%  
 
 
p value = 0.0954 
(two-way Anova) 
Black Caribbean 1.6% 2.9% 2.0% 
South East Asian 8.2%  6.3%* 
European 21.6% 17.9%** 21.3%** 
South Asia 18.0% 22.1 52.2%*** 
Middle East 2.0% Not stated Not stated 
 
Table 3.17 comparison of ethnicity in this dataset and that seen nationally (HPA 2009) and in London 
between 1995 and 1997 (Maguire et al. 2002). The data for these studies has been collected slightly 
differently. The following caveats apply: * = country of birth East & South East Asia, ** = white ethnicity, 
*** = country of birth South Asia.  
 
The proportion of TB patients co-infected with HIV was 29.2%. This is significantly 
higher than the overall proportion in England and Wales in 2003 of 8.3% (Ahmed et al. 
2007). This may be because London has a larger proportion of HIV-infected patients than 
 176 
the rest of the UK (HPA 2008). Additionally, the Royal Free Hospital has one the largest 
HIV/AIDS centres in the country.  
 
HIV status was not associated with drug resistance, site of disease, smear positivity or 
ethnicity. These findings are similar to those of Rodger and colleagues who found no 
association between HIV status and either smear positivity or drug resistance in TB 
patients in London (Rodger et al. 2010).   
 Rates of drug resistance in this study were divergent with national data. Resistance to at 
least one first line drug was seen in 12.8% of isolates. This is a higher rate than that seen 
in London as a whole in 2008 (8.5%) (HPA 2009). Isoniazid mono-resistance was the 
most commonly seen resistance profile (6.5% of isolates), which is comparable to 
national rates of 6.0% in 2008 (HPA 2009). Multidrug resistance was seen in 2.9% of 
isolates, which is higher than the national average in 2008 (1.1%) (HPA 2009). This may 
be because complex or drug resistant cases are often transferred from surrounding 
hospitals for the Royal Free for their care.  
 
There was no evidence linking either ethnicity or country of birth to drug resistance. This 
may be because the absolute numbers of drug resistant strains is quite small and therefore 
may not reach statistical significance. Additionally, the dataset includes few patients from 
areas with high rates of drug resistance, including Eastern Europe, the former Soviet 
Union and the Far East (WHO 2008).  
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There was variation between the sites of disease in this dataset compared to national data. 
HPA data from 2008 revealed that 46% of patients had extrapulmonary disease only, 
whilst 54% had pulmonary disease (with or without extrapulmonary involvement). These 
data from the Royal Free show that only 32.3% had extrapulmonary disease only, whilst 
67.7 had pulmonary disease (with or without extrapulmonary involvement). These figures 
may be discrepant because patients at the Royal Free with extrapulmonary disease may 
be under-represented in this dataset. Extrapulmonary sites, such as lymph nodes, are 
often only sampled once and may remain culture negative. Alternatively, samples may 
not be obtained at all and a diagnosis may be made on clinical evidence alone. These 
situations may mean that an organism will not be available genotyping.  
 
There was an association between ethnicity and smear positivity. European patients were 
more likely, whilst South Asian patients were less likely to have smear positive disease 
(p=0.0004). A possible explanation for this data is that given the majority of TB patients 
in the UK are non-European, other causes may be higher on the list of differential 
diagnoses. It is possible that these patients go undiagnosed for longer, which allows their 
disease to progress and develop into a higher bacterial burden. The data collected here 
does not allow this hypothesis to be examined. A retrospective cohort study of the time 
difference between onset of symptoms, first presentation and diagnosis would be required 
for this.  
 
Likewise, there was an association between country of birth and smear positivity. UK 
born TB patients were more likely to have smear positive disease (p=0.322). This 
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association is less strong than that demonstrated between ethnicity and smear positivity, 
possibly because a large proportion of TB patients born in the UK are from ethnic groups 
with high rates of TB. Therefore, the diagnosis of TB in these patients may be reached 
more rapidly than in those of white ethnicity born in the UK.  
  
One hundred and one isolates (21.1%) clustered with at least one other isolate. This is 
significantly lower than the 46% of strains that were in clusters in the Netherlands 
between 1993 and 1997 (van Soolingen et al. 1999) and 31.8% seen in Madrid between 
2002 and 2004 (Iñigo et al. 2008) but more similar to the 22.7% of strains in clusters in 
London between 1995 and 1997 (Maguire et al. 2002).  
 
The clustered isolates were used to calculate the rate of laboratory contamination and 
active transmission. Of the isolates typed, 1.3% of positive cultures of M. tuberculosis 
were likely to be laboratory contaminants. This rate is comparable to, or better than, other 
centres (Anonymous 1997; Burman and Reves 2000; Ruddy et al. 2002; de Boer et al. 
2002). Contamination events occur due to a number of reasons. Clerical errors can occur 
(Nitta et al.), but one study showed that these were less common than laboratory 
contamination, as the samples that cultured presumed contaminants contained fewer 
organisms than other positive samples being processed at the same time (Mitchison DA 
et al. 1980). Additionally, the use of common reagent containers has been shown to be a 
source of cross contamination between clinical sample (de C Ramos et al. 1999).  
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The need for standardised procedures and good technique is essential. One study showed 
that 93% of laboratory contamination events were attributable to a single technician, 
probably because she was left-handed and the equipment within the biological safety 
cabinet was not arranged in a suitable manner (Bauer et al. 1997).  
 
For this reason, a number of interventions are in place at our laboratory and are reflected 
in the Standard Operating Procedures (RFH Microbiology 1; RFH Microbiology 2). Only 
eight samples are processed in the biological safety cabinet at any one time with only one 
specimen being opened at a time. There are workflows for right- and left-handed 
individuals to avoid droplet contamination and the cabinet is cleaned with an appropriate 
decontaminating agent regularly. Additionally, any disposable equipment, such as Pasteur 
pipettes or inoculating loops are kept outside the cabinet to avoid contamination, or 
discarded at the end of the day if they have been inside the cabinet.  
 
Once the probable contaminants in this study were removed from the clusters, it was 
calculated that 6.3% of typed isolates were from patients involved in active transmission 
events. This rate is lower than several other studies (1.9.5; Table 1.2). Of note, this rate is 
lower than a study in London between 1995 and 1997 (14%) (Maguire et al. 2002). This 
may be due to the smaller geographical area of this study;. Some TB patients in an active 
chain of transmission may seek medical attention elsewhere and therefore will be 
excluded from the sample. This will therefore falsely decrease the level of transmission.  
 
 180 
The largest cluster, contained eight indistinguishable strains, and included four members 
of the same Somali family. They were diagnosed over a 13 month period from March 
2003 and April 2004 after entering the UK in 1990. Almost 50% of TB patients born 
outside the UK are diagnosed within five years of entering the country (HPA 2009). 29% 
of TB patients have been in the UK for ten or more years before TB is diagnosed. The 
members of this family would be positioned near the top end of the inter-quartile range (2 
– 15 years) (HPA 2009). All eight members of the cluster had fully sensitive pulmonary 
disease. Three of the four family members were sputum smear positive. Epidemiological 
links between this family and the remaining four members of the cluster were not found 
following further investigation and contract tracing.  
 
Two isolates from a cohabiting couple were indistinguishable and accounted for one 
100% cluster. Both patients were diagnosed with pulmonary TB by bronchoscopy. 
Transmission of M. tuberculosis to household contacts is a common event and the female 
of the couple was diagnosed following routine contact tracing (Becerra et al. 1986; Wang 
and Lin 2000; Kilicaslan et al. 2009; Sia et al. 2010).  
 
Two other 100% clusters were of note. Two men in their fourth decades were shown to 
have indistinguishable strains. They had both spent considerable amounts of time in 
prison. They were not in the same institution at the time of their diagnoses but records 
showed that they had both moved around several prisons in the capital during the 
preceding years. Two further clustered isolates were cultured from one male and one 
female in their fifth decades. Both had been intermittently homeless and had histories of 
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misusing alcohol. However, the individuals could not be linked epidemiologically by 
contact tracing. This does however indicate that strains are circulating within specific 
communities.  
 
The RFH IS6110 database shows that 60 of the 67 70% lineages contain six or fewer 
isolates. There were seven lineages containing eight or more isolates. It is difficult to 
compare this to other geographic locations as most molecular epidemiological TB studies 
concentrate on the degree of clustering and active transmission. However, a study in 
northern Tanzania showed that approximately one third of strains were members of only 
two 70% lineages as defined by IS6110 and MIRU typing (McHugh et al. 2005). This 
may be a result of a more static human population than is seen in London. Indeed, the 
Greater London Authority estimates that in 2006 almost one in three (31.67%) 
individuals living in London were born outside of the UK (Greater London Authority 
2006). These large lineages were secondarily typed using MIRU-VNTR. 
 
Secondary typing of Lineage 15 as assigned by IS6110 RFLP was confirmed by MIRU-
VNTR typing. Two further isolates shared identical MIRU-VNTR genotypes with other 
members of this lineage despite being originally categorised as low copy number strains. 
Review of the original RFLP revealed that not only is RFLP a technically difficult 
method but it requires subjective interpretation. The additional finding that both of these 
isolates were isoniazid resistant, and indeed one was multi-drug resistant, adds weight to 
the argument that these strains should be included in the outbreak lineage despite their 
putative IS6110 RFLP genotype. Poor quality images are often difficult to interpret, in 
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our experience. For example, the RFLP image shown in figure 3.2 shows some variation 
in DNA quantity between loaded isolates. This is despite procedures put in place to 
combat this, such as DNA quantification both prior to, and after, restriction. DNA was 
quantified using serially diluted lambda DNA and agarose gel electrophoresis with 
ethidium bromide staining. More accurate results may have been obtained if the DNA 
was quantified using a spectrophotometric method. Strains that show no bands were 
analysed again to confirm that DNA was successfully extracted and that there were 
genuinely no copies of IS6110 present. Lanes that showed large, intense bands were 
analysed thoroughly by using the contrast and intensity functions on the software to 
accurately assign the centre of such bands. This lineage (related at 80% by IS6110 and 
94% by MIRU-VNTR) contained 16 isolates. Fourteen of these isolates were resistant to 
at least isoniazid and genotyping at the HPA MRU revealed they were part of the North 
London isoniazid-resistant outbreak (Ruddy et al. 2004). 
 
IS6110 RFLP lineage 19 was subdivided into two smaller lineages by MIRU-VNTR 
genotyping. The original lineage contained 15 isolates, which were split into one lineage 
of seven isolates (lineage 19a) and one of four isolates (lineage 19b). Two isolates that 
were placed in the original lineage by IS6110 RFLP genotyping were not related at 70% 
by MIRU-VNTR typing and therefore are not genuine members of this lineage. This 
finding indicates that 24-loci MIRU-VNTR is more discriminatory in this setting than 
IS6110 RFLP.  
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The remaining four lineages were confirmed by secondary MIRU-VNTR typing. For 
example, of the isolates for which a MIRU-VNTR type was available, 15 of 18 isolates in 
lineage 41 were related at 70% by the secondary typing method. Therefore, these 15 
isolates are genuinely related within this lineage. All six lineages are summarised in table 
3.18. The observation that not all isolates were confirmed at 70% similarity by MIRU-
VNTR typing indicates that this method is more discriminatory than IS6110 RFLP. 
 
Large lineages indicate an over-representation of a group of closely related strains in a 
population. Successful lineages have been previously documented. The W/Beijing family 
(van Soolingen et al. 1995), the Kilimanjaro and Meru lineages in northern Tanzania 
(McHugh et al. 2005) and the Haarlem family (Kremer et al. 1999) are all lineages of 
strains that are over-represented in a community. The over-representation of a group of 
strains may indicate their success or ‗fitness‘. The strains may have a selective advantage 
over other strains within the same geographic locus. 
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IS6110 
RFLP 
Lineage 
Number of 
original 
members 
Number of 
MIRU-VNTR 
types available 
Number of 
isolates 
confirmed 
at ≥70% 
Comments 
15 16 10 10 (100%) Two additional members 
identified by MIRU-VNTR 
19 15 13 11 (85%) Subdivided into two 
lineages (19a & 19b) 
41 21 18 15 (83%)  
45 10 8 7 (88%)  
54 13 8 6 (75%)  
61 13 3 3 (100%)  
 
Table 3.18. Summary of the number of isolates in the IS6110 RFLP lineages that were confirmed as being 
70% related by MIRU-VNTR, the secondary typing method.  
 
The Beijing/W family are an example of this is a group of strains that was first seen in the 
Beijing area of China (van Soolingen et al. 1995). They have a characteristic spoligotype, 
but are more loosely related by other typing methods. Representatives of the W/Beijing 
family are now seen worldwide and have been intensively investigated. The success of 
this group of strains has been hypothesised to be linked to its virulence, fitness (Zhang et 
al. 1999), mutability (Ebrahimi-Rad et al. 2003), acquisition of drug resistance and 
immune-modulatory abilities (Lopez et al. 2003; Reed et al. 2007).  
 
Isolates within such lineages may be studied to examine why they are so prevalent and to 
ascertain any measurable advantage that allows them to spread widely. Fitness assays 
(Chapter 6) and mutation rate experiments can be used to measure any advantage that is 
possessed by these strains (O‘Sullivan 2008). 
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The secondary typing of these strains using mycobacterial interspersed repeating units 
(MIRU), chapter 4, allows a more complete characterisation of the strains found in this 
location at this particular time. This will allow clusters and chains of transmission to be 
confirmed or refuted as well as the definitive characterisation of lineages. Additionally, 
the isolates that possess fewer than five copies of IS6110 may be studied.  
 
3.3.1 MIRU-VNTR Discussion 
Some loci were more variable than others.  Locus 154 was amongst the least variable 
with only two alleles seen (1 and 2 copies). Over 90% of the isolates possessed two 
copies at this locus. The three most variable loci were 2163, 2165 and 4052. No single 
allele accounted for more than 40% of the isolates at these loci. These findings are 
concordant with other published data demonstrating the most and least variable loci 
(Supply et al. 2006).  The summary of the variability of the loci are displayed in table 
3.19. 
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Locus No. Of 
Alleles 
Copy 
No. 
% Copy 
No 
% Copy 
No 
% Copy 
No 
% Copy 
No 
% Copy 
No 
% Allele % 
154 2 1 8.0 2 92.0           
424 5 1 10.8 2 50.0 3 17.6 4 20.3 6 1.4     
577 6 1 1.8 2 38.4 3 10.7 4 45.5 5 2.7 9 0.9   
580 5 1 7.3 2 78.9 3 7.3 4 0.9 5 5.5     
802 4 1 30.3 2 17.2 3 42.4 4 10.1       
960 6 2 7.2 3 22.5 4 45.0 5 16.2 6 4.5 7 4.5   
1644 5 1 23.4 2 14.4 3 49.5 4 11.7 5 0.9     
1955 7 1 2.1 2 7.2 3 57.7 4 16.5 5 13.4 6 1.0 7 2.1 
2059 4 0 17.6 1 11.8 2 68.1 4 2.5       
2163 6 1 1.9 2 34.3 3 21.9 4 23.8 5 10.5 6 7.6   
2165 5 1 1.9 2 34.3 3 21.0 4 37.1 6 5.7     
2347 5 1 3.9 2 2.4 3 15.0 4 78.0 10 0.8     
2401 5 0 2.5 1 18.3 2 48.3 3 3.3 4 27.5     
2461 6 1 20.2 2 69.0 3 3.1 4 3.9 5 3.1 7 0.8   
2531 6 3 4.0 4 4.0 5 60.3 6 29.4 7 1.6 10 0.8   
2687 4 1 83.3 2 13.8 4 1.4 6 1.4       
2996 7 1 15.2 2 11.4 3 3.8 4 19.0 5 44.8 6 1.0 7 4.8 
3007 4 1 1.3 2 18.8 3 77.5 4 2.5       
3171 4 1 8.5 2 10.3 3 71.8 4 9.4       
3192 5 2 6.4 3 63.3 4 7.3 5 21.1 6 1.8     
3690 3 1 3.3 2 83.6 3 13.1         
4052 5 1 15.8 2 21.1 3 31.6 4 10.5 5 21.1     
4156 3 0 25.0 1 50.0 3 25.0         
4348 4 1 5.7 2 72.1 3 20.5 4 1.6       
 
Table 3.19. Summary of the variability of MIRU-VNTR loci. Loci where a single allele accounts for ≤40% 
of isolates are the most variable and are highlighted in green. Loci where an allele accounts for 40-50% of 
isolates are highlighted in yellow. Loci where an allele is seen in 50-60% of isolates are in orange, whilst 
loci where an allele accounts >60% of isolates (the least variable) are highlighted in red. 
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It was not possible to amplify all 24 MIRU-VNTR loci for any of the isolates analysed. It 
is widely reported that some loci are more difficult to amplify than others. Considerable 
effort was expending to optimise these triplexed PCR reactions. This process involved 
performing magnesium and primer concentration titrations. Additionally, the injection 
time of the automated sequencer was altered in an attempt to detect low level 
amplification of some loci. Failed reactions were often repeated if the level of 
discrimination was not sufficient. Failed reactions occurred commonly at loci 4052, 4156 
and 4348. All three of these loci are grouped together in a similar region of the genome 
and are amplified using primers labelled with the yellow fluorophore NED.  
 
The consistent failure to amplify these loci warrants further investigation. The complex 
optimisation performed by Supply and colleagues, particularly related to magnesium 
concentrations for different master mixes, is testament to this (Supply 2005). 
Additionally, other groups have noted that some loci are more problematic than others 
and have raised concerns regarding the conditions used for amplification (Velji et al 
2010). This group also highlighted the importance of standardising the amplification 
conditions, even including the polymerase enzyme, to ensure reproducibility of 
hypervariable loci. Furthermore, centres performing MIRU-VNTR typing on large 
numbers of isolates have also experienced difficulties in amplifying some loci (Dr. T 
Brown, NMRL, personal communication). 
 
In summary, MIRU-VNTR has several advantages over other typing methodologies, for 
example; it is highly discriminatory when 15 or 24 loci are used, it may be automated, the 
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genotypes may be analysed objectively between centres. These data suggest that it is 
more discriminatory than IS6110 RFLP and can additionally distinguish isolates that 
possess fewer than five copies of IS6110 (section 1.9.4.2), which has been described 
elsewhere (Kremer et al. 2005). The method is less prone to technical difficulties and can 
provide useful data even if not all 24 loci are amplified. The observation that two 
potentially linked strains were omitted from an outbreak lineage due to poor RFLP image 
quality is worrying. The MIRU-VNTR genotypes, together with their phenotypic 
susceptibilities, suggest that they are indeed related.  
 
Some isolates appear to be indistinguishable using MIRU-VNTR, such as 02:099 and 
03:427 (these two isolates were classified as low copy number strains by IS6110 RFLP). 
However, due to failed PCR reactions, only nine corresponding loci could be amplified in 
both isolates. No epidemiological links were found between the patients and considering 
the gaps in the MIRU-VNTR data, describing these isolates are indistinguishable may be 
disingenuous.   
 
The clinical usefulness of MIRU-VNTR typing is evident from these data. Small 
quantities of DNA are required so that MIRU-VNTR typing may be performed on 
cultures of M. tuberculosis at an earlier stage than is required by IS6110 RFLP. Indeed, 
given that small quantities of DNA are required, and the degree of automation involved, 
it is possible to generate a genotype within 24 hours of a positive culture being identified. 
This advantage, together with its ability to genotype the approximately one in five strains 
in London that possess fewer than five copies of IS6110 means that of MIRU-VNTR 
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should be used as a first line typing technology. MIRU-VNTR is now widely adopted 
globally as a typing tool due to its ease of use, easily interpretable and transportable data 
and rapid turnaround. It should therefore be considered as a first-line genotyping 
methodology and other methods, such as IS6110 RFLP, may be used as secondary tools.  
 
In summary, the Royal Free genotyping database shows a diverse population of TB 
patients, which is largely concordant with the conventional epidemiology of TB in 
London (Maguire et al. 2002; HPA 2009).   
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Chapter 4: ESAT-6 and the Host Response 
 
 
4.1 Introduction 
 
The aim of this current study was to test the hypothesis that the antigen specific response 
seen in the patients‘ T cells was related to the biology of the infecting organism as 
compared to that of the host. Here, three hypotheses are examined; firstly, those patients 
whose T cells do not respond to ESAT-6 stimulation may be infected with related strains 
of M. tuberculosis and therefore the response may be associated with the biology of a 
variant strain. Secondly, the organisms isolated from patients whose T cells did not 
respond to ESAT-6 stimulation may lack the esxA gene, or may possess the gene, but 
with mutations. Thirdly, the level of gene expression of esxA in the isolates may play a 
role in the ESAT-6 specific IFN-γ response. 
 
Proteins secreted by M. tuberculosis during growth are thought to be important in 
protective immunity against tuberculosis (Andersen et al. 1991). The study of short-term 
culture filtrates identified a novel low-molecular-mass protein with a mass of 6kDa that 
was immunogenic in murine models. The antigen, named early secretory antigen target 6 
(ESAT-6), was found to stimulate a dose-dependent IFN-γ response in the ex-vivo murine 
T-cells (Sorensen et al. 1995 ;Andersen et al. 1995 ;Brandt et al. 1996).  This antigen was 
detected in M. tuberculosis reference strains H37Rv and H37Ra, a clinical isolate of M. 
tuberculosis and M. africanum, as well as in M. kansasii, M. szulgai and M. marinum. 
Interestingly, the antigen was absent from vaccine strains of M. bovis BCG (Sorensen et 
al. 1995; Harboe et al. 1996).  
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The gene encoding this protein was identified by sequencing, and further analysis showed 
that ESAT-6 was a polypeptide of 95 amino acids. Identified directly upstream from the 
gene encoding ESAT-6 was a co-transcribed gene named lhp or esxB (Berthet et al. 
1998). This gene was annotated Rv3874 in the genome sequence of M. tuberculosis 
H37Rv (the gene encoding ESAT-6 was Rv3875 and named esxA or esat6) (Cole ST et al. 
1998). The gene product, isolated from the low-molecular-mass short-term culture filtrate 
had an apparent molecular mass of 10kDa and was named culture filtrate protein-10 
(CFP-10) (Berthet et al. 1998). Renshaw and colleagues demonstrated that ESAT-6 and 
CFP-10 are found to exist in solution in 1:1 ratio (Renshaw et al. 2005). Additionally, 
there appeared to be several related proteins in encoded in the M. tuberculosis genome 
and these were termed the lhp/esat-6 gene family (Berthet et al. 2005).  
 
Comparative genome analysis showed that several regions of difference, including RD1, 
were present in M. tuberculosis H37Rv and M. bovis, but absent from the vaccine strain 
M. bovis BCG, and was reasoned to be a contributor to the vaccine strain‘s attenuation 
(Mahairas et al. 1996; Gordon et al. 1999; Behr et al. 1999). The genes esat6 and lhp 
were found to be in the M. tuberculosis RD1 (spanning the open reading frames Rv3871 
– Rv3879) in a cluster with a further 12 genes (figure 4.1). Analysis of the M. 
tuberculosis proteome revealed that there were several proteins similar to ESAT-6. This 
ESAT-6 family comprises 14 members ranging in size from 90 to 120 amino acids 
(Tekaia et al. 1999). Additional homologues were also described in Streptomyces 
coelicolor and Corynebacterium diphtheriae (Gey Van Pittius et al. 2001). 
 
 192 
The roles of ESAT-6, CFP-10 and RD1 in mycobacterial virulence and immunity were 
investigated.  An esat6 knockout mutant of M. bovis created by Wards and colleagues 
demonstrated reduced virulence by histopathological examination of lesions in animal 
models (Wards, de Lisle, and Collins 2000). Additionally, the loss of RD1 was shown, by 
Pym and colleagues (Pym et al. 2002a) to have contributed to the attenuation in M. bovis 
BCG and the vaccine strain M. microti. M. bovis BCG and M. microtti were 
complemented by knocking-in RD1, RD3, RD4, RD5, RD7 and RD9. The strains 
complemented with RD1 demonstrated altered colonial morphology towards that of 
virulent tubercle bacilli as well as increased virulence in mice, by the observation of 
increased growth rates, granuloma formation and splenomegaly, compared to controls. 
The affect of deleting RD1 from M. tuberculosis H37Rv was demonstrated by Lewis and 
colleagues. The M. tuberculosis H37Rv RD1 knock-out showed reduced growth rates 
(similar to M. bovis BCG controls) in the human-macrophage-like cell line THP-1, 
human monocyte-derived macrophages as well as mice (Lewis et al. 2003).  
 
 
Figure 4.1 The genes present in the RD-1 along with the flanking genes are shown as an extended RD-1 
(extRD-1) locus of M. tuberculosis. The arrows indicate the direction of transcription. The clear boxes 
represent genes present in RD-1 region, which is deleted consistently in all strains of BCG (Ganguly, 
Siddiqui, and Sharma 2008b).  
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The inoculation of mice with complemented M. bovis BCG and M. microtti with genes 
encoding ESAT-6 and CFP-10 was unsuccessful in generating ESAT-6-specific T-cell 
responses. This was only achieved when the vaccine strains were complemented with the 
entire RD1 region, suggesting that flanking genes are necessary for ESAT-6 secretion 
(Pym et al. 2002a). Additionally, reduced lysis of pneumocytes and macrophages, as well 
as reduced tissue invasion have been shown by RD1 knock-outs of M. tuberculosis 
reference strains H37Rv, Erdman and CDC1551 (Hsu et al. 2003).  The lytic activity of 
ESAT-6 in pneumocytes has also been shown in cell culture (Kinhikar et al. 2010). 
  
Involvement of ESAT-6, CFP-10 and surrounding genes in RD1 in virulence and 
immunomodulation have been described. For example, Ganguly and colleagues (Ganguly 
et al. 2007) showed that ESAT-6 and CFP-10 down-regulated the bacterial 
lipopolysaccharide (LPS)-induced reactive oxygen species (ROS) production, which is 
important for killing intracellular pathogens. Other examples are listed in table 4.1.  
 
Process  
 
Mechanism implicated Reference(s) 
Pathogenesis/ 
virulence 
Cell lysis (Hsu et al. 2003; Gao et al. 2004) 
Granuloma formation  (Volkman et al. 2004) 
Cytokine suppression  (Stanley et al. 2003) 
Type I Interferon (IFN) induction  (Stanley et al. 2007) 
Phagosomal maturation arrest (Tan et al. 2006) 
Cytosolic bacterial translocation  (van der Wel N. et al. 2007) 
Interaction with Toll-like receptor  (Pathak et al. 2007) 
Immunomodu
-lation 
Down-regulation of macrophage cell 
signaling 
(Basu et al. 2006; Ganguly et al. 
2007; Ganguly et al. 2008a) 
Down-regulation of dendritic cell and T-
cell functions  
 
(Natarajan et al. 2003; Latchumanan 
et al. 2005; Sinha et al. 2007) 
 
Table 4.1 Summary of the effects of the products of extRD1 (adapted from (Ganguly, Siddiqui, and Sharma 
2008b)). 
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Many secretion systems involved in bacterial virulence have been described (Lee et al. 
2001; Finlay et al. 1997), but not in M. tuberculosis. The precise mechanism of ESAT-6 
and CFP-10 secretion was not clear as the proteins lack a secretory signal sequence 
(Pallen 2002) and appeared to be sec-independent (Economou 1999). Guinn and 
colleagues (Guinn et al. 2004) showed that the export of ESAT-6 and CFP-10 were 
impaired and M. tuberculosis attenuated by disrupting five genes within RD1, indicating 
that these genes play a role in secretion.  
Furthermore, a specialised Sec-independent secretion pathway, termed the snm pathway 
has been described (Stanley et al. 2003). Genes necessary for the secretion of ESAT-6 
and CFP-10 were located outside of RD1 (termed the extended RD1 – extRD1) (Gao et 
al. 2004) and was named the ESAT-6 secretion system (ESX-1) (Brodin et al. 2004). 
Indeed, the individual genes of the extRD1 were investigated by Brodin and colleagues. 
Inactivation of pe35 (Rv3872 – upstream of esxA and esxB and within RD1) impaired 
expression of CFP-10 and ESAT-6 and therefore may play a role in regulation (Brodin et 
al. 2006). Further evidence of the regulation of snm secretion from outside the extRD1 
has been demonstrated. Two genes located in the gene cluster Rv3616c-Rv3614c, named 
snm9 and snm10, have been shown to be essential to snm secretion. Mutants of M. 
tuberculosis lacking these genes due to secrete ESAT-6 and CFP-10, and are attenuated 
in mice and macrophage models (MacGurn et al. 2005). The involvement of ESX-1 was 
further elucidated by Champion and colleagues (Champion et al. 2006), who found that 
the unstructured C terminus of CFP-10 was recognised by Rv3871, which itself interacts 
with the membrane protein Rv3870. Mutations in this gene impaired CFP-10 secretion 
via ESX-1. Furthermore, the yeast Saccharomyces cerevisiae was complemented with 
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ESX-1 by Teutschbein and colleagues (Teutschbein et al. 2009). This group demonstrated 
that this sec-independent secretory system involved ATP-dependent chaperones and 
membrane proteins, encoded in the extRD1. They also showed that both ESAT-6 and 
CFP-10 exist as hetero- and homo-dimers.    
 
The possibility of utilising these antigens in assays for the diagnosis of TB was explored 
shortly after the description of the antigen. ESAT-6 and CFP-10 specific immune 
responses were seen in mice (Brandt et al. 1996), guinea pigs (Elhay, Oettinger, and 
Andersen 1998; Colangeli et al. 2000) and human lymphocytes (Lalvani et al. 1998; 
Ulrichs et al. 1998; Mustafa et al. 1998; Ravn et al. 1999).   
 
The tuberculin skin test (TST) is used to measure an individual‘s exposure to M. 
tuberculosis and therefore identify latent infection. Purified protein derivative (PPD) is 
inoculated subdermally and the scale of the delayed-type hypersensitivity response, 
indicating long-term T cell memory, is measured in the size of the induration generated. 
PPD is a culture filtrate of tubercle bacilli (Seibert and Dufour 1948) that contains over 
200 antigens that are shared with M. bovis BCG and most non-tuberculous mycobacteria 
(Huebner, Schein, and Bass, Jr. 1993). Therefore, interpretation of this test is hampered 
due to exposure to environmental mycobacteria, previous BCG vaccination (Tissot et al. 
2005; Wang et al. 2002) and in the immunocompromised. The development of assays 
measuring the immune memory response to specific M. tuberculosis antigens is an 
advance on this assay.  
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The potential of the use of these antigens in diagnostic assays was further explored. The 
enumeration of T cells that secreted IFN-γ in response to ESAT-6 (with or without CFP-
10) stimulation was achieved by enzyme linked immunospot (ELISPOT) assay (Pathan et 
al. 2001; Chapman et al. 2002, Lalvani et al. 2001a; Lalvani et al. 2001b). ESAT-6 
specific T cells were detected in patients with culture-confirmed pulmonary TB, 
presumed previous M. tuberculosis infection, TB lymphadenitis and household contacts 
but not in unexposed controls (Pathan et al.2001). No cross reactivity was seen in 
unexposed controls who had been BCG vaccinated. This group then used this assay to 
measure the extent of latent M. tuberculosis infection in 100 healthy adults in Mumbai, 
India compared to 40 BCG-vaccinated UK residents. Of the Mumbai cohort, 80% 
responded to at least one of ESAT-6 and CFP-10, whilst no UK patients did (Lalvani et 
al. 2001a). This method was also shown to be useful in HIV-infected individuals. The 
TST suffers from poor sensitivity and specificity in HIV patients (Huebner, Schein, and 
Bass, Jr. 1993) but Chapman and colleagues demonstrated that ESAT-6 or CFP-10 
specific T cells were detectable in this patient group (Chapman et al. 2002).  
 
ESAT-6, together with CFP-10 is used a stimulatory antigen in these assays. Both assays 
utilise the antigens ESAT-6 and CFP-10 but the QuantiFERON-TB Gold in-tube assay 
(QFT-IT) additionally uses the antigen TB7.7, encoded in RD11 (section 1.5.1).  
 
A recent meta-analysis of these assays showed that they are both a huge improvement on 
the conventional TST (Diel, Loddenkemper, and Nienhaus 2010). The analysis 
investigated the role of these assays in the detection of active TB as a surrogate for latent 
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TB infection, as there is no established gold-standard for this. The sensitivity and 
specificity of TST, QFT-IT and T-SPOT.TB are summarised in table 4.2. Additionally, 
the meta analysis showed low rates of indeterminate results for both IGRA. These rates 
were considerably higher in immunocomprimised patients (Diel, Loddenkemper, and 
Nienhaus 2010).  
    
 Sensitivity % (95% CI) Specificity % (95% CI) 
TST 69.9% (67 – 72) Not measured 
QFT-IT 81.0% (78 – 83) 99.2% (98 – 100) 
T-SPOT.TB 87.5% (85 – 90) 86.3% (81 – 90) 
 
Table 4.2 Summary of the sensitivity and specificity of commercial IGRA and TST in the diagnosis of 
active TB (Diel, Loddenkemper, and Nienhaus 2010).  
 
The analysis of IGRA in children was less favourable (Bamford et al. 2010). The use of a 
single IGRA alone was no better at diagnosing active TB than TST. The analysis found 
that a negative IGRA did not rule out TB, but that the combined use of IGRA and TST 
increased the sensitivity to over 90% regardless of which IGRA was used.  
  
The use of these assays is recommended in the diagnosis of latent TB infection by NICE. 
Alongside the tuberculin skin test, or Mantoux, and chest x-ray these assays are used 
when contract tracing individuals who have been exposed to a confirmed case (NICE 
2006). 
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IGRAs measure the IFN-γ response from circulating lymphocytes. Several studies have 
investigated the response to cells obtained from the lung, the primary site of M. 
tuberculosis infection (Barry et al. 2003; Wilkinson et al. 2005; Breen et al. 2005). Breen 
and colleagues showed that IFN-γ responses were demonstrable in such cells from TB 
patients. However, data obtained by our group has demonstrated that not all tuberculosis 
patients give a positive IFN-γ response, despite being later confirmed to have active 
disease by conventional methods (Breen et al. 2005; Breen  et al. 2008a). Immunological 
and clinical data in this chapter was obtained from Dr. Ronan Breen. All other practical 
work was performed by the author.  
 
The hypothesis of this chapter is that the biology of the infecting organism has an effect 
on the immunological response of the patients‘ T cells. One aspect of this is the gene 
expression of the antigen in question, esxA. Gene expression may be measured in a 
number of ways. As well as allowing the detection of multiple targets, microarrays may 
be used to measure gene expression see Miller and Tang for review (Miller and Tang 
2009). Gene expression in M. tuberculosis in response to varying environmental 
conditions and exposure to antibiotics has been monitored (Kaushal et al. 2002; Betts et 
al. 2003; Voskuil et al. 2003; Rengarajan et al. 2005). Oligonucleotide arrays have been 
used to investigate gene expression related to drug resistance (Wilson et al. 1999; Keller 
et al. 2004; Fu and Shinnick 2007). 
Microarrays are incredibly useful for screening for up and down-regulation across an 
entire genome but they are expensive and can be technically difficult to perform. 
Additionally, any findings must be confirmed by another method, such as reverse 
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transcriptase PCR or Western blotting. A more targeted method than microarrays to 
investigate the expression of individual genes is the use of reverse transcriptase 
polymerase chain reaction (RT PCR). Gene expression (determined by the detection of 
mRNA) may be measured absolutely or relatively. Absolute measurement involves using 
quantitative PCR (qPCR) and the establishment of a standard curve (Schmittgen and 
Zakrajsek 2000). 
 
The alternative is to measure the relative change in gene expression compared to a 
reference gene. This may be performed using the ∆∆Ct method (Livak and Schmittgen 
2001). This method measures the relative change in gene expression in the target gene 
compared to not only a reference gene, but also to a reference strain. The advantage of 
the relative quantification is that it is not necessary to quantify the RNA entering the 
assay.  
 
This reference gene must be selected carefully and should ideally be expressed at a 
constant rate by all strains. For this study, the housekeeping genes sigA and 16S rRNA 
were chosen as reference genes. sigA encodes the principle sigma factor in M. 
tuberculosis, which is a regulatory transcription factor (Gomez, Chen, and Bishai 1997). 
16S rRNA encodes the small subunit of the bacterial ribosome.  
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4.2 Results 
 
4.2.1 IFN-γ release assay 
 
Colleagues in the respiratory and immunology departments of the Royal Free Hospital 
collected respiratory samples from 17 suspected pulmonary TB patients following ethics 
approval. IFN-γ responses were measured by flow cytometry and a percentage change 
compared to a negative control was calculated (Breen et al. 2005).  
 
PPD-specific, IFN-γ producing CD4+ T cells were present in the respiratory samples 
obtained from all patients. The proportion of CD4+ T cells producing IFN- γ in response 
to PPD exposure range from 2.69% to 67.11% and are shown in table 4.3. However, 
analysis of CD4+ T cells exposed to ESAT-6 showed that three patient samples had no 
IFN-γ producing CD4+ cells. The full range of responses is listed in table 4.3 as well as 
the ratio of ESAT-6 to PPD responding cells. Samples were also processed for 
microscopy and mycobacterial culture.  
 
 
4.2.2 IS6110 RFLP genotyping 
 
The IS6110 RFLP profile was available for 14 of the 17 strains studied. Analysis of these 
profiles demonstrated that none of the strains were closely related - all 14 strains were 
distinct and none were related at a similarity of greater or equal to 70% (figure 4.2). In 
addition, none of these strains were members of any of the large lineages described in 
chapter 3.  
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Figure 4.2 Dendrogram showing the relatedness of the patient isolates. The level of relatedness is displayed 
on the left-hand side. The fingerprints are shown in the centre and the isolate numbers are on the right. 
 
 
4.2.3 esxA PCR and sequencing 
 
The gene encoding ESAT-6, esxA, was detected in all strains of M. tuberculosis isolated 
from the 17 patients in the study.  Sequence analysis showed no mutations in esxA in any 
of the M. tuberculosis strains. A summary of the immunological, PCR and sequencing 
data is shown in table 4.3.  
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Patient 
isolate 
CD4+ IFN- γ 
response to 
ESAT-6 (%) 
CD4+ IFN- γ 
response to 
PPD (%) 
ESAT-6:PPD 
response 
ratio 
esxA PCR esxA 
sequence 
04:614 0.00 16.65 0 Positive Wild Type 
04:607 0.00 13.94 0 Positive Wild Type 
04:552 0.00 3.85 0 Positive Wild Type 
04:406 0.03 8.97 0.003 Positive Wild Type 
04:539 0.74 25.58 0.029 Positive Wild Type 
03:497 4.08 67.11 0.061 Positive Wild Type 
04:629 1.90 20.35 0.093 Positive Wild Type 
04:193 6.35 67.11 0.104 Positive Wild Type 
04:473 3.67 31.09 0.118 Positive Wild Type 
04:545 4.37 35.02 0.125 Positive Wild Type 
04:525 10.06 79.32 0.127 Positive Wild Type 
05:218 0.92 6.45 0.143 Positive Wild Type 
04:279 4.22 28.41 0.149 Positive Wild Type 
04:248 3.93 24.40 0.161 Positive Wild Type 
04:393 1.02 4.94 0.206 Positive Wild Type 
03:494 0.68 2.69 0.253 Positive Wild Type 
05:189 12.39 48.00 0.258 Positive Wild Type 
 
Table 4.3 Summary of INF-γ responses, PCR results and sequencing data. WT = wild type. Immunological 
data from (Breen et al.) 
 
 
4.2.4 Reverse transcriptase quantitative polymerase chain reaction (RT qPCR) 
 
A reverse transcriptase quantitative polymerase chain reaction (RT qPCR) was designed 
to measure the expression of esxA. Reference genes were chosen to be sigA and 16S 
rRNA (Chapter 2, section 2.3.3). 
 
Although ESAT-6 was first identified in the filtrate of short-term cultures of M. 
tuberculosis (Sorensen et al. 1995), it was not known during which growth phase the 
gene was optimally expressed. An experiment was designed to measure esxA expression 
in M. tuberculosis H37Rv during lag, log and stationary phases of growth.  
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Cultures were incubated (in triplicate) for the optimal time (as ascertained from the time-
trial experiment). RNA was then extracted, RT qPCR was performed and relative gene 
expression was calculated using the ∆∆Ct method (Livak and Schmittgen 2001).   
 
4.2.4.1 Establishing a reference gene  
 
The use of the 16S rRNA gene as a reference gene generated highly variable results 
between biological replicates. Work carried out by our group showed that using sigA as a 
reference gene provided more reproducible data (O‘Sullivan 2007). The 16S rRNA gene 
was therefore substituted with sigA and these experiments produced more reliable data so 
this gene was selected as the reference gene for all subsequent analysis. One explanation 
of highly variable results was the consistently high level of 16S rRNA gene expression 
which resulted in the inability of the assay to demonstrate small differences in expression. 
This is demonstrated in three example strains in table 4.4. 
 
 Mean esxA CT Mean 16S CT Mean sigA CT 
04:552 28.55 11.09 21.28 
04:607 28.30 11.45 20.64 
04:614 30.16 11.61 21.29 
 
Table 4.4 comparison of mean CT values for esxA, 16S and sigA for three patient isolates. Lower CT 
values indicate the presence of larger quantities of mRNA and therefore higher expression.    
 
4.2.4.2 esxA Expression Time Trial 
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The RT qPCR data was analysed from the time trial experiment using M. tuberculosis 
H37Rv to ascertain the time of optimal translation of esxA. The amplification of esxA 
mRNA from each time point was compared to the reference gene at the same time point. 
This was then compared to the level of gene expression relative to the cultures at day 
zero. The relative fold change in gene expression was calculated using the ∆∆Ct method 
(Livak and Schmittgen 2001). Cultures at day 28 (stationary phase) demonstrated the 
largest relative increase in esxA expression. For this reason, day 28 (stationary phase) was 
selected as the time point for RNA extraction for all of the clinical strains. Relative gene 
expression for days 4, 14 and 28 are shown in table 4.5.  
 
 
 Relative fold change (2
-∆∆Ct
) 
Day 0 vs. 7 5.21 
Day 0 vs. 14 4.46 
Day 0 vs. 28 9.98 
 
Table 4.5 Change in esxA expression over time.  
 
 
4.2.4.3 esxA Expression by Q-RT-PCR 
RT qPCR data was available for 11 strains. The relative fold change of expression of 
esxA compared to the reference gene sigA and the reference strain M. tuberculosis H37Rv 
at day 28 varied from 1.10 to 109467.16-fold. The data for all 11 isolates are shown in 
table 4.6.  
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Strain 
Relative fold 
change (2
-∆∆Ct
) 
ESAT6:PPD IFN-γ 
response 
04:552 3.24 0 
04:607 1.98 0 
04:614 1.28 0 
04:539 2.04 0.029 
03:497 8.58 0.061 
04:629 3.46 0.093 
04:545 6.31 0.125 
04:525 3.24 0.127 
04:279 4.86 0.149 
04:248 1.10 0.161 
04:391 109467.16 0.206 
 
Table 4.6. Fold change of esxA expression in each clinical change relative to M. tuberculosis H37Rv 
compared to ESAT/PPD IFN-γ response.  
  
 
The correlation between gene expression and ESAT-6:PPD response was plotted using 
regression analysis and is shown in figure 4.3 and demonstrates a non-linear relationship 
between the relative expression of esxA and ESAT6/PPD response, and therefore, no 
direct association between the two.  
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Figure 4.3 Regression analysis plotting relative change in esxA expression and ESAT-6:PPD response.  
 
 
 
4.3 Discussion 
 
Some strains produced no IFN-γ at all following exposure to ESAT-6. The CD4+ cells 
did, however, respond to PPD stimulation, indicting that they were capable of mounting a 
cytokine response. These patients were all shown subsequently to have culture-confirmed 
TB, so the possibility that this phenomenon was related to the biology of the infecting 
organism was examined.  The genotyping database was interrogated to determine 
whether this sub-set of patients were infected with a related strain, however the typing 
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data showed that the differences in IFN-γ responses (in these non-responding cases as 
well as more widely) were not due to a specific strain type. Those that failed to generate a 
response following ESAT-6 stimulation were not infected with related strains and there 
were no relationships between any of the isolates at a level of 70% or greater (figure 5.2). 
The strains were also shown not to be members of any of the six large lineages discussed 
in chapters 3 and 4.  
 
The presence of esxA was proven in all isolates, regardless of IFN-γ response. Likewise, 
no mutations were discovered, leading to the conclusion that the failure of patients‘ 
CD4+ cells to produce IFN-γ in response to ESAT-6 stimulation is not due to deletion or 
mutation of the gene causing a modified or inactive protein. 
 
The time-trial experiment was performed to ascertain the time of optimal esxA expression 
in M. tuberculosis H37Rv. Results indicated that this occurred at 28 days (stationary 
phase). Stationary phase cultures (day 28) were sampled due to the data obtained from 
the time trial experiment. No published data was available outlining the time of optimum 
expression of esxA, so this experiment was performed to provide the best opportunity to 
demonstrate differences between strains.   
 
The exact physiological state of M. tuberculosis in the lung is unclear. Therefore, the 
relevance of stationary state cultures to what is seen in vivo is equally uncertain. Indeed, 
there are two models for persistent bacilli in the lung; slowly replicating organisms that 
interact with components of the immune system (Ehlers 2009) and non-replicating 
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organisms that are reawakened with resuscitation promoting factors (Garton et al. 2008). 
The physiological state of these organisms is not fully understood and therefore the 
relevance of in vitro models is subject to discussion. However, stationary phase cultures 
were sampled in this work as expression of esxA in these isolates was greatest at this 
time.  
 
Using sigA rather than 16S rRNA as a reference gene provided more reproducible data. 
This may be partly due to the high level of expression of 16S which results in the 
inability of the assay to demonstrate small differences in expression. The use of sigA, 
which is expressed at a lower level (table 5.4) allows these variations to be seen.  
 
The gene expression data shows that all strains demonstrated an up-regulation of esxA 
when compared to M. tuberculosis H37Rv. This may be because ESAT-6 is an 
immunomodulator and virulence factor that is not required for survival in the laboratory-
adapted strain M. tuberculosis H37Rv. One isolate showed very high-levels of up-
regulation of esxA compared to M. tuberculosis H37Rv. The expression of esxA was 
increased over 100,000-fold in this isolate, which was cultured from a TB patient whose 
CD4+ T cells demonstrated the largest ESAT-6:PPD IFN-γ response (0.206 in isolate 
04:391, table 5.6; figure 5.3). However, the IFN-γ response in this patient‘s cells was not 
statistically significantly higher than the next largest responder (04:248), whose isolate 
had an esxA expression comparable to that of M. tuberculosis H37Rv.  The increase in 
gene expression in this isolate was remarkable. This was seen in two biological, and three 
technical, replicates. It may be possible that the growth rate of this strain is significantly 
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different to the others, that is, it may have reached stationary phase significantly earlier 
than day 28. The growth rates of the isolates were not measured, however. This may be 
necessary to ensure that all of the experiments were performed during stationary phase to 
allow comparisons between the strains. This warrants further investigation of the 
expression of other genes associated with this isolate to determine if this level of up-
regulation is a common factor. This may be achieved by using RT PCR to look at a range 
of genes in this isolate, or by utilising a microarray. To investigate whether 04:391 has 
generally higher levels of expression when compared to its peers, it may be beneficial to 
investigate housekeeping gene expression whilst in steady state. Additionally, the 
expression of these genes may also be compared during times of stress, possibly in a 
chemostat model (Hampshire et al 2004). Microarrays have the benefit of being able to 
analyse multiple genes in a single assay. However, in the work described, a single RT 
PCR was designed as a small number of genes were being targeted.  
 
The summation of these data leads us to the conclusion that the failure of an 
immunological test to diagnose M. tuberculosis infection is not a consequence of the 
modified genotype of the organism. However, there may be post-transcriptional, 
translational or post-translational factors that may have an effect on the secreted protein, 
and therefore the T-cell response. The nature of the excreted may be assessed by protein 
purification and Western blotting.  
 
These findings confirm that the relationship between host and organism in M. 
tuberculosis infection is a complex one. We are led to the conclusion that the failure of 
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the patients‘ CD4+ T cells to respond to ESAT-6 stimulation may be due to a function of 
the hosts‘ immune response with little contributory effect of the bacterium. It has been 
shown previously in animal models that an increased susceptibility to disease is seen 
when there are defects in CD4 T cell function (Saunders et al. 2002; Scanga et al. 2000), 
or with IFN-γ expression or recognition (Cooper et al. 1993; Flynn et al. 1993). Increased 
susceptibility has also been seen in such patients (Havlir and Barnes 1999; Ottenhoff et 
al. 2005). The relationship between immunological response and clinical presentation 
could be further investigated by the analysis of the patients‘ HLA types.  
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Chapter 5: The Relative Fitness of Over-Represented Strains and 
Acquired Isoniazid Resistance 
 
5.1 Introduction 
 
The measure of the success of a bacterium may be considered by the extent to which it is 
able to survive, divide and spread between susceptible hosts. In order to achieve this, it 
must be assumed that the rate of division is paramount in the organism‘s success. The 
time taken for a bacterium to divide, or generation time, may therefore be taken as a 
measure of fitness. The fitness of an organism may be measured in a number of ways; for 
example, the measurement of growth rates in vitro, either in appropriate media 
(Billington, McHugh, & Gillespie 1999; Bjorkman et al. 1999; Gagneux et al. 2006b) 
including chemostat (Modi & Adams 1991), in competition assays (Bouma & Lenski 
1988; Schrag, Perrot, & Levin 1997) or in animal models (with or without competition) 
(Bjorkman, Hughes, & Andersson 1998; Heym et al. 1997; Li et al. 1998; Wilson, de 
Lisle, & Collins 1995). Fitness may also be inferred by the measurement of the size of 
clusters (van Soolingen et al 2000; van Doorn et al 2006). Conversely, large clusters may 
not always indicate a strain with enhanced fitness. For example, outbreaks in prisons 
often occur due to the prolonged exposure of susceptible individuals to infective cases 
(Sosa et al 2008). 
 
Decreased virulence of isoniazid resistant M. tuberculosis in guinea pigs was reported in 
the 1950s, with the organisms displaying the highest levels of resistance exhibiting the 
largest loss in virulence (Middlebrook & Cohn 1953; Mitchison DA 1954) .There is 
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assumed wisdom that the acquisition of antimicrobial resistance will result in a biological 
cost (Gillespie & McHugh 1997). It is now known that the correlation between acquired 
resistance mutations and fitness cost is far from linear.  
 
It is true that although a fitness cost is likely as a result of the acquisition of antimicrobial 
resistance, there are a number of different compensatory mechanisms that enable the 
organism to persist. These mechanisms often allow the retention of antimicrobial 
resistance as well as the reversion to fitness to some or all of the degree of the sensitive 
ancestor organism (Andersson & Levin 1999). Although there are several documented 
compensatory mechanisms for other bacteria (Moore, Rozen, & Lenski 2000; Reynolds 
2000; Maisnier-Patin & Andersson 2004), the only documented compensatory 
mechanism that has been proposed in M. tuberculosis is the hyper-expression of the alkyl 
hyperperoxide reductase gene, ahpC, in isoniazid resistant isolates with katG mutations 
(Sherman et al. 1996). However, this mutation in the promoter region of ahpC has been 
seen in isolates that do not possess katG mutations, so this mechanism is far from 
confirmed (Gagneux et al. 2006a).   
 
The degree of fitness cost suffered due to the acquisition of resistance-conferring 
mutations may be ascertained by in vitro or in vivo studies, or by the measurement of the 
prevalence of these mutants in the community. If particular resistance-conferring 
mutations are common in the community then it may be inferred that the strains are still 
successful and have not suffered a significant loss. Indeed, studies on strains carrying the 
most common resistance mutations have confirmed this. Sander and colleagues 
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demonstrated that the when the most commonly occurring mutations causing 
streptomycin, amikacin and clarithromycin resistance were induced in M. smegmatis, 
these strains suffered little of no fitness cost in in vitro competition assays (Sander et al. 
2002). Likewise, the most commonly seen mutations in rpsL causing streptomycin 
resistance in clinical isolates of M. tuberculosis are the same as those that have been 
shown experimentally to exhibit no fitness cost in S. typhimurium and E. coli (Bottger et 
al. 1998). Additionally, the mutation causing most clinically seen isoniazid resistance 
(katG Ser-315-Thr) is not associated with any fitness cost in mouse models (Pym, Saint-
Joanis, & Cole 2002). Furthermore, the most commonly occurring rpoB mutations 
conferring rifampicin resistance in M. tuberculosis are associated with a smaller fitness 
cost when compared to less frequently occurring mutations ( Billington, McHugh, & 
Gillespie 1999; Mariam et al. 2004: Gagneux et al. 2006b; Huitric et al. 2006;). 
 
If a resistant strain is prevalent in the community, and is therefore said to have suffered a 
minimal fitness cost, then it stands to reason that the strain must be transmitting 
successfully between individuals. For this reason, not only is the degree of prevalence of 
a particular mutation important, but also the size and frequency of clusters of cases 
associated with the mutated strains. In a Dutch cohort, strains with the most frequently 
occurring isoniazid-conferring mutation (mutation at katG codon 315) were found in 
clusters as often as isoniazid susceptible strains (van Soolingen et al. 2000), whilst 
isoniazid resistant strains with other mutations were less likely to be found in clusters 
than those with mutations at codon 315 (van Doorn et al. 2006). A study in San Francisco 
found that isoniazid resistant strains of M. tuberculosis with the katG mutation Ser-315-
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Thr or a mutation in the inhA promoter region were more likely to be found in clusters 
(Gagneux et al.2006a).   
 
Outbreaks of drug resistant strains are well documented. For example, the outbreak of an 
MDR strain in New York (Frieden et al. 1996) may be attributable to coincidence or the 
increased susceptibility of the immunocompromised hosts rather than properties of the 
organism. Likewise, an MDR TB outbreak in a London hospital was more likely to be 
due to improper airflows in a patient‘s room than the increased fitness of the strain itself 
(Breathnach et al. 1998).  
 
Continued transmission in an ongoing outbreak of isoniazid resistant M. tuberculosis in 
London has been reported (HPA 2009). The first 100 cases in this outbreak were 
investigated to ascertain the number of secondary cases of active and latent disease 
(Neely et al. 2010). Analysis revealed that a large number of contacts (11%) were 
diagnosed with active disease whilst 13% of contacts were said to have latent TB 
infection. These rates were considerably higher than those previously described. NICE 
guidance states that the reviewed literature (Ansari et al. 1998; Esmonde & Petheram 
1991; Hardinge, Black, & Chamberlain 1999; Hussain et al. 1992; Irish, Jolly, & Baker 
1997; Kumar, Innes, & Skinner 1992; Ormerod 1992; Teale, Cundall, & Pearson 1991) 
indicates that approximately 1% of contacts progress to active disease (NICE 2006). 
 
The phylogeographic background of the bacterium may also play a role in the fitness and 
drug resistance of M. tuberculosis. Differences in immunogenicity and virulence have 
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been reported and are reviewed (Gagneux & Small 2007). The Beijing family of strains is 
often cited as being particularly associated with drug resistance. A comparison of twelve 
studies in South East Asia and countries of the former Soviet Union show a high 
proportion of MDR strains. These countries have poor TB control strategies, which 
undoubtedly contribute to the number of cases of MDR-TB, however, the high 
prevalence of strains belonging to the Beijing lineage may also be a factor (Borrell & 
Gagneux 2009).   
 
Fitness of drug-resistant strains can be measured in laboratory studies or be shown to be 
successful by their prevalence in the community. It is useful to quantify this when 
considering whether acquired drug resistance has caused a fitness cost on a group of 
strains. If the majority of a group of related strains is drug susceptible, then it may be 
considered that the acquisition of drug resistance is either relatively recent, or is 
associated with decreased transmissibility. Conversely, if a group of related strains are 
largely drug resistant, then it may be proposed that the acquisition of resistance has had 
little of no effect on the fitness of the organism and is associated with ongoing 
transmissibility. This may be summarised as the relative rate of transmission (RRT) in the 
following formula:  
 
RRT =  no. sensitive members of group 
    no. resistant members of group 
  
 Where:  RRT <1 resistance associated with increased transmissibility 
   RRT >1 resistance associated with decreased transmissibility 
 
 
Equation 5.1. Calculation of the relative rate of transmission (RRT). 
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The lineages identified in the Royal Free database are populated with successful, and 
evolutionarily-related, strains. It may be argued that these strains possess some 
evolutionary advantage that allows them to succeed in a particular population. The most 
densely populated lineages in the Royal Free database were examined to establish 
whether there were any factors that may contribute to the success of their strains. In 
addition, the strains isolated from the extended family in North London were investigated 
to assess whether they possessed a fitness advantage.   
 
5.2 Results 
The six most populated lineages from chapter 3 (lineages 15, 19, 41, 43, 54 and 61) were 
investigated. Demographic data was obtained from WinPath at the Royal Free Hospital. 
Drug susceptibility tests were performed at the Health Protection Agency‘s 
Mycobacterium Reference Unit. 
 
The most outstanding characteristic was the prevalence of drug resistance in lineage 15 
and the genotype of the 16 isolates was investigated further. The isoniazid resistance-
causing mutation was ascertained for all isolates by PCR and sequence analysis. DNA 
extraction, PCR amplification and sequencing were performed by Dr. Alastair McGregor 
as part of his MSc degree project under the supervision of the author. Sequence analysis 
was performed by the author.   
 
Additionally, the generation time of each strain was measured (chapter 2, section 2.4.3) 
and compared to the reference strain M. tuberculosis H37Rv, both fully sensitive strains in 
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lineage as well as unrelated isoniazid sensitive and resistant strains. The generation times 
of the isolates were measured by both Dr. Alastair McGregor and the author.   
 
5.2.1 Lineage 15 
 
Analysis of the IS6110 database revealed six lineages that contained 10 or more isolates 
(Chapter 3, table 3.14). The drug susceptibilities of these strains were investigated (table 
5.1). It was seen that lineage 15 (figure 5.1) contained a higher proportion of drug 
resistant strains. The relative rate of transmission for each lineage was calculated as 
follows (table 5.1). 
 
 
Figure 5.1 Dendrogram of IS6110 fingerprints of strains within lineage 15.  
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Lineage 
No. 
Number of 
isolates 
% (number) 
resistant 
Resistance profile(s) Relative Rate of 
Transmission 
(RRT) 
15 16 87.5% (14)  10 x INH mono-resistance 
1 x INH and eth resistance 
1 x INH, RIF, clari & eth resistance 
2 x streptomycin mono-resistance 
0.14 
19 15 6.7% (1)  
U = 3 
INH mono-resistance 11 
41 21 9.5% (2)  
U = 2 
INH mono-resistance 
RIF & INH resistance 
8.50 
43 10 0% (0) N/A N/A 
54 13 0.8% (1) 
U = 1 
INH mono-resistance 11 
61 13 0.8% (1) 
U = 1 
INH mono-resistance 12 
 
Table 5.1 The six most populated 70% lineages in the RFH database. The lineages were assigned a number 
consecutively from the start of the dendrogram. Thr relative rate of transmission of each lineage has been 
calculated. U = unknown (sensitivities not available). INH = isoniazid, RIF = rifampicin, clari = 
clarithromycin, eth = ethambutol.  
 
 
 
All isolates were referred to the MRU for susceptibility testing. Due to their phenotypic 
drug resistance patterns, the MRU performed genotyping and they were confirmed to be 
part of the North London isoniazid resistant outbreak (Ruddy et al. 2004). It was noted 
that the isolates were not identical by IS6110 RFLP genotyping (performed at the Royal 
Free Hospital), but closely related at > 80% similarity (figure 5.1). One strain (04:606) 
was not viable and no DNA was available, so no further analysis of this was possible. 
DNA only was available from 02:292. Amplification and sequencing of katG and the 
promoter region of inhA showed heterogenous polymorphisms, which are summarised in 
table 5.2. Cytosine was substituted for thymine (C→T) at a locus 15bp upstream from the 
start codon of the mabA gene (which is co-transcribed with inhA) in eight of the ten 
isolates that were isoniazid resistant. The two other isoniazid resistant isolates possessed 
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mutations that substituted serine for thrionine at codon 315. No isoniazid-encoding 
mutations were found in these loci of the two sensitive isolates in the lineage. A non-
resistance causing mutation resulting in the substitution of arginine with leucine at codon 
463 was detected in one of the isoniazid sensitive controls (04:011).  
 
Type Isolate Resistant to Sensitivities Polymorphism 
Lineage 15 
02:302 S HRZE None detected 
07:118 H RZES katG S315T 
03.313 S HRZE None detected 
02.113  HRZES None detected 
04.503 H RZES inhA C→T  
07.116 H, ethi RZES  inhA C→T  
03.303 H RZES inhA C→T  
04.493 H RZES inhA C→T  
04:198 H RZES inhA C→T  
03.039 H RZES inhA C→T  
04.194 H RZES katG S315T 
04.018 H,R,clari,ethi ZES inhA C→T 
05.046  HRZES None detected 
04.211 H RZES inhA C→T 
H resistant 
control 05.177 H RZES inhA C→T 
H sensitive 
control 05.094  HRZES None detected 
H sensitive 
control 04.011  HRZES katG R463L  
 
Table 5.2 Resistance profiles of strains in lineage RFH-15 and corresponding isoniazid resistance 
mutations. Key: H = isoniazid, R = rifampicin, S = streptomycin, Z = pyrazinamide, E = ethambutol, ethi = 
ethionamide, clari = clarithromycin. Polymorphisms: katG S315T = serine to thrionine substitution at 
codon 315, inhA C→T = cytosine to threonine substitution at 15bp upstream of the start codon of mabA.  
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MIRU-VNTR typing was performed on the isolates to confirm their relatedness. All 
available MIRU-VNTR types are displayed in table 5.3.  
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02:113     4    3 3 3     4 4 2 2 5 1    3 3        
02:302 2 2      3 3  1 5 4 4 2 2 5 1  3 3 3      2 
03:039 2 2 4    3 3 3 1 6 4 4 2  5 1  3 3 3      2 
03:303 2 2 4 2  4 3  1 6 4   2  5 1    3 3      2 
03:313     4    3 3 3     4   2            3 2      
04:194 2  4 2  4 3 3 1   4   2  5 1    3 3        
04:198   2 4 2 1 4 3 3 1   4 4 2 2   1 5   3 3        
04:211 2 2      4 3 3 1   4   2  5 1    3 3      2 
04:606 2 2 4 2 1 4 3 3 1   4 4 2 2 5 1 5 3 3 3      2 
05:046     4 2 1               2   5   3               
 
Table 5.3. MIRU-VNTR genotypes of the isolates in lineage 15. Blank cells indicate that an amplicon was 
not generated at the locus.  
 
 
 
 
 
 
Figure 5.2. MIRU-VNTR dendrogram of lineage 15. 
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The generation time of all isolates and controls was measured. The median generation 
time was compared to that of the laboratory strain M. tuberculosis H37Rv as well as the 
susceptible controls.  
 
 
 
 
Type Isolate Resistant to Polymorphism 
Median 
generation 
time G 
(hours) 
 
Relative 
fitness to 
H37Rv 
 
Relative 
fitness to 
02:113 
Relative 
fitness to 
05:046 
Lineage 15  
isolates 
02:302 s None detected 16.3 1.05 1.10 1.02 
07:118 h katG S315T 21.5 0.79 0.83 0.77 
03.313 s None detected 17.5 0.98 1.02 0.95 
02.113 
fully 
sensitive 
 
None detected 17.8 
 
0.96 
 
1.00 0.94 
04.503 h inhA C→T  19.1 0.89 0.93 0.87 
07.116 h, eth inhA C→T  17.3 0.99 1.03 0.97 
03.303 h inhA C→T  18.5 0.92 0.96 0.90 
04.493 h inhA C→T  16.9 1.01 1.06 0.99 
04:198 h inhA C→T  17.4 0.98 1.03 0.96 
03.039 h inhA C→T  21.8 0.78 0.82 0.76 
04.194 h katG S315T 18.4 0.93 0.97 0.91 
04.018 h,r,c,eth 
inhA C→T -
767 22.9 
 
0.75 
 
0.78 
 
0.73 
05.046 
fully 
sensitive None detected 16.7 
 
1.03 
 
1.07 1.00 
04.211 h 
inhA C→T -
767 18.1 
 
0.94 
 
0.98 
 
0.92 
H res control 05.177 h 
inhA C→T -
767 18.6 
 
0.92 
 
0.96 0.90 
H sens control 05.094 
fully 
sensitive None detected 19.5 
 
0.88 
 
0.91 0.86 
H sens control 04.011 
fully 
sensitive katG R463L  21.2 
 
0.81 
 
0.84 0.79 
 
 
Table 5.4 Resistance profiles of strains in lineage RFH-15, corresponding isoniazid resistance mutations 
and relative fitness. Key: h = isoniazid, r = rifampicin, s = streptomycin, z = pyrazinamide, e = ethambutol, 
eth = ethionamide, c = clarithromycin 
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Figure 5.3. Generation times of the isolates in lineage 15. Error bars indicate one standard deviation. The 
median generation times of the isolates were not significantly different (p = 0.2956 - one-way Anova with 
Kruskal-Wallis post test).  
 
The IS6110 RFLP fingerprints of the strains in lineage 15 were further investigated. The 
fingerprints were not identical, but were closely related at > 80% (figure 5.1). There are 
two fully susceptible isolates (05:046 and 02:113) that are hypothesised as the precursor 
strains, and may be used to develop a map of evolution through the alteration of IS6110 
patterns and acquired resistance-conferring mutations from that point on. A hypothetical 
relationship between the strains, the insertion/deletion of IS6110 and the acquisition of 
antimicrobial resistance is shown in figure 5.4.  
 223 
 
 F
ig
u
re
 5
.4
 S
p
li
t 
tr
ee
 a
n
al
y
si
s 
- 
R
el
at
io
n
sh
ip
 o
f 
th
e 
st
ra
in
s 
in
 l
in
ea
g
e 
1
5
, 
in
cl
u
d
in
g
 i
n
se
rt
io
n
 (
→
) 
an
d
 d
el
et
io
n
 (
→
) 
o
f 
IS
6
1
1
0
 f
ro
m
 t
h
e 
h
y
p
o
th
es
is
ed
 
p
ro
g
en
it
o
r 
st
ra
in
s 
(0
2
:3
0
2
 a
n
d
 0
2
:1
1
3
).
 A
ll
 s
tr
ai
n
s 
ar
e 
is
o
n
ia
zi
d
 r
es
is
ta
n
t,
 e
x
ce
p
t 
0
5
:0
4
6
 &
 0
2
:1
1
3
, 
w
h
ic
h
 a
re
 f
u
ll
y
 s
en
si
ti
v
e 
(f
u
ll
y
 s
en
s)
, 
an
d
 0
2
:3
0
2
 &
 
0
3
:3
1
3
, 
w
h
ic
h
 a
re
 s
tr
ep
to
m
y
ci
n
 m
o
n
o
-r
es
is
ta
n
t 
(S
 m
o
n
o
-®
).
 T
h
e 
is
o
n
ia
zi
d
 r
es
is
ta
n
ce
-c
o
n
fe
rr
in
g
 m
u
ta
ti
o
n
s 
ar
e 
h
ig
h
li
g
h
te
d
 a
n
d
 a
d
d
it
io
n
al
 r
es
is
ta
n
ce
s 
(®
) 
ar
e 
in
 b
lu
e 
(R
 =
 r
if
am
p
ic
in
, 
cl
ar
i 
=
 c
la
ri
th
ro
m
y
ci
n
, 
et
h
i 
=
 e
th
io
n
am
id
e.
 T
h
e 
fi
rs
t 
tw
o
 d
ig
it
s 
in
 t
h
e 
is
o
la
te
 n
u
m
b
er
 i
n
d
ic
at
e 
th
e 
y
ea
r 
o
f 
is
o
la
ti
o
n
, 
fo
r 
ex
am
p
le
, 
0
2
:1
1
3
 w
as
 i
so
la
te
d
 i
n
 2
0
0
2
. 
D
o
tt
ed
 a
rr
o
w
s 
in
d
ic
at
e 
th
at
 a
 s
tr
ai
n
 m
ay
 h
av
e 
ev
o
lv
ed
 f
ro
m
 m
o
re
 t
h
an
 o
n
e 
p
o
ss
ib
le
 p
re
cu
rs
o
r.
 C
o
lo
u
re
d
 c
ir
cl
es
 
re
la
te
 t
o
 t
h
e 
M
IR
U
-V
N
T
R
 g
e
n
o
ty
p
es
. 
Is
o
la
te
s 
w
it
h
 t
h
e 
sa
m
e 
co
lo
u
r 
ci
rc
le
 a
re
 i
n
d
is
ti
n
g
u
is
h
ab
le
 b
y
 M
IR
U
-V
N
T
R
 g
e
n
o
ty
p
in
g
. 
T
h
e 
re
la
ti
v
e 
fi
tn
es
s 
to
 
M
. 
tu
b
er
cu
lo
si
s 
H
3
7
R
v
 i
s 
in
 b
ra
ck
et
s.
  
 
 224 
5.2.2 Extended Family with streptomycin-resistant TB 
 
A 26 year old Somalian man presented to the TB team at the Royal Free Hospital with 
cough, fever, lethargy and headache. His chest X-ray showed cavitations and nodular 
shadowing. A chest CT scan confirmed this and a diagnosis of active TB was made. He 
was commenced on standard quadruple therapy and contact tracing was initiated. Twenty 
members of the extended family were screened (figure 5.5). Screening was performed 
according to NICE guidance (NICE 2006), and involved an interview, tuberculin skin 
test, chest X-ray and interferon gamma release assay (IGRA). Screening revealed a 
further seven cases of active TB and two cases of latent TB. Including the index case, 
there were 8 cases of active TB and six of these patients were culture positive.  
 
The six strains isolated from the extended family were all highly resistant to streptomycin 
and were confirmed to be indistinguishable from one another by MIRU typing (15 loci 
MIRU 42433 23315 14323, performed at HPA MRU). This outbreak occurred prior to 
the adoption of 24-loci MIRU-VNTR typing. This number of loci were analysed as 
standard by the HPA Mycobacterium Reference Unit at this time.  
 
The hypothesis is that the strain involved in this outbreak has suffered a negligible fitness 
cost as a result of acquiring streptomycin resistance because more close contacts had 
active disease or latent infection than would normally be expected. Fitness studies were 
performed on those strains that were isolated from the active cases (table 5.5).  
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Figure 5.5 Family tree of extended family with a high rate of TB. Dotted line indicates siblings. All 
individuals in this family tree were contact traced. TB = active disease, LTB = latent TB, C+ = culture 
positive, C- = culture negative 
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Patient Median 
generation 
time (hours) 
Relative fitness 
to  H37Rv 
M 26 23.3 0.73 
F 10 19.2 0.89 
M 15 20.3 0.84 
F 24 19.4 0.88 
M 28 22.5 0.76 
M 32 17.3 0.99 
Table 5.5 Fitness data of the strains isolated from the extended family with a high rate of active TB and 
latent TB infection.  
 
 
Figure 5.6. Generation times of the isolates from the extended family. Error bars indicate one standard 
deviation. The median generation times of the isolates were not significantly different (p = 0.1683 - one-
way Anova with Kruskal-Wallis post test).   
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5.3 Discussion 
 
The aim of this work was to investigate a large drug resistant lineage of M. tuberculosis 
and a family-based outbreak of streptomycin resistant M. tuberculosis. The hypothesis 
was that the acquisition of drug resistance confers a fitness deficit and that this may be 
related to genotype.  
5.3.1 Lineage 15 
 
The strains in lineage 15 are closely related, as indicated by their >80% similarity by 
IS6110 fingerprinting. However, although these strains are shown to cluster together with 
the North London isoniazid resistant outbreak strains, the data shown in this chapter 
demonstrates that the strains are far from homogeneous. The outbreak strains have 
evolved as they have been transmitted between individuals, and are no longer identical to 
the strain at the point source of the outbreak. The isolates were cultured from patients 
between 2002 and 2007, so there was ample opportunity for the acquisition of drug 
resistance as well as insertion or deletion is IS6110 given its half life of two to five years 
(de Boer et al. 1999).   
 
Firstly, the antibiograms of the strains vary widely and include fully sensitive, isoniazid 
and streptomycin monoresistant as well as MDR strains. This is concordant with the 
reports of MDR cases in the North London outbreak (Maguire H, Forrester, & Adam 
2006). Furthermore, the point mutations causing isoniazid resistance vary even within 
clusters of strains that are indistinguishable by IS6110 RFLP and MIRU-VNTR typing. It 
may be reasoned that the strain was already successfully circulating in the North London 
area and the acquisition of antimicrobial resistance occurred secondarily. It has already 
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been demonstrated that strains in this outbreak have become multi-drug resistant by the 
independent acquisition of unusual rpoB mutations (Jenkins et al. 2005).  
 
The outbreak strains studied in this chapter were isolated between 2002 and 2007, and 
there are a total of eight insertions and seven deletions of IS6110 during this time. It 
appears that the strains have gained and lost the insertion sequence IS6110 at a higher 
rate than described elsewhere; an insertion or deletion between every 2-5 years (de Boer 
et al. 1999; Yeh et al. 1998). The estimation of the time it takes for these insertion 
sequences to change was largely generated by studying serial isolates from individual 
patients. One hypothesis for this increased rate of change is the stress caused by 
transmitting between hosts. It may be possible to serially passage these strains to 
ascertain whether the rate of insertion and deletion slows in a less competitive 
environment.     
 
Finally, the fitness of the resistant strains is not significantly different from either the 
laboratory strain M. tuberculosis H37Rv, the susceptible strains in lineage 15 or unrelated 
isoniazid susceptible and resistant strains. This indicates that if there was any fitness cost 
initially associated with the acquisition of resistance-conferring mutations then this was 
either very small, or the organisms have compensated for it since. This allows the 
organisms to successfully transmit between individuals despite the acquisition of drug 
resistance. Indeed, related strains have been isolated from individuals around the country 
and cases now exceed 300 (Maguire H, Forrester, & Adam 2006). The investigation of 
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the mutation rate of these strains with the addition of whole genome analysis may prove 
insightful in this regard.  
 
Not all isolates had an equal number of data points for the fitness experiments. The 
experiment was designed with nine replicates per isolate. However, practical constraints, 
including contamination and lack of growth in the 1:10,000 dilution tubes were 
experienced. Additionally, some variation was seen between the replicates. These 
biological experiments are difficult to control and various factors may result in 
problematic data. For example, M. tuberculosis clumps together in liquid culture. Every 
effort was made to break up the clumps of organisms prior to inoculation, but even small 
variations may result in variation in generation times. Additionally, although the 
sampling and inoculation of the cultures was tightly monitored, small variations in the 
phase of growth of the organisms may result in some variation.  
 
The evolution of the organisms in lineage 15 (the North London isoniazid resistant TB 
outbreak) are hypothesised in figure 5.4. The proposed progenitor strain (02:113) was 
isolated in 2002. This organism is fully susceptible to first line anti-tuberculosis agents. A 
second strain (02:302), also isolated in 2002, is indistinguishable using both IS6110 and 
MIRU-VNTR genotyping, but has developed streptomycin mono-resistance. The figure 
shows hypothesised routes of evolution from these early strains. The insertion and 
deletion of IS6110, alteration in MIRU-VNTR type and the acquisition of antimicrobial 
resistance is displayed. Additionally, the fitness of the strains relative to the reference 
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strain H37Rv are displayed. These data demonstrate that the strains have suffered no 
significant fitness deficit despite the alteration in genotype.  
 
Investigating the broader evolutionary origins of these strains might prove enlightening. 
Gagneux and colleagues showed that strains in the group that he defined as European-
American were three times more likely to give rise to a secondary case compared with 
other strains (Gagneux et al. 2006c). LSP and SNP analysis may reveal if the origins of 
these isolates has contributed to their success. 
  
Given that the organisms studied from this diverse outbreak are as fit as the reference 
strain M. tuberculosis H37Rv as well as the fully susceptible outbreak strains, it seems 
reasonable to conclude that, in the absence of interventions, the outbreak will grow. Data 
indicating a high rate of infection in close contacts (11%) (Ruddy et al. 2004) suggests 
that these are highly competitive strains. However, epidemiological factors may play 
their part; many patients in this outbreak are prisoners and drug users who reside in 
confined dwellings with limited ventilation.  
 
Reversion to drug susceptibility, even when antibiotic pressure is removed, is rarely seen 
(Andersson & Hughes 2010). Considering that these strains appear to have already 
compensated for any acquired fitness cost, reversion seems unlikely. Additionally, 
patients infected with drug resistant M. tuberculosis who are started on empirical 
treatment will respond less well, remain infectious for longer and risk the development of 
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further resistance. The additional factor of a fit, successful strain in this setting is 
ominous.  
  
In conclusion, it appears that this lineage, which is associated with the North London 
isoniazid resistant outbreak, comprises a heterogenous collection of closely related 
strains. These strains appear to have thrived in the community, generating large numbers 
of clinical cases whilst evolving independently via the acquisition of antimicrobial 
resistance and the alteration of their genotypes.   
 
5.3.2 Extended Family with TB 
 
Contact tracing in the extended family generated a large number of active and latent cases 
of TB. Of the 20 individuals screened, seven (35%) were considered to have active 
disease and were treated accordingly, whilst two (10%) were offered prophylaxis for 
latent TB infection. These rates are considerably higher than those seen elsewhere. NICE 
guidance states that the reviewed literature (Ansari et al. 1998; Esmonde & Petheram 
1991; Hardinge, Black, & Chamberlain 1999; Hussain et al. 1992; Irish, Jolly, & Baker 
1997; Kumar, Innes, & Skinner 1992; Ormerod 1992; Teale, Cundall, & Pearson 1991) 
indicates that approximately 1% of contacts progress to active disease (NICE 2006). 
Contact tracing interviews conducted by the TB nurses revealed nothing extraordinary in 
their domestic arrangements that might increase the likelihood of transmission. This 
makes the high number of secondary cases highly unusual. The finding that the isolates 
were indistinguishable by 15-loci MIRU-VNTR typing supports their epidemiological 
link. These strains were isolated after the 2002 – 2007 database was closed and the 
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genotyping was performed at the National Mycobacteria Reference Laboratory using 
their standard 15-loci profile. The additional information gained by amplifying further 
MIRU-VNTR loci is open to debate. In such an outbreak when the individuals are clearly 
linked over a short period of time, it may be argued that additional loci are unnecessary.  
 
The generation time of the organism isolated from the index case appeared to be longer 
than that of the organisms isolated from the other family members as well as laboratory 
strain M. tuberculosis H37Rv (25.6 hours vs. 17.0 hours), but this was not statistically 
significant (p = 0.4232 - Kruskal-Wallis test). The organisms isolated from five further 
cases demonstrated generation times that were far more similar to the reference strain and 
considerably shorter than the index isolate (table 6.5). The organism appears to have 
suffered negligible fitness cost despite acquiring streptomycin resistance and is therefore 
not prohibited from transmitting between various human hosts. This has been reported 
previously. For example, an isolate of M. tuberculosis from a patient in an outbreak of 
MDR TB was shown to be fitter than other strains in the outbreak (including the strain 
cultured from the index case). The patient deteriorated rapidly and died and it was 
therefore proposed that the strain had adapted to the environment of its host (Gillespie et 
al. 2002). 
 
It would be interesting to investigate whether the strains possess the most commonly seen 
mutations in rpsL causing streptomycin resistance in M. tuberculosis as these have been 
shown experimentally to exhibit no fitness cost in S. typhimurium and E. coli (Bottger et 
al. 1998). 
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In conclusion, the strain appears to be highly successful at transmitting between hosts, 
despite being highly resistant to streptomycin. Additionally, any fitness cost experienced 
by the organism appears to be ameliorated in subsequent hosts.     
 
 
In summary, we have described two outbreak situations involving drug resistant strains. 
In both settings it has been demonstrated that if the organisms experienced any fitness 
cost as a result of the acquisition of these resistance-conferring mutations, they have since 
compensated for it. The isoniazid resistant outbreak strains appear to be more 
heterogenous than the family outbreak strain. This is not unexpected given the time 
frames involved. The longer time-line involved in the north London outbreak has allowed 
the organisms to alter their IS6110 RFLP patterns so that a split tree diagram of evolution 
may be hypothesised. What is unexpected, however, is the diversity of isoniazid 
conferring mutations present. This indicates that the successful strains independently 
acquired resistance whilst propagating in the community. The isolates from the family 
outbreak were cultured over only a few months, so diversity is far less likely and this is a 
more classical point-source outbreak.  
 
The relationship between the acquisition of drug resistance and fitness cost is far from 
straight forward. It is clear from these examples that where a resistance-conferring 
mutation is associated with little or no fitness cost that these successful strains will thrive 
and propagate, given the opportunity.  
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Chapter 6: The Role of Molecular Epidemiology in Clinical Practice 
 
6.1 Introduction 
 
Although the two processes frequently work in unison, it is important to distinguish 
traditional epidemiology and genotyping. Traditional epidemiology can identify cases of 
TB that are related in time and space, but this is often not sufficient. Genotyping is 
required to definitively identify outbreaks and chains of transmission. Genotyping is 
extremely useful in several clinical settings, for example, in the identification and 
investigation of outbreaks, the detection of false positive cultures and the differentiation 
of re-infection and relapse. Prospective, real-time genotyping of M. tuberculosis isolates 
can therefore benefit both the laboratory, and the clinical teams. Our clinical colleagues 
often identify trends or links between patients that may be related to the infecting 
organism. It is important therefore, to investigate whether these observed findings are 
linked via the organisms‘ genotype. In this chapter, the diagnostic utilisation of 
genotyping is examined. 
 
6.2 Example 1: Paradoxical reaction and Strain Type   
 
A paradoxical reaction (PR) in a tuberculosis patient is characterised as the transient 
worsening of symptoms or the appearance of new lesions or symptoms despite 
appropriate anti-tuberculosis therapy (Breen et al. 2004). It was hypothesised that the 
appearance of a paradoxical reaction may be related to strain type.  
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Between January 2002 and December 2003 all adult patients seen
 
at our centre with 
culture positive MTB had IS6110 RFLP typing
 
performed on one isolate. A case note 
review was performed retrospectively
 
for clinical evidence of PR (Breen et al. 2004)  
Isolates from 145 patients were typed but 45 were excluded as the notes for 24 were 
unavailable or
 
incomplete and 21 patients were lost to follow up or care was transferred). 
This large exclusion rate was due to the fact that this analysis was performed 
retrospectively and the notes were not available for all patients. Of the 100 (69%) 
patients‘ notes reviewed, 52 were male and the age range was 16–81 years. Ethnicity data 
showed that 48% were black African, 16% Asian,
 
and 19% from the UK. PR occurred in 
20 patients (20%) (HIV positive
 
10/26 (38%); HIV negative or unknown 10/74 (14%)). 
All patients
 
with PR had distinct IS6110 RFLP profiles suggesting 20 separate
 
strains 
(figure 6.1). Only four of the twenty strains (03:390, 03:334, 03:063 and 03:092) were 
related to another at ≥70%. This number is surprisingly low considering that one third of 
the isolates (318/478, 66.5%) on the whole database were related to another isolate at this 
level (section 3.3.5).  
 236 
 
Figure 6.1 Dendrogram of patient strains isolated from patients with paradoxical reactions.  
 
The possibility exists that paradoxical TB reactions may be
 
a consequence of specific 
host response genes, such as HLA (Perrin et al. 2005). It is noteworthy that not all 
patients in this group could be included for analysis as this retrospective study did not 
offer the opportunity re-interview patients who notes were incomplete. However, the data 
available do indicate that there is no association between genotype and paradoxical 
reaction in the patients that were studied.  
 
6.3 Example 2: Suspected Contamination due to a Faulty Bronchoscope 
 
In order to allow intervention in real time, genotyping results are often required rapidly. 
This is evident in the identification of laboratory contamination (chapter 3) and the 
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investigation of suspected outbreaks (chapter 5). In this example, MIRU-VNTR 
genotyping was used to investigate a suspected iatrogenic outbreak of M. tuberculosis 
involving a bronchoscope. Such outbreaks are not uncommon and many have been 
documented in the literature (Cetre et al. 2005; Chroneou et al. 2008; Diaz Granados et 
al. 2009). 
M. tuberculosis was isolated from four patients on the same bronchoscopy list at the 
Royal Free Hospital. The bronchoscope used was subsequently found to be faulty and 
could not be thoroughly decontaminated. It was possible that these infections had been 
transmitted during the procedure or were episodes of contamination of the obtained 
samples from non-infected patients. A specimen from a further patient was culture 
negative, but positive by ProbeTec Strand Displacement Amplification (SDA) assay 
(Becton Dickinson, Oxford, UK). Organisms from the four culture-positive patients, 
together with the specimen from the SDA-positive patient were strain typed using 12 loci 
MIRU-VNTR.  
 
The data showed several differences between the isolates (table 6.1), both in loci and 
allele number. Some PCR reactions failed, but these did not detract from the information 
provided. Twelve-loci MIRU-VNTR was performed on these isolates as robotic and 
automated sequencing technologies were not available at this time. Twelve loci were 
amplified by conventional PCR and examined using agarose gel electrophoresis with 
ethidium bromide. This allowed a rapid assessment of whether the strains were unique. 
Had the strains been indistinguishable using these limited loci, then secondary typing 
using IS6110 RFLP would have been used.  
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 MIRU loci and corresponding alleles 
Isolate 2 4 10 16 20 23
2
 24 26
2
 27 31 39 40 
03:409 
Patient A 
2 2 2  2 5 1 7 3 5 4 3 
03:420 
Patient B 
2 2 3 4 1 5 1 1 3 3 2  
03:434 
Patient C 
2 2 3 1 2 8 1 5 2 3 2  
03:435 
Patient C 
 2 3 1 2 8 1  2 3 2  
03:485 
Patient D 
2 2 5 1 2 5  1 3 3 2 2 
 
Table 6.1 Summary of MIRU-VNTR type for the four isolates in the suspected bronchoscope outbreak. 
Blank cells indicate a failed PCR reaction 
 
 
PCR products could not be generated from the specimen from the SDA-positive patient 
as the SDA DNA extraction method was unsuitable for use with the MIRU-VNTR PCR.  
 
MIRU-VNTR typing demonstrated that the four isolates were different strains. IS6110 
RFLP typing would have taken a number of weeks whereas these MIRU-VNTR results 
were available within two days. These results had an important impact clinically; the TB 
team continued with anti-tuberculosis therapy as the evidence indicated that the four 
patients were genuinely infected with distinct strains (Shorten et al. 2005).  Had 
genotyping not been available, or delayed in the case of IS6110 RFLP, then the decision 
to treat each patient would have had to be made purely on a clinical basis. Indeed, those 
with other differential diagnoses or those with symptoms inconsistent with TB may have 
been denied treatment until further specimens were obtained. During this time, their 
disease may have progressed and they may have infected others. 
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6.4 Example 3: Differentiation of relapse and re-infection 
 
 
A 34 year old female patient from the Congo presented at Accident and Emergency 
complaining of cough, fever, night sweats, shortness of breath at rest, being unsteady on 
her feet and dizziness. She was admitted to the infectious diseases ward.  
 
Chest x-ray showed changes in the upper right zone. Sputum obtained from the patient 
was smear positive for acid fast bacilli.  SDA performed on the sample was also positive. 
A fully susceptible isolate of M. tuberculosis was subsequently cultured from the sputum.  
An HIV test performed on the patient was positive. The patient‘s CD4 count was 11 cells 
per μL, but no viral load was recorded. Standard anti-TB and anti-retrovirals were started. 
The patient was recorded to be 100% compliant with her treatment and the CD4 count 
and viral load were after one month of treatment were 40 cells per μL and 1420 copies 
per mL, respectively.  
 
The patient returned to the Royal Free hospital two years later following a trip to Congo. 
She was unwell and complained of fever and sweats. Chest x-ray revealed evidence of 
old TB in the upper right zone as well as consolidation in the mid left mid zone. She was 
diagnosed with advanced HIV (CD4 count 18 cells per μL, viral load 164 copies per mL) 
 
The patient was unable to produce any sputum, so underwent a bronchoscopy. An 
inflammatory lesion was observed in the left main bronchus. The sample obtained during 
bronchoscopy was microscopy and SDA positive. The lung biopsy showed a 
granulomatous inflammatory infiltrate composed of inflammatory cells, macrophages and 
an occasional multinucleate giant cell. Acid fast bacilli were seen and fungal stains were 
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negative. M. tuberculosis that was highly resistant to streptomycin was cultured from the 
specimen. 
 
The clinical team noted that the patient had been compliant with her previous TB 
treatment so questioned whether this may be a case of re-infection rather than relapse. 
IS6110 RFLP genotyping was performed on the isolates cultured from the samples 
obtained upon her first presentation and the isolate from two years later. The IS6110 
genotypes are shown in figure 6.2.   
 
 
 
 
 
Figure 6.2 The IS6110 RFLP genotypes of the isolates obtained from the patient on two occasions, 
approximately 17 months apart. The isolates from December 2003 (04:030 and 04:043) were fully 
susceptible. The isolate from April 2005 (05:131) was highly resistant to streptomycin.  
 
 
 
IS6110 RFLP genotyping revealed that the isolates were different (50% similarity) and 
indicated that the patient had been re-infected with another stain, rather than experienced 
relapsed. She was seen in the TB clinic on 10/08/2005. The clinical team felt that she was 
poorly compliant with her anti-retroviral treatment as her viral load had risen from less 
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than 50 to greater than 12,000 copies per mL. Her TB has responded well, however, and 
was declared cured after six months‘ treatment. 
 
6.5 Example 4: Genotype and Contract tracing  
 
A 34 year old woman from Indonesia was referred by her general practitioner to Accident 
and Emergency following a cough and breathlessness that had not responded to 
erythromycin. She was previously well, but was 7 weeks pregnant and had been in the 
UK for 20 months. She had been BCG vaccinated as a child. She had a history of cough 
and sputum production, fevers and weight loss of 2kg in the last 3 months (despite being 
pregnant). She had become breathless in the previous 2 weeks.  
 
She was admitted and a sputum sample was positive for acid fast bacilli and she was 
started on standard anti-TB treatment and prednisolone. A chest x-ray and CT taken at 
this time showed extensive shadowing and a cavity in the upper right lobe (figures 6.3 
and 6.4).  
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Figure 6.3 Chest x-ray three weeks after presentation. The cavity in the upper right lobe is indicated with an 
arrow.  
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Figure 6.4 Chest CT three weeks after presentation. The cavity in the upper right lobe is indicated with an 
arrow.  
 
 
A fully sensitive isolate of M. tuberculosis was cultured and the patient progressed well 
on treatment for nine months, apart from a suspected paradoxical reaction after 21 days 
of treatment. The patient was HIV negative. The chest x-ray at completion of treatment 
was indicative of resolution (figure 6.5).   
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Figure 6.5. Chest x-ray at the completion of treatment. 
 
 
Once the diagnosis had been made, contact tracing was begun. The patient‘s partner was 
a 40 year-old Iranian man who had had an intermittent cough for four weeks. He was a 
smoker who was otherwise very well. He had no history of TB, had lived in the UK for 
several years and had been BCG vaccinated as a child.  
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He received a chest x-ray, which was reported as normal (figure 6.6). He also had a 
Tuberculin skin test (Heaf), which was positive (grade IV). He had three smear negative 
(and subsequently culture negative) sputum samples and his CRP was less than 1mg/L.  
 
 
 
Figure 6.6. Chest x-ray of male contact at day 8 of the patient‘s treatment.  
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He was reviewed 10 weeks after his partner had begun anti-TB treatment. He had no new 
symptoms and his CRP remained less than 1mg/L. His chest x-ray however, indicated the 
possibility of an abnormality in the left lower zone (figure 6.7).  
 
 
 
Figure 6.7. Male contact‘s chest x-ray 10 weeks after his partner had started anti-TB treatment.  
 
 
He produced an induced sputum sample that was microscopy negative, but M. 
tuberculosis NAAT positive.  
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The patient remained well, but the team were unsure how to manage him, given that he 
was a close contact of a smear positive case. His skin test was positive, although he was 
born outside the UK and was therefore more likely to have been exposed to tuberculous 
and non-tuberculous mycobacteria. As he had a positive NAAT, had minor respiratory 
symptoms and the chest x-ray was not clear, he was sent for a chest CT (figure 6.8).  
 
 
 
 
Figure 6.8. Chest CT of male contact at week 12 of the patient‘s treatment. The highlighted area in the left 
lower zone is magnified in figure 6.8a.  
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Figure 6.8a Chest CT of male contact at week 12 of the patient‘s treatment. The highlighted area in the left 
lower zone is magnified.  
 
 
 
It was then decided to treat the male contact for active TB. A fully susceptible strain of 
M. tuberculosis was subsequently cultured from an induced sputum sample. MIRU-
VNTR typing of the isolates from the two patients revealed them to be indistinguishable 
(table 6.2), and therefore indicative of transmission from the female patient to her partner. 
Twelve-loci MIRU-VNTR was performed on these isolates as robotic and automated 
sequencing technologies were not available at this time. The isolation of indistinguishable 
strains by 12-loci MIRU-VNTR from such close household contacts within four months 
of each other is an extremely strong indicator of transmission. It is unlikely that adding 
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further MIRU-VNTR loci would produce different results given the short time frame 
between presentation of the individuals.  
 
 
 MIRU-VNTR locus 
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1 
 
3 
 
Table 6.2. 15 loci MIRU-VNTR typing results of the two patients.  
 
 
 
In conclusion, MIRU-VNTR demonstrated that the two individuals were infected with an 
indistinguishable strain of M. tuberculosis. This is not entirely surprising considering 
their relationship and domestic arrangements. However, the two patients presented with 
different clinical phenotypes and had different radiological findings.  Furthermore, if 
NICE guidance had been followed then the male patient would not have been diagnosed 
as quickly. The patient‘s first chest x-ray was normal and as such, no further follow up 
should have been initiated (figure 6.9). The subsequent clinical investigation and 
genotyping allowed the diagnosis of active TB that had been contracted from his partner.  
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Figure 6.9 NICE guidance for contact tracing. The male patient initially had a normal chest x-ray so should 
have been discharged, as indicated by the red circles. Adapted from (NICE 2006). 
 
 
6.6 Discussion   
 
In summary, as well as studying the evolutionary relationships between M. tuberculosis, 
genotyping can provide extremely useful information that is relevant to our clinical 
colleagues. The real-time investigation of suspected and known outbreaks can be used to 
rationally guide contact tracing and early detection and intervention, especially in the 
case of drug resistant strains.  
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It would be naïve to believe that genotyping M. tuberculosis alone can control the spread 
of infection, but its use, alongside classic epidemiology and contact tracing is important. 
Additionally, the use of genotyping alongside social network analyses, which focuses 
contact tracing investigations on locations rather than individuals can accurately identify 
and define transmission events (Barnes et al. 1997; Cook et al. 2007; Fitzpatrick et al. 
2001; Klovdahl et al. 2001). Furthermore, high rates of ―false clusters‖ have been seen 
when using only 12 MIRU-VNTR loci (Gopaul et al 2006). The use of this laboratory 
data alone would generate many false alarms that may initiate unnecessary public health 
interventions. Therefore, the use of an appropriate genotyping tool alongside 
epidemiological data can ensure that public health resources are used rationally.  
 
The fact that TB often has a long incubation period and disease course, and is not 
geographically constrained makes the combination of laboratory and clinical 
epidemiology even more important. Outbreaks can occur over years, rather than weeks or 
months with other infectious diseases (Fitzpatrick et al. 2001; Ruddy et al. 2004), which 
means that identifying both cases and contacts as rapidly as possible is imperative. The 
establishment of a national, prospective MIRU-VNTR genotyping database by the Health 
Protection Agency will enable the identification of related cases and outbreaks in real- 
time.  
 
The utilization of automated 24-loci MIRU-VNTR can enable a genotype to be available 
within days of a positive culture being confirmed. This will bridge the gaps between the 
laboratory, the clinical TB team and those engaged in public health. It is reasonable to 
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suggest that some outbreaks may have been identified sooner had such technology and 
systems been in place. For example, some outbreaks are identified initially due to an 
unusual drug-susceptibility pattern (Edlin et al. 1992; Ruddy et al. 2004). If real-time 
genotyping is available for all isolates of M. tuberculosis, further resources may be able 
to be provided at an earlier stage.  
 
Additionally, if real-time genotyping is available to all TB services, then the 
identification of false positive cases due to contamination can be achieved more quickly 
(Ruddy et al. 2002). This will prevent patients being inappropriately treated and 
investigated, which will, in turn, allow resources to be targeted to genuine cases. The 
monitoring of laboratory cross-contamination will not only provide the clinical teams 
with confidence in the laboratory service, but it will reassure them that the correct 
patients are being treated. Furthermore, real-time monitoring of contamination events will 
help to improve and maintain laboratory standards. 
 
The use of genotyping may be used to bridge the gap between laboratory and clinical 
investigations. Patients presenting with unusual phenotypes may be investigated to 
determine whether this may be organism-related. In a period when cases of tuberculosis 
are once again increasing (HPA 2009), the coordination of laboratory and clinical data 
can only bring benefits in the understanding of the disease. The inescapable interaction 
between the biology of the organism and the host must be studied in tandem in the 
continued search for improved diagnostics, treatments and vaccines.  
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In conclusion, the advances in the knowledge of the genome of M. tuberculosis over the 
previous two decades have a direct impact on the clinical and public health management 
of the disease. Enabling the link between the transfer of laboratory data into the clinical 
realm and vice versa must be continued to identify new cases, contacts and outbreaks in 
the short term, whilst improving the possibility of eradication in the long term.  
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Chapter 7: Final Discussion 
Tuberculosis is an ongoing global concern. The United Nations has predicted that the 
world‘s population will reach in excess of 9 billion by 2050. Almost all of this increase 
will be seen in the developing world; six of the eight countries predicted to contribute to 
this increase are in Africa or South Asia (United Nations 2005). The Global Plan to Stop 
TB 2011-2015 (WHO 2010) has set targets for reducing cases and deaths in the next five 
years. However, there is concern because the increase in population density that is 
predicted will affect areas with high rates of TB. Therefore, if the initiatives are not 
successful, then increases in the population in the areas with high rates of TB may lead to 
an increase in numbers of cases. Other concerns surround the development and spread of 
drug resistance. The United Nations has instigated several Millennium Development 
Goals, including tackling infectious diseases, such as tuberculosis (United Nations 2000). 
Halting the continued dissemination of disease can only be achieved with concerted 
action, including increased detection of active disease and latent infection, improved, 
shortened therapy (including the development of novel agents) and a more effective 
vaccine. 
 
The hypothesis presented here is that the characterisation of the genotype of M. 
tuberculosis could be used to give an insight into the biology of the organism that relates 
to its clinical phenotype. The hypothesis was addressed by performing M. tuberculosis 
genotyping alongside the collection of demographic data for all culture positive TB 
patients at the Royal Free Hospital, Hampstead, London. We have shown that this 
geographic location is the home of a diverse population of M. tuberculosis by the 
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demonstration of a low rate of transmission (6.3%) compared to other studies (table 1.2). 
Additionally, IS6110 RFLP genotyping revealed in excess of 60 70% lineages. This 
finding, in combination with the high rates of migration in London demonstrates a 
diverse collection of strains. The identification of over-represented lineages amongst the 
dataset allowed the association between genotype and phenotype to be studied.  
 
It is clear from the data presented in chapter 3 however, that IS6110 RFLP used alone is 
not sufficient to address all of the issues raised, as has been found by other authors 
(Gillespie, Dickens, & McHugh 2000; van Deutekom et al. 2005). As shown in chapter 3, 
nearly one in five isolates of M. tuberculosis in this data set posses too few copies of this 
insertion sequence for this method to be utilised for their differentiation. This finding, 
combined with the deficiencies identified when interpreting poor quality images from this 
technically demanding tool make it an imperfect genotyping method. MIRU-VNTR was 
shown to be a valuable secondary genotyping method in this setting. The higher level of 
discrimination seen in subdividing lineages generated by IS6110 RFLP, together with the 
comparative ease of use and transportability of the data makes a compelling case for its 
adoption as the genotyping method of choice, as is the case for the UK national typing 
strategy. The advantages, disadvantages and applications of various genotyping 
methodologies are summarised in table 7.1. 
 
Genotyping M. tuberculosis has multiple benefits in the study and control of the disease. 
Calculation of the rate of transmission as 6.3%, as performed in chapter 3, allows the 
rational allocation of public health resources to areas with the highest burden. It also 
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allows outbreaks to be identified more rapidly, such as those in North London and within 
households described in chapters 3 and 5. The identification of such outbreaks 
subsequently allows the targeting of public health interventions. The identification of 
contamination events, whether they be pre-analytical or within the laboratory are 
essential for good patient care. The realisation that the resilient nature of this organism 
can cause false positive cultures in even the most specialised of laboratories must drive 
up standards of practice.  
 
Genotyping 
methodology 
Relative 
discrimination 
Advantages Disadvantages Uses 
IS6110 RFLP High Highly 
discriminatory 
Unsuitable for 
<5 copies of 
IS6110 
Technically 
difficult 
Outbreak/epidemiological  
and evolutionary 
investigation 
 
12-loci MIRU-
VNTR 
Moderate  
Easy to perform 
 
Automatable 
Data easily 
transportable 
Moderate 
discrimination 
Outbreak/epidemiological 
investigation 
15-loci MIRU-
VNTR 
High  
Cost associated 
with automation 
Outbreak/epidemiological 
investigation 
24-loci MIRU-
VNTR 
High Outbreak/epidemiological 
and evolutionary 
investigation 
Spoligotyping Low Data easily 
transportable 
Low 
discrimination 
Phylogenetic and low 
discrimination 
epidemiological 
investigations 
Whole genome 
sequencing 
High Highly 
discriminatory 
High cost In depth evolutionary 
analysis 
 
Table 7.1 The advantages, disadvantages and applications of IS6110, MIRU-VNTR, spoligotyping and 
whole genome sequencing.  
 
It is imperative to ascertain what question is being asked when genotyping M. 
tuberculosis. The in-depth evolutionary study of the organism may require the use of 
several methodologies, investigating numerous genomic targets (Gagneux & Small 
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2007). However, 24-loci MIRU-VNTR typing data has shown concordance with 
phylogenetic groups in over 90% of cases (Brown et al 2010). Conversely, only 12 loci 
may be necessary to refute an apparent outbreak in a specific setting (Shorten et al. 
2005). It is worth noting however, that the use of 12-loci MIRU-VNTR in isolation in 
prospective genotyping can generate a large number of ―false clusters‖ resulting in 
unnecessary public health interventions (Gopaul et all 2006). Therefore, it is important to 
select the genotyping tool appropriate for the question being asked.   
 
It is worthwhile considering the limitations of this type of data. Studies that use 
molecular genotyping as their foundation are inherently limited by the fact that one can 
only genotype the strains that are isolated. Approximately 60% of TB patients in this data 
set and nationally (HPA 2009) who were diagnosed with TB were culture positive for M. 
tuberculosis. Whilst it is fair to say that a significant proportion of patients who 
commence anti-tuberculosis treatment in the absence of a positive culture are likely to 
have active infection, the isolation of an organism is nevertheless reassuring for the 
clinical team. This demonstrates the need for improved diagnostic tools because the early 
detection of cases, alongside appropriate treatment and contact tracing, is essential in 
preventing the spread of TB (WHO 2006). Ultimately however, this means that the 
conclusions drawn between the relationship between genotype and clinical phenotype 
may be biased. It is known that the relative fitness of some clinical strains varies 
(O‘Sullivan et al 2010) and that this may therefore affect the chance of their recovery 
from clinical specimens. There appears to be no evidence, however, that certain lineages 
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of M. tuberculosis are more difficult to culture, perhaps suggesting that the proportion 
that are cultured and genotyped are representative of the population as a whole.  
 
It would be worthwhile expanding this dataset to include demographic data (for example, 
country of birth, ethnicity and HIV status) on all TB patients, rather than just those who 
provided and positive culture. The analysis of the demographic data of all TB patients 
may provide further insight into the population within our geographic region. It may 
identify particular groups of patients who present with particular phenotypes of those 
who are less likely to have their diagnosis confirmed with culture. Investigations into the 
possible reasons for this may be performed and more resources could be targeted at 
obtaining positive cultures from these patients. 
 
The differences in the country of birth and ethnicity of patients seen in these data 
compared to nationally have been described in chapter 3. The differences are likely to be 
due to the ethnic makeup of the catchment area of the Royal Free Hospital. Data collected 
by The Greater London Authority demonstrates that large numbers of Somalis live in the 
London boroughs that are served by the Royal Free. It is logistically important to identify 
which patient groups are at risk within the surrounding area. Ultimately, the aim must be 
to encourage patients to engage with a healthcare setting. This may be achieved by 
providing literature in the appropriate languages, engaging with hard to reach patient 
groups, such as the homeless and those that misuse drugs or alcohol, together with the 
use of culturally sensitive practices.  
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The analysis of country and birth and ethnicity data provided the surprising conclusion 
that European patients and those born within the UK were more likely to have smear 
positive pulmonary disease. One hypothesis for this finding is that TB may not always be 
suspected initially in these patients. Symptomatic patients from sub-Saharan Africa and 
South Asia may be investigated for TB more rapidly, whilst diagnosis in the 
European/UK-born group may be delayed. This would allow an increase in bacterial load, 
leading to the increased probability of smear positivity.  
 
Further investigation of this dataset with regard of phylogeographic groups may be 
revealing. For example, it would be of interest to ascertain whether isolates in this 
database with one copy of IS6110 were more likely to belong to Principle Group IV, 
similar to those described by Baker and colleagues (Baker et al. 2004).  Additionally, the 
country of birth of the TB patients could be investigated alongside the phylogeographic 
groups of their isolates as others have done (Dale et al. 2005; Reed et al. 2009). 
  
The rate of transmission in this study was lower than that described in a previous study in 
London (Maguire et al. 2002). It is likely that this is due to the restricted geographical 
location and limited time-frame of the study. TB is an infection with a prolonged 
incubation and disease course. It is also not geographically constrained. It is likely that 
not all patients within chains of transmission have been identified within this study as 
symptoms in some patients developed outside this time frame or that they presented to 
other healthcare centres. For these reasons, the establishment of a prospective nationwide 
genotyping database at the Health Protection Agency is extremely positive.  
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Differences in discriminatory power between methods are well documented (Kremer et 
al. 2005) and false clusters of strains have been seen when using one method alone 
(Gillespie, Dickens, & McHugh 2000). It has been hypothesised that to establish 
evolutionary links between isolates, more than one genotyping methodology is required 
(McHugh et al. 2005). The benefit of this approach can be seen when examining the 
apparent lineages identified by IS6110 RFLP in chapter 3. One group of strains (lineage 
19) appeared to be closely related at ≥70% by IS6110 RFLP. Subsequent secondary 
typing with MIRU-VNTR revealed that the isolates were sub-divided into two smaller 
lineages. This was particularly well demonstrated in the minimum spanning tree (figure 
4.8), in which it can be seen that members of lineage 19b have evolved from members of 
19a.  It would be fascinating to look deeper into the field epidemiology of the patients in 
this lineage to ascertain the chain of transmission and the time-line involved, in 
comparison with the stability of the MIRU-VNTR loci gained and lost.  
 
The identification of a lineage of closely related strains in chapter 3 that were noticeably 
more drug resistant than other lineages in the dataset was of great interest. It was 
confirmed that the isolates were part of the ongoing North London isoniazid resistant 
outbreak (Ruddy et al. 2004) but further analysis revealed findings that were unusual in a 
normal outbreak setting. It is clear that the strains are closely related, as shown by two 
genotyping methods, but they were not identical, as one might expect.  
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The large proportion of drug resistant strains in this lineage indicated that the acquisition 
of resistance mutations had not had a detrimental effect on their ability to transmit 
between hosts. This was confirmed by in vitro fitness assays that demonstrated that the 
generation time of the resistant strains was not significantly longer than that of the fully 
susceptible strains in the lineage as well as the laboratory reference strain M. tuberculosis 
H37Rv. In depth analysis of the genotyping, along with sequence analysis of drug 
resistance genes showed how the strains have evolved independently during the course of 
the outbreak whilst remaining competitive (figure 6.4). The presence of more than one 
isoniazid conferring mutation in the lineage, alongside the addition and deletion of the 
insertion sequence IS6110, clearly demonstrates the independent evolution of these 
organisms. Unusual rpoB mutations have already been documented in MDR strains 
within the outbreak (Jenkins et al. 2005), so it would be interesting to ascertain the nature 
of all the mutations causing resistance in these isolates to examine how divergent they 
were.  
 
The North London isoniazid resistant outbreak strains that were studied in this work were 
isolated between 2002 and 2007, and there are a total of eight insertions and seven 
deletions of IS6110 during this time. It appears that the strains have gained and lost the 
insertion sequence IS6110 at a higher rate than described elsewhere (de Boer et al. 1999; 
Yeh et al. 1998). It is possible that these strains have evolved more rapidly, whilst 
maintaining their competitiveness and acquiring resistance mutations.  This may be due 
to selective pressure during the outbreak, or maybe because of a permissive genotype. 
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The analysis of mutation rates and DNA repair in this group of strains may shed some 
light on this situation.  
 
The organisms identified in this large outbreak are clearly successful. These genotypes 
are associated with the acquisition of drug-resistance conferring mutations with minimal 
fitness cost. Other genotypes, notably the Beijing/W family, are associated with a 
particular phenotype, such as progression to active disease (de Jong et al. 2008), 
pulmonary cavitation (Kato-Maeda et al. 2001), host immune response (Lopez et al. 
2003; Theus, Cave, & Eisenach 2005), growth rates in ex-vivo monocytes (Theus, Cave, 
& Eisenach 2005) and macrophages (Zhang JID 1999), the ability to cause disseminated 
disease (Caws et al. 2008; Garcia de Viedma et al. 2005; Thwaites et al. 2008) and 
pulmonary smear negativity (Dale et al. 2005). Additionally, Beijing strains have been 
associated with radiologically advanced disease (Drobniewski et al 2005). The lineage of 
strains identified here has an associated phenotype that confers and advantage. They have 
therefore taken the opportunity to propagate within London and beyond. Similar analyses 
on related outbreak strains that have been isolated more recently would be fascinating.   
 
The North London isoniazid resistant outbreak consists of large numbers of Caucasian 
and Black Caribbean patients (Ruddy et al. 2004), which is divergent from national UK 
data (HPA 2009). Gagneux and colleagues (Gagneux et al. 2006) noted that patients 
infected with isolates in the European-American group were more likely to give rise to 
secondary cases than other groups. Baker and colleagues (Baker et al 2004) and Brown 
and colleagues (Brown et al 2010) additional found that M. tuberculosis lineage correlate 
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with country of birth. Given that is has been shown that phylogeographic groups align 
with the country of birth of TB patients (Dale et al. 2009) it is possible that these 
outbreak strains may be European-American in origin.  
 
In summary, it appears that this lineage, which is associated with the North London 
isoniazid resistant outbreak, comprises a heterogenous collection of closely related 
strains. These strains appear to have thrived in the community, generating large numbers 
of clinical cases whilst evolving independently via the acquisition of antimicrobial 
resistance and the alteration of their genotypes.   
 
The hypothesis that bacterial genotype is related to disease phenotype was further 
examined in chapter 5. Patients who were subsequently culture positive for M. 
tuberculosis underwent a novel immunological test (Breen et al. 2005), with varying 
results. The assay measured the immunological response to a single M. tuberculosis 
antigen (ESAT6) in vitro. The finding that not all patients gave a positive reaction was 
intriguing and the possibility that this was a phenomenon was associated to a clonal M. 
tuberculosis genotype was investigated. 
 
The differences in IFNγ production by the patients‘ T cells were not related to the 
genotype of the infecting organism. There was no relationship between the isolates in this 
patient group according the analysis of IS6110 RFLP (figure 5.2) and all strains 
possessed a unaltered copy of the gene encoding ESAT6 (esxA) (table 5.3). All strains 
except one exhibited minimal changes in the regulation of this gene when compared to a 
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reference strain. One isolate showed considerable up-regulation of this gene, but this was 
not linked to the infected patient‘s IFNγ response (table 5.6). The IFNγ response in the 
patient from whom this isolate was cultured was the highest amongst the cohort, but was 
not statistically significantly higher than those of the other patients. Additional work is 
needed to further elucidate this finding. It may be possible that the growth rate of this 
strain is significantly different to the others, that is, it may have reached stationary phase 
significantly earlier than day 28. This warrants further investigation of the expression of 
other genes associated with this isolate to determine if this level of up-regulation is a 
common factor. This may be achieved by using RT PCR to look at a range of genes in 
this isolate, or by utilising a microarray. Further investigative avenues for these strains 
include the analysis of the other genes within the RD1, including lhp that encodes the co-
expressed CFP-10. It may be of interest to examine the expression of the genes encoding 
the other ESAT-6 homologues (Tekaia et al. 1999). To assess whether the isolate that 
showed high levels of upregualtion of esxA (04:391) has generally high levels of 
transcription it may be of interest to investigate a number of housekeeping genes, 
including other sigma factors and genes encoding heat shock proteins.  
 
The interpretation of RT PCR data in this setting prompts some debate regarding the 
reference genes used and the manor in which the data is analysed. This fascinating group 
of patients raised a question regarding a single antigen of M. tuberculosis. The design of 
an RT PCR for this gene, along with appropriate controls, allowed this question to be 
answered directly. Alternatively, it may be beneficial to use a microarray when 
investigating the regulation of multiple gene targets. In the case of the isolate that was up-
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regulated significantly, the utilisation of a microarray would provide an insight to a larger 
proportion of the genome, which may begin to answer some of the questions raised. It is 
useful to note that regardless of the method used, RT PCR or microarrays, the careful 
selection of reference genes is imperative. The utilisation of a gene that is consistently 
expressed at a level that allows for variation in the target gene to be recorded is vital 
(table 5.4). As seen in chapter 5, the selection of a gene that is consistently expressed at a 
high level can make an assay insensitive. 
 
The finding that not all patients in this group demonstrated a positive IGRA result despite 
having culture confirmed TB is intriguing. This suggests that IGRA must be interpreted 
as part of the whole picture of TB diagnostics and not alone. As with any diagnostic tool, 
whether it be laboratory based, radiological or clinical, the sum of these is far greater than 
the individual parts. 
 
From these data it was concluded that the hosts‘ genotype may play a more significant 
role in this setting. Different disease phenotypes have been shown in patients and animal 
models. For example, increased susceptibility to disease has been shown in animal 
models when defects in CD4 T cell function (Saunders et al. 2002; Scanga et al. 2000), or 
with IFN-γ expression or recognition (Cooper et al. 1993; Flynn et al. 1993). Increased 
susceptibility has also been seen in such patients (Havlir & Barnes 1999; Ottenhoff et al. 
2005). These associations between disease phenotype with host genotype indicate that the 
variations in immune response in these patients may be driven by anomalies within the 
immune systems of the patients. This warrants further investigation in the areas of patient 
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HLA typing and immune function tests. HLA typing was not performed on the patients in 
this dataset as the emphasis was on the biology of the infecting organism. Additionally, 
ethics approval was not in place to perform this analysis retrospectively on any patient 
material that was collected for diagnostic purposes. 
 
In attempting to understand the relationship between pathogen genotype and disease 
phenotype, a number of methodologies were utilised. The technologies used were 
appropriate at the beginning of this work, but of course technological advances have not 
ceased in the following years. The development of next generation sequencing makes it 
possible to sequence an entire bacterial genome in hours, rather than weeks, at a fraction 
of the cost (Metzker 2010). As this type of technology become more prevalent, it is worth 
noting that the amount of data generated is vast. Indeed, the techniques involved in 
sequencing megabases of DNA are relatively simple when compared to the data analysis 
software and hardware that is required subsequently. The phylogeographic evolution of 
M. tuberculosis has subsequently been described by analysing SNPs and LSPs (Gagneux 
& Small 2007). These polymorphisms may be considered as surrogates for the 
evolutionary process, but the technology to study every SNP in an entire genome is very 
real. The application of such technology to this dataset may answer some of the 
unanswered questions.  
 
As with all new technologies, it will take some time to establish the real meaning of the 
generated data. Whole genome sequencing has been used clinically to subdivide clusters 
of M. tuberculosis infection (Schurch et al. 2010). It has also been shown that the genome 
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of the reference strain M. tuberculosis H37Rv varies between different research centres 
(Ioerger et al. 2010). This finding may have an impact on wide-reaching aspects of 
tuberculosis research. This reference strain is used globally in the development of 
vaccines, drugs and diagnostics and it is therefore concerning that the strains held in 
different centres vary significantly. One may see different vaccine or drug responses with 
these different strains. It may therefore be necessary to agree on a consensus strain that is 
distributed globally to all relevant research centres.  
 
It will take some time to establish the degree of difference expected between strains 
before the technology may be adopted widely. This will be achieved by sequencing the 
entire genome of multiple strains, which will take time and some existing data may need 
to be reviewed – indeed analysis of multiple isolates of M. tuberculosis H37Rv indicates 
that some bases were incorrectly sequenced originally and may need to be reissued 
(Ioerger et al. 2010). Whole genome analysis may play a role in the analysis of successful 
lineages, such as those identified in this work. Novel virulence factors and potential drug 
targets may be identified by the large scale adoption of this technology.  
 
Additionally, genotyping can play an important role in the development of both new 
antimicrobial agents and vaccines. As demonstrated in this thesis, clinical strains can vary 
widely in many respects. The genomic differences which appear through evolutionary 
processes and are partially demonstrated with genotyping may alter many crucial aspects 
of the organisms‘ physiology. For example, a novel antimicrobial agent may not be 
considered to be active against M. tuberculosis until it has been shown to be effective 
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against a range of genotypically distinct strains. Furthermore, clinical trials involving 
novel agents and regimens are using wide-reaching geographical locations partly for this 
reason. Likewise, multiple unrelated strains should be screened when investigating 
potential vaccine targets and when assessing the protective effects of novel vaccines.  
 
The utilisation of M. tuberculosis genotyping arguably provides the greatest benefit in a 
clinical setting. In chapter 7, the rapid confirmation of four genuine cases of tuberculosis 
enabled appropriate treatment to be commenced promptly, which prevents ongoing 
transmission. Additionally, the instigation of contact tracing allows the identification of 
actively and latently infected individuals and their subsequent management. The 
collaboration between the laboratory and clinicians was further demonstrated in the 
investigation of a group of patients presenting with a paradoxical reactions and also in the 
case of household transmission. Such continued collaboration will further enhance both 
the understanding of the biology of the M. tuberculosis and the clinical presentation of its 
hosts. These two disciplines must work together to help to eradicate the disease.   
 
In conclusion, genotyping M. tuberculosis plays a pivotal role in the holistic approach to 
understanding tuberculosis. The relationship between genotype and phenotype is 
complicated, but the identification of outbreaks and over-represented lineages of strains 
can further add to the understanding of the evolutionary success of the organism. 
Prospective, real-time genotyping can enable the monitoring and control of disease as 
well as its prevention. Bridging the gaps between the laboratory and clinical practice is 
essential for the eradication of this global pathogen. 
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